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Abstract  
Introduction 
Pancreatic cancer (PDAC) confers a high mortality rate as it often presents at an advanced stage. 
Screening could improve early detection and survival. However, the prevalence of the disease and 
absence of specific screening tools mean that screening of the general population would result in 
many false positive tests. This may mean unnecessary overtreatment including surgery with 
considerable morbidity. Current screening techniques have associated risks including exposure to 
radiation and induction of pancreatitis. It is therefore essential to identify high risk screening 
populations and improve both specificity and safety of the screening modality. The European 
Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) was established to 
identify individuals with a genetic predisposition for PDAC to offer secondary screening.  
Thesis Aims 
The aims of this thesis were to identify subpopulations of high risk families who are at the greatest 
risk of pancreatic cancer in order to undertake targeted screening. Furthermore, to minimise the 
risks and complications to individuals participating in the EUROPAC secondary screening study for 
early PDAC. 
Materials and Methods 
Familial Pancreatic Cancer (FPC) was defined as autosomal dominant predisposition for PDAC. 
Hereditary Pancreatitis (HP) is an autosomal dominant predisposition for pancreatitis associated 
with an approximately 40% life time risk of PDAC. Families with other recognised cancer syndromes 
conferring a predisposition to PDAC were also recruited. At recruitment, blood samples for DNA 
storage and cell lines were obtained for the analysis of potential candidate genes implicated in FPC. 
Individual and familial demographic, lifestyle and disease related data were collected to facilitate 
analysis of possible risk factors which could influence penetrance in these high risk groups. On 
confirmation of a familial predisposition, eligible individuals were invited to participate in the 
EUROPAC secondary screening study for early pancreatic cancer. The screening protocol comprised 
blood tests and imaging techniques along with analysis of molecular markers in pancreatic juice.  
Results 
273 potential FPC kindreds were identified and recruited; 89 had 3 or more affected family 
members. In FPC, age is a major risk factor but the pattern of age related risk is the same as in the 
general population. However, this is consistently 100 fold greater in FPC. No evidence was found for 
earlier age of onset in FPC contrary to other reports. Selection bias based on proband is proposed as 
an explanation for the apparent differences seen in the literature. Reporting bias could also explain 
the relationship of smoking and PDAC in FPC kindreds. No further causative mutations were found 
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during the preparation of this thesis but a PALB2 mutation was found in three families (possibly 
associated with breast cancer). A model for risk was proposed, but in this thesis only secondary 
screening based on previous estimates is described. The methodology involved Endoscopic 
Retrograde Cholangiopancreatography (ERCP) and 7 cases of pancreatitis resulted. Consequently, 
stenting and use of diclofenac was introduced resulting in a significant reduction in ERCP associated 
pancreatitis (3 of 31 screens). Use of secretin to allow sampling of pancreatic juice from the 
duodenum was also piloted to further improve safety. This thesis provides data to support risk 
stratification in FPC and an improved screening modality. A total of 212 HP kindreds were identified. 
A variable clinical picture and cancer risk was found in the HP families with p.R122H, p.N29I and 
p.A16V all conferring a significantly increased lifetime risk for the development of pancreatic cancer, 
in addition to the earlier age of onset of exocrine and endocrine failure. Cancer risk was shown to be 
increased with smoking and diabetes. Risk of PDAC increases with age equally for HP and the general 
population but was 28 fold higher in each age group with HP.   
Conclusion 
My thesis has identified specific lifestyle and disease derived risk factors which may influence risk for 
the development of PDAC in high risk groups. As a direct result of this thesis, amendments made to 
the screening protocol have improved safety and minimised harm to those individuals undertaking 
screening for early pancreatic cancer under the auspices of EUROPAC. 
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Introduction 
 
1.1 Pancreatic ductal adenocarcinoma 
 
1.1.1 Incidence and prevalence 
 
Exocrine pancreatic cancer accounts for over a quarter of a million deaths worldwide each 
year with approximately one third arising in Europe [1]. Despite being only the thirteenth 
most common malignancy worldwide, it is the eighth most frequent cause of cancer 
mortality [2]. The lethality of this disease is further evident by the fact that mortality rates 
continue to approximate to incidence [2]. There has been only a marginal decline in both 
age-standardised incidence and mortality rates over the past 20 years [1, 3].  
Pancreatic ductal adenocarcinoma (PDAC) accounts for almost 90% of all malignant 
neoplasms of the exocrine pancreas. This encompasses variants including mucinous non-
cystic adenocarcinoma, signet-ring cell carcinoma and mixed-ductal endocrine carcinoma. 
They exhibit similar histological characteristics and clinical outcomes. This group of exocrine 
tumours is commonly collectively referred to as “pancreatic cancer”. In 2008, a total of 
8,085 cases of pancreatic cancer were diagnosed in the UK [1]. This figure comprises a total 
of 4,001 males and 4,084 females.  
1.1.2 Survival data 
 
The overall five year survival rate in patients with PDAC remains poor at 5.6% [4]. This figure 
has remained relatively static for decades. The poor prognosis conferred by a diagnosis of 
PDAC, can be explained by the frequent late presentation of the disease at an advanced 
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stage. Surgical resection remains the only treatment modality to offer potential cure. 
Unfortunately, only up to 20% of those presenting with PDAC will have disease which is 
amenable to resection. Hence, potentially curative treatment cannot be offered in the 
majority of patients. PDAC remains largely chemoresistant, despite a gathering body of 
evidence to support improved survival following treatment with certain chemotherapeutic 
agents [5-8]. The combination of surgical resection and chemotherapy with 5-fluorouracil 
(5-FU) was demonstrated to be effective in early cancers, with significantly improved 
survival of 20-30% at five years [5]. Hence, there is an incentive to identify PDAC at an early 
stage to improve long term survival. A small series from Japan has shown that very early 
cancers (<2cm diameter, no lymph nodes involved), although rare, result in a 60% 5-year 
survival rate. Survival was 100% at two years [9]. Current median survival of patients with 
tumours that present clinically is measured in months. Early symptoms of pancreatic cancer 
are poorly characterised, not very specific, and are often missed by patients and their 
clinicians.  
 
1.1.3 Current treatment strategies 
 
Radical surgery for pancreatic cancer is only possible for around 20% of patients due to the 
frequency of vascular involvement and distant metastases at presentation [10]. Historically, 
the combination of significant perioperative mortality rates, coupled with overall 5-year 
survival rates of less than 1%, has led some clinicians to regard radical intervention in the 
treatment of PDAC as futile [11] [12]. This view, however, has been largely abandoned over 
the past 20 years, as centralisation of pancreatic surgery has resulted in dramatic 
improvements in perioperative management, with operative mortality rates of between 1% 
20 
 
- 4% now typical of most high-volume specialist centres [13-16]. Significant improvements in 
resectability rates, morbidity, and late postoperative survival, are also associated with 
greater caseloads which occur with the centralisation of services [17]. 
As eluded to earlier in this section, the advent of adjuvant chemotherapeutic agents has led 
to 5 year survival rates approaching 30% in a subgroup of patients, having undertaken 
surgical resection with subsequent adjuvant chemotherapy [5, 6] . However, the 
appropriateness of surgical intervention must be carefully considered by the Multi-
Disciplinary Team (MDT), as the presence of locally advanced disease with vascular 
encasement, or identification of distant metastases, precludes the majority of those 
presenting with PDAC from attempted resection. Surgical intervention in the treatment of 
pancreatic cancer remains the only option for cure. Hence, in individuals with disease which 
is not amenable to surgery, palliative chemotherapy may be offered, pending assessment of 
their performance status. In some who present with advanced disease, there is a rapid 
clinical deterioration following diagnosis. Therefore, palliative care and symptom relief with 
the aim of a dignified and comfortable death may be the only treatment modality which can 
be offered. It is imperative that all members of the MDT work closely to deliver patient 
focused care at all stages of their treatment, addressing both physical and psychological 
concerns. 
1.1.4 Surgical treatment 
 
The majority, approximately 70%, of PDAC arise in the head of the pancreas. Hence, the 
standard surgical technique of partial pancreatoduodenectomy accounts for between 80-
90% of all radical operations performed for this patient group [13]. Pylorus-preserving 
procedures have been widely adopted due to the associated preservation of gastrointestinal 
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function, and comparable oncological clearance when compared with historical techniques 
in previous randomised trials [18, 19], providing the remaining duodenal margin is viable 
and tumour-free. Historically, controversy has reigned regarding the role of extended 
lymphadenectomy in improving survival outcomes [20]. However, more established 
evidence from randomised controlled trials has failed to demonstrate any survival 
advantage associated with extended lymphadenectomy, and have indicated the potential 
for additional perioperative morbidity, when compared with standard surgical techniques 
[21, 22]. In certain cases, limited venous resection may be undertaken in those individuals in 
whom the tumour extends to involve the hepatic, portal or superior mesenteric vein, 
providing adequate macroscopic tumour clearance can be achieved [23-25].  The 
radiological extent of any vascular involvement is carefully evaluated by the MDT pre-
operatively, as this is a key determinant in establishing resectability of the tumour.  
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1.1.5 Chemotherapy in the treatment of PDAC 
 
A series of large randomised controlled trials from both Europe and the US have led to the 
establishment of evidence in support of a role for chemotherapy in PDAC. Initial evidence in 
support of chemoradiotherapy regimes conferring a survival advantage [26, 27] has been 
superseded by a series of large trials which reveal that, in fact, radiotherapy exerts a 
deleterious effect and that optimal adjuvant treatment is achieved through the use of 
chemotherapy in isolation [5, 6, 28]. Although initial evidence cited 5-FU as the gold 
standard chemotherapeutic agent in the adjuvant treatment of PDAC, more recent evidence 
has suggested that gemcitabine confers a longer median disease free survival coupled with a 
favourable toxicity profile [8]. More recently,  definitive evidence from The European Study 
Group for Pancreatic Cancer ESPAC-3 trial did not demonstrate significant differences in 
progression-free survival, or quality of life scores, with the use of gemcitabine over 5-FU and 
folinic acid [29]. 
 
1.2  PDAC: Aetiology 
 
1.2.1 Age, sex and ethnicity as risk factors for PDAC 
 
Age, sex and ethnicity have all been implicated as risk factors for the development of PDAC. 
Population analyses have demonstrated that advancing age has an associated increased risk 
for development of the condition. US National Cancer Institute Surveillance and End Results 
(SEER) data are cross sectional analyses performed across five year age ranges. Data below 
pertains to the risk of developing pancreatic, colonic and breast cancer with advancing age. 
It can be seen that the peak lifetime risk of developing pancreatic cancer approaches 0.5% 
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at approximately 85 years of age. The increasing incidence of PDAC seen with advancing age 
in the US is reflected in worldwide data [30] [31].  
  
 
 
 
 
 
 
 
 
Figure 1: SEER data: cross-sectional analysis across 5 year age ranges identifying risk of development of breast, colorectal 
and pancreatic cancer with increasing age [4] 
SEER data was obtained for the US population and shows that pancreatic cancer risk peaks in the 85-90 year age range, 
somewhat later than risk for breast and colorectal malignancy. 
 
In addition to the trend of increasing incidence seen in the older population, there is 
established evidence to support a male preponderance to the development of PDAC. The 
slight female preponderance seen in UK females from 2007 data is not reflected in 
worldwide and historical data, where an increased incidence of PDAC has been typically 
recorded in males [32]. SEER data are cross sectional analyses performed across five year 
age ranges. SEER data recorded an incidence of 13.9 per 100,000 in US males compared to 
10.7 per 100,000 in females, for the period 2000-2009. Statistics derived from worldwide 
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cancer registry information estimate the number of male deaths attributable to pancreatic 
cancer at 120,000 per annum, as compared to 107,000 female deaths [33]. Variation in risk 
has also been observed between those of different racial and ethnic origins. Data from SEER 
analysis relating to PDAC diagnoses according to race identified an increased incidence in 
the black population within the US. The incidence within the black male population was the 
highest observed among any group at 18.1 per 100,000. An apparent preponderance to the 
disease has been noted amongst other ethnic groups worldwide. For example, an elevated 
rate of pancreatic cancer is seen within the Ashkenazi Jewish population. This apparent 
predisposition to pancreatic carcinoma is usually associated with an inherited genetic 
alteration, commonly, a BRCA2 mutation.  
1.2.2 Cigarette smoking and other tobacco use as risk factors for PDAC 
 
Many environmental and disease derived risk factors have been implicated in the 
development of sporadic pancreatic cancer. The most significant association is that of 
tobacco smoking [34-55]. 
A large number of cohort and case control studies have been performed examining the 
relationship between smoking and the development of PDAC. From this large volume of 
evidence, it is now widely accepted that tobacco smoking is associated with a dose 
dependent increased risk for the development of PDAC with an average increased risk of 
approximately 2 fold [34-55]. Furthermore, it is estimated that 20-30% of sporadic cases are 
attributable to smoking [56].  
In a recent meta-analysis of 82 published papers by Iodice et al [56], including 42 case 
control, 35 cohort and 5 nested case control studies, the pooled relative risk (RR) for the 
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development of pancreatic cancer in current smokers was 1.74 compared to non-smokers. 
Very few studies have reported findings which refute this association [57-59]. In a cohort of 
14,397 Taiwanese, Liaw et al recorded a RR of 0.3 (95% CI 0.1-0.9) for pancreatic cancer in 
the subgroup of male smokers versus their non-smoking counterparts despite the fact that 
the study did show a significant elevated risk for cancer in general for this same group of 
smokers. Of the 14,397 participants, 11,096 were male and amongst this group 15 
pancreatic cancer deaths were recorded, compared to 110 liver cancer deaths [57]. This is a 
surprising ratio of pancreatic to liver cancer deaths, given that pancreatic cancer is 
considered to be a more likely cause of cancer death in the general male population [60]. 
Thus, suggesting a bias in the population or misreporting of causes of death. Two case-
control studies undertaken in Japan [58] and Canada [59] have also reported a RR of <1.0 in 
specific study subgroups. Nishi et al, in a study of 141 cases and 282 controls identified a RR 
of 0.3 (95% CI 0.1-0.8) in a subgroup of current smokers consuming 1-2 cups of coffee daily 
[58]. In a Canadian study of 312 cases and 2919 controls, Hanley et al reported an odds ratio 
(OR) of 0.76 (95% CI 0.76-1.36) and 0.79 (95% CI 0.44-1.44) in a cohort of males smoking 5-
15 and 15-25 pack years, respectively [59]. This reached significance, with a p value of 
0.0059 on adjusting for age and province. However, it should be noted that individuals 
smoking over 25 cigarettes per day had a significantly increased risk of pancreatic cancer 
(1.83, 95% CI 1.23–2.72) even in this study, and the protective effect of low level smoking 
lost significance after multivariate analysis (p=0.49) [59]. 
Several authors have reported an increase in the risk of development of pancreatic cancer in 
females compared to their male smoker counterparts [43, 61-63] . In a Swedish cohort study 
of 45,906 males and 37,147 females, a reported adjusted RR of 6.90 (95% CI 1.91-24.93) was 
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demonstrated in the subgroup of females smoking for >40 pack years. This was compared to 
an adjusted RR of 4.05 (95% CI 1.81-9.05) in the corresponding male cohort [43]. However, 
this apparent female preponderance has not been consistently reported. Evidence from the 
UK Million Women Study, the largest women’s health study to date, reported a RR of 2.39 
(95% CI 2.10-2.73) amongst current smokers [36], which is comparable to results recorded 
by other large cohort studies [54, 64]. In view of this, there does not appear to be a large 
gender associated increased risk for the development of pancreatic cancer in smokers. 
There is more consistent evidence supporting a dose-dependent relationship in cigarette 
smoking and pancreatic cancer. Large cohort and case control studies have consistently 
identified an increase in risk for the development of PDAC with increasing number of pack 
years [34, 36, 39-42, 46, 65]. 
There is limited evidence to suggest that smokers develop pancreatic cancer at earlier ages 
than their non-smoking counterparts. In an analysis of 29,239 histologically confirmed PDAC 
cases, Brand et al at the University of Pittsburgh, concluded that current smokers were 
diagnosed with pancreatic cancer 8.3 years younger than never smokers [66]. 
Evidence regarding former smoking demonstrates a general trend of decreasing risk with 
increasing number of years since stopping tobacco use, as may be expected. In their 2008 
meta-analysis, Iodice et al reported an overall RR of 1.20 amongst former smokers from the 
82 papers included [56]. Evidence across a wide range of cohort [54, 55, 62, 65] and case-
control studies [39, 45, 50, 61, 63] has consistently demonstrated no increase in risk in ex-
smokers 10-15 years after stopping cigarette use.  The most recent evidence from a large 
group of 29,239 histologically confirmed pancreatic cancers, reported that past smoking was 
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less influential upon risk than current smoking, suggesting a key role for health education 
and smoking cessation in the prevention of pancreatic cancer [66]. 
In addition to the use of tobacco in cigarettes, tobacco is used in different forms across the 
world. The risk of pancreatic cancer conferred through cigar and pipe smoking has been 
assessed by several groups [39, 44, 61, 63, 67-70]. Although early evidence in case control 
studies by Wynder [67] and Howe [63] demonstrated only a marginally elevated risk 
associated with pipe and cigar use (RR 1.3 95% CI 0.5-3.2 and RR 1.22 95% CI 0.5-2.67 
respectively), more recent studies have identified a consistent 2 to 3 fold increased risk in 
heavy lifetime pipe or cigar use [39, 61, 70, 71]. In a study of 526 cases versus 2153 controls, 
Alguacil reported a 40% increased risk for pancreatic cancer with the regular use of 
smokeless tobacco. These data demonstrated an apparent trend in increasing risk with 
increasing exposure, however, this did not reach significance [70].  
Further to exposure through cigar and pipe smoking, tobacco use in water pipes, which is 
increasing in China, India, Pakistan and the Middle East, has only been evaluated by one 
case control study to date [42]. In this study of 194 cases and matched controls, a 
significantly increased risk for the development of pancreatic cancer was seen in sub groups 
of long term smokers, with additional non cigarette tobacco use. In those of greater than 30 
years duration of cigarette smoking, a vastly increased risk was seen in those using non-
cigarette tobacco products such as water pipes, than those who exclusively smoked 
cigarettes (OR 11.6 [95% CI 3.8-35.5] and OR 4.3 [95% CI 1.7-11.2] respectively) [42]. 
However, in isolation this relatively small case control study does not provide sufficient 
evidence to substantiate a link between alternative tobacco use and pancreatic cancer. 
28 
 
In addition to the risk posed by direct tobacco exposure, particularly through cigarette 
smoking, the risk conferred through indirect or passive exposure has also been examined by 
a number of authors [40, 42, 44, 72]. Evidence remains inconsistent regarding the role of 
passive smoking in the aetiology of pancreatic cancer, despite the suggestion of an 
increased risk in a number of case control studies [40, 42, 71, 72]. Results from a large US 
cohort did not demonstrate any associated increase in risk [48]. Interestingly, in a recent 
large US cohort of women, Bao et al [73] concluded that maternal smoking significantly 
increased the risk of pancreatic cancer, whereas paternal smoking did not exert such an 
effect (RR 1.42 [95% CI 1.07-1.89] vs RR 0.97 [95% CI 0.77-1.21]) [73]. This remains elevated, 
although not significantly so, when the analysis is limited to never smokers. From their 
results, Bao et al hypothesised as to the presence of a potential in-utero effect of passive 
smoking. Passive smoking in adult life was not associated with any increased risk in this 
86,673 female cohort [73].  
1.2.3 Molecular changes associated with smoking and implicated in PDAC 
 
The influence of smoking in the mutagenesis of genes including CDKN2A methylation, K-
RAS2, TP53 and DPC/SMAD4 which have been implicated in pancreatic carcinogenesis is, as 
yet, unproven. The exact mechanism of tobacco smoke derived carcinogens in the 
precipitation of pancreatic carcinogenesis has yet to be fully understood. There is 
established evidence to indicate the influence of tobacco smoking in the aetiology of 
pancreatic cancer, as cigarette use is implicated as the causative agent in approximately 
25% of cases [33, 35, 56].  
Despite this, the molecular changes which precipitate pancreatic carcinogenesis in smokers 
remain poorly understood and the influence of tobacco derived carcinogens upon 
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alterations in the main genes discussed above is still not established. When examining a 
potential relationship between K-RAS2 and smoking in the aetiology of pancreatic cancer, 
evidence is conflicting. In an analysis of 109 incident cases of pancreatic cancer, Crous-Bou 
reported that the tobacco derived carcinogenic nitrosamine 4-methylnitrosamino-1-(3-
pyridyl)-1-butanone (NNK) had the potential to exert genotoxic effects, in terms of inducing 
point mutations in K-RAS2 [74]. K-RAS2 mutations have been demonstrated to occur at a 
relatively early stage in the process of pancreatic carcinogenesis, as discussed above and 
have been seen in association with pancreatic cancer following NNK exposure in animal 
models [75]. However, from their series of cancer cases, Crous-Bou et al concluded that 
there was no significant association between smoking and K-RAS2 mutations in pancreatic 
adenocarcinoma. In fact, those patients with K-RAS2 mutations were less likely to be ever 
smokers than those with wild-type K-RAS2. K-RAS2 mutations in those smoking >48 pack 
years was associated with an OR of 0.14 (95% CI 0.02-1.59) whereas the OR in those having 
smoked <28 pack years was 0.81 (95% CI 0.03-8.94) [74]. These results did not reach 
significance. However, they have been used to suggest an inverse association between 
tobacco exposure and K-RAS2 mutations in pancreatic cancer cases.  
Nevertheless, the compelling evidence seen implicating tobacco related carcinogen 
exposure with K-RAS2 mutations in pancreatic cancer in animal models has been replicated 
by some studies in humans. Early evidence from Hruban et al found an increased frequency 
of K-RAS2 mutations in 86% of current smokers versus only 68% of non-smokers (p=0.046) 
[75]. More recent evidence from a 2007 series of 83 pancreatic adenocarcinoma patients 
provides further evidence in support of such an association. Jiao et al reported a significant 
association between regular and heavy smoking (>36 pack years), and point mutations in 
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codon 12 of K-RAS2 (p=0.003) [76]. In this series, there was no demonstrable association 
between tobacco exposure and CDKN2A mutations or hypermethylation [76]. Further 
earlier series by Malats et al in 1997 [77] and Berger in 1999 [78] have also proposed a 
relationship between smoking and K-RAS2 mutations. However, 2009 evidence from the 
Johns Hopkins group following sequencing of >750 million base pairs of 39 genes in 114 
pancreatic cancer patients, concluded that there was no significant difference seen in the 
frequency of K-RAS2 or CDKN2A mutations in ever smokers [35]. This group also analysed 
the presence of TP53 mutations in an ever, versus never, smoking cohort. The results 
demonstrated the presence of TP53 mutations in 50/64 (78%) of the ever smoking cohort 
compared to 44/50 (88%) never smokers, these results were not significant, so do not 
constitute evidence for an inverse trend [35].  
Despite the most recent evidence from the Johns Hopkins group, refuting an association 
between smoking and the key genetic changes seen in pancreatic carcinogenesis, there 
were a significantly elevated number of mutations seen in the ever smoking group [35]. 
Smokers reportedly exhibited a mean number of 75.5 mutations per tumour, as opposed to 
the 56.2 mean mutations seen per tumour in non-smokers. From this, it was therefore 
concluded that the mechanism of tobacco derived carcinogens in pancreatic carcinogenesis 
is not driven by any influence upon the major genes. Indeed, when K-RAS2, CDKN2A, 
SMAD/DPC4 and TP53 were excluded from the analysis, an increased mean number of 
mutations were consistently demonstrated in ever smokers [35]. This report followed an 
earlier US study in 550 pancreatic cancer cases by Slebos, which did not identify any 
increased frequency of K-RAS2 or TP53 mutations in ever versus non-smokers [79].  
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Hence, it can be seen that the evidence supporting a role for tobacco related carcinogens in 
influencing the major genes involved in pancreatic carcinogenesis remains inconsistent. 
Therefore, in order to determine the mechanism of pancreatic carcinogenesis precipitated 
by tobacco derived carcinogens, research into other potential molecular changes which may 
influence this pathway is required. A better understanding of the type of mutation events 
expected will assist greatly in this; for example, the types of mutation expected to result 
from free radicals ingested through tobacco smoke.  
Tobacco smoke contains carcinogens such as aromatic amines and nitrosamines, which 
generate oxygen free radicals. Several authors have hypothesized that single-nucleotide 
polymorphisms (SNPs) in tobacco carcinogen-metabolising enzymes may arise through the 
action of oxygen free radicals [80-82]. It is proposed that this may influence pancreatic 
carcinogenesis, by altering the direct effect of tobacco derived carcinogens, or influence the 
pro-inflammatory oxidative effect which tobacco constituents exert. Hence, increasing 
pancreatic cancer risk [80]. An example of one such carcinogen-metabolising enzyme is 
cytochrome P-450. Cytochrome P-450 encodes for arylhydrocarbonhydroxylase (AHH) which 
is an enzyme involved in the activation of tobacco related precarcinogens, for example, 
polycyclic amines, aromatic amines and nitrosamines. Such activation is usually via a 
mechanism of N-hydroxylation catalyst by hepatic cytochrome P-450 [80, 81]. SNPs in the 
cytochrome P-450 (CYP1A1) gene encoding for AHH have been inconsistently associated 
with an increase in risk for the development of several cancers in Asian populations [82].  
 In a study including 309 pancreatic cancer cases, there was a non-significant increased risk 
for the development of pancreatic cancer seen in an African-American subgroup of 26 
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patients, but no increase seen in Caucasian individuals (OR 1.4 [95% CI 0.42-4.6]), in 
association with mutations in cytochrome P4501A1 (CYP1A1) [80].  
Evidence from Li et al makes a more compelling case to support a role for cytochrome P-450 
in the aetiology of smoking related pancreatic cancer. In a majority Caucasian cohort, SNPs 
in CYP1A2 in ever smokers were associated with an OR of 1.6 (95% CI 1.0-2.7) compared to 
never smokers [83]. A significantly elevated risk was seen in female ever smokers, with a 3 
fold increased risk of pancreatic cancer (95% CI 1.5-7.6) [83]. A similar apparent hormonal 
modulation of risk was seen in a further study by Suzuki et al, who recorded an elevated OR 
of 4.36 (95% CI 2.15-8.84) in a female subgroup who had smoked >20 pack years [81]. This 
has led to the hypothesis of gender related risk factors acting synergistically in influencing 
risk in subgroups of female heavy smokers. 
In addition to the increased risk of pancreatic cancer seen in smokers with cytochrome P-
450 mutations, aberrant genes encoding for enzymes which are involved in the 
detoxification of aromatic amines and nitroamines have also been implicated in the 
aetiology of smoking related pancreatic cancer. One example is that of N-acetyltransferase 
(NAT). There are two human NAT isoenzymes; NAT 1 and 2. NAT1 is expressed in all tissues, 
including the pancreas and NAT2 is specific to the liver and gastrointestinal tract [81]. There 
is limited evidence to suggest that SNPs in NAT1 confer an approximate 1.5 fold increased 
risk for the development of pancreatic cancer in heavy smokers, although no significant 
association has been identified for NAT2 [81, 83]. It is hypothesised that SNPs in NAT1 cause 
such a modification of risk in smokers via alteration of the detoxification of tobacco derived 
aromatic amines and nitrosamines. 
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SNPs in a number of other recognised carcinogen-metabolising enzymes have also been 
proposed in the aetiology of smoking related pancreatic carcinoma. Glutathione S-
transferases (GSTs) are a group of phase II isoenzymes which are involved in protection of 
cells from reactive chemical intermediates and from oxidative stress as a result of exposure 
to carcinogens including tobacco related toxins. Their mechanism of action is as a catalyst in 
the addition of reduced glutathione to reactive chemicals including tobacco smoke derived 
carcinogens.  Homozygous deletions in GST genes may be associated with lack of this 
enzyme and result in increased cytogenetic damage [84]. Studies aiming to determine the 
significance of SNPs in genes encoding for GSTs have thus far yielded inconsistent results. In 
a series of 309 cases versus 964 control subjects, Duell reported an association between 
heavy tobacco use and GST homozygous deletions in increasing the risk of pancreatic cancer 
[80]. In a small Asian population subgroup, this study recorded a 2 fold increased risk for the 
development of pancreatic cancer, independent of smoking [80]. When analysis of the large 
Caucasian cohort (261 cases, 890 controls) was undertaken, an apparent synergistic 
relationship was seen between heavy cigarette use and GST null genotypes, in certain 
groups. When a subgroup of Caucasian female smokers of > 40 years duration were 
considered, an OR (adjusted for age and sex) of 7.2 (95% CI 2.2-23.1) was recorded [80]. This 
evidence, therefore, supports an association between GST null phenotypes and cigarette 
smoking in the aetiology of pancreatic cancer. However, later data concerning this apparent 
relationship contradicts the earlier findings by Duell. Jiao et al analysed the same association 
in a US cohort of 352 pancreatic cancer patients, and did not identify any GST genotype-
smoking interaction [84]. It is therefore too early to glean any significance from this 
apparent association between deletions in the GST gene and smoking. This conclusion, or 
lack thereof, may also be drawn in relation to other carcinogen-metabolising genes. 
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Inconsistent evidence also exists as to the significance of SNPs in homologous 
recombination repair genes. One such example is the x-ray cross-complementing group of 
proteins (XRCC). This group of proteins participate in homologous DNA repair in response to 
double-strand DNA breaks, as a result of oxygen free radical action. Impairment of 
homologous recombination results in genetic instability which may precipitate 
carcinogenesis. Limited evidence from three studies has alluded to an increased risk of 
pancreatic cancer in those with XRCC1 [85], XRCC2 [86, 87] and XRCC3 [86, 87] mutations. It 
has been proposed that this effect is significantly increased by concurrent heavy tobacco 
use. Data from Jiao et al published in 2008, identified a significant trend (p=0.05) for 
increasing risk with increasing cigarette consumption. The OR in the subgroup of patients 
who had smoked <22 pack years was 1.43 (95% CI 0.59-3.48) compared to 3.42 (95% CI 
1.47-7.96) in those having smoked >22 pack years [86]. 
Hence, it can be seen that there is limited evidence to support a role for SNPs in carcinogen-
metabolising genes in the aetiology of smoking related pancreatic cancer. At present, due to 
the paucity of data available, no definite conclusions can be made. More work needs to be 
undertaken to confirm which polymorphisms may be associated with smoking related 
pancreatic carcinogenesis. The further understanding of such polymorphisms, and their role 
in cancer development, will provide an important opportunity for health education and 
reduction of pancreatic cancer risk.  
 
1.2.4 Obesity and elevated body mass index as risk factors for PDAC 
 
Over recent years, an increasing body of evidence has grown in support of a causal 
association between obesity and pancreatic cancer. In a recent meta-analysis of 21 studies, 
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encompassing 8062 pancreatic cancer cases, an increase in RR of 1.12 (95% CI 1.06-1.17) 
was seen with each 5 kilogram per metre2 (kg/m2) increase in body mass index (BMI) [88]. 
This positive association between increasing BMI and pancreatic cancer was demonstrated 
in both males and females. 
Additional large cohort studies undertaken in Korea [89], Austria [90], Sweden [91] and the 
US [92-94] have recorded similarly elevated risk in association with increasing BMI. 
Estimations of risk vary between cohorts, from a modest association (RR 1.20 [95% CI 1.07-
1.33] p=0.001) seen in white US male veterans with BMI greater than 35 [94], to a greater 
than 2 fold elevation in risk, recorded in an Austrian cohort of 145000 individuals with  BMI 
of over 30 (RR 2.34 [95% CI 1.17-4.66] p=0.02) [90].  
 
1.2.5 Alcohol as a risk factor for PDAC 
 
Many authors have attempted to quantify the relationship between alcohol consumption 
and PDAC [34, 39, 54, 71, 88, 95-97] with varying conclusions. Currently, there is no 
consistent evidence supporting a causal relationship between alcohol consumption and risk. 
However, a small number of series have demonstrated significantly increased risk in certain 
subgroups of their analyses [54, 71, 96-98]. In their large cohort of 470,681, Jiao et al 
identified a significant increase in risk in those consuming more than 3 drinks, or 40g of 
ethanol per day (RR 1.45 [95% CI 1.17-1.80] p=0.002) [96]. This risk was further amplified 
when considering the consumption of heavy liquor (RR 1.62 [95% CI 1.24-2.10] p=0.001) 
[96]. These findings have been replicated in a number of case-control series. Most notably, 
in their 2010 study of 326 cases versus 652 controls, Talamini et al demonstrated a 
progressive increase in risk with rising increments of alcohol consumption. Those individuals 
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consuming more than 35 alcoholic beverages per week were reported to have a significantly 
increased risk for the development of PDAC than those consuming 7 drinks or less (OR 3.42 
[95% CI 1.79-6.55] p=0.01) [97]. In a further case-control series, Suzuki et al reported a 
moderate increase in RR in those consuming high levels of alcohol (OR 1.90 [95% CI 1.00-
3.62] p=0.036) [98]. Despite this failing to reach significance, Suzuki identified an apparent 
association between PDAC and alcohol consumption in accordance with certain SNPs. Suzuki 
hypothesises that SNPs in one-carbon metabolising enzymes, and their repercussions on 
folate metabolism, may exert some influence upon risk. It is proposed that such 
polymorphisms influence DNA methylation. In combination with high alcohol intake, it is 
suggested that these SNPs may result in alterations to protooncogenes and tumour 
suppressor genes [98]. In their analysis of 157 cases and 785 controls, Suzuki et al identified 
an apparent trend between SNPs in methylene tetrahydrofolate reductase (MTHFR), 
methionine synthase (MTR) and methionine synthase reductase (MTRR) and alcohol 
consumption in PDAC risk. The subset of individuals with MTHFR 677 CC genotype who 
consumed high levels of alcohol were found to have a significantly elevated risk of PDAC (OR 
4.50 [95% CI 1.44-14.05] p=0.008) [98]. A trend for increased risk in association with high 
alcohol consumption was also reported in those with genotypes MTR AA and MTRR 66 G 
[98]. However, these findings have not been consistently replicated [99, 100]. 
In addition to the potential increased risk conferred by SNPs in MTHFR and MTRR, some 
studies have identified a possible association between PDAC and SNPs in the alcohol 
metabolising genes: alcohol dehydrogenase (ALDH2) and aldehyde dehydrogenase (ADH) 
[101]. In a series of 160 cases and 800 controls, Kanda et al reported a significant increase in 
risk in polymorphisms of ADH1B, in the subset of patients consuming greater than 30g of 
alcohol per day (OR 2.99 [95% CI 1.39-6.44] p=0.005) [101]. The group also demonstrated 
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non-significant associations between SNPs in ALDH2 and ADH1C and heavy alcohol intake 
with the development of PDAC, with p values of 0.284 and 0.020, respectively [101]. Despite 
this limited body of evidence, there is no consistent data in support of a causal relationship 
between alcohol and PDAC. 
 
1.2.6 Diabetes mellitus as a risk factor for PDAC 
 
Evidence surrounding the role of diabetes in the aetiology of pancreatic adenocarcinoma 
remains controversial. At the time of writing, opinion remains divided as the cause or effect 
relationship between diabetes and pancreatic cancer. In the first large meta-analysis 
examining this association, Everhart et al concluded that individuals with a longstanding 
diagnosis of diabetes were at increased risk for the development of pancreatic cancer [102]. 
A total of 20 case control and cohort studies were included in the analysis. The key criterion 
for inclusion in the analysis was that study data should be derived from pancreatic cancer 
cases, with diagnoses of diabetes of greater than 1 year duration.   Results from the meta-
analysis concluded that those with diabetes of five years or greater duration had an increase 
in RR for pancreatic cancer (RR 2.0 [95% CI 1.6-2.8]) [102]. This evidence supports a causal 
association between diabetes and pancreatic cancer. 
A number of large cohort studies analysing this association have been undertaken in 
different worldwide populations [36, 38, 64, 103-111]. The majority of these large cohort 
studies have reported an elevated RR of between 1.44 [107] and 2.48 [64]. Despite this, 
there is considerable variation in the methodology of these studies with regard to 
mechanism of diagnosis of diabetes. More specifically, self-reported history, versus fasting 
glucose or glucose tolerance testing; and in duration of follow-up. Use of fasting glucose 
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levels, or glucose tolerance testing, provides accurate evidence for a formal diagnosis of 
diabetes, and is therefore preferable; as compared to self-reporting diagnoses which may 
lead to considerable bias. Those cohort studies in which the author undertook fasting 
glucose measurement, or glucose tolerance testing, to confirm the diagnosis of diabetes [64, 
103, 108-113], demonstrated a consistently elevated RR. Albeit, over variable durations of 
follow-up. The majority of studies, including two meta-analyses [102, 114], support a 
modest causal relationship between diabetes and pancreatic cancer. In the more recent 
meta-analysis by Huxley et al, conflicting conclusions are drawn following their analysis of 
17 cohort and 19 case control studies. The combined OR for all included studies was 1.83 
(95% CI 1.66-1.99) [114]. However, in analysis of risk variation with duration of diabetes, the 
group found that those with a five year or more history of diabetes had a significant 50% 
reduction in risk, compared to those with a shorter duration of diabetes (RR 1.5 versus 2.2 
p=0.005) [114]. Their evidence, therefore, supports the theory that diabetes may be the 
reflection of an early manifestation of the disease, rather than any causal association. 
However, data from those individuals with diabetes of five or more years standing, still 
exhibit an increased RR of 1.5 (95% CI 1.3-1.8) [114]. This, therefore, supports a modest 
causal association, as a diagnosis of diabetes greater than five years prior to that of 
pancreatic cancer is unlikely to reflect an early manifestation of a tumour, given overall 5 
year survival of approximately 5%. 
Despite largely historical evidence pertaining to diabetes as a manifestation rather than 
cause of pancreatic cancer [115-117], evidence accumulated to date appears to support a 
causal association between diabetes and pancreatic cancer.  
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1.2.7 Chronic pancreatitis as a risk factor for PDAC 
 
Definitive evidence for the role of chronic pancreatitis in the aetiology of PDAC was 
established by Lowenfels [37] et al in their 1993 multi-centre cohort study of 2015 
individuals with chronic pancreatitis. At 10 and 20 years of follow-up, an elevated 
cumulative risk of 1.8% (95% CI 1.0-2.6%) and 4.0% (95% CI 2.0-5.9%), respectively, was 
reported in this cohort, with a standardised incidence ratio of 14.4. This association has 
been replicated in a number of other studies across different patient populations. In their 
series of 420 Chinese chronic pancreatitis patients, Wang et al reported a 27.2 fold increase 
in expected incidence of PDAC [118]. In a further Czech series of 223, Dite et al reported 
PDAC development in 4.5% of the subset of individuals with alcohol related pancreatitis 
[119]. However, it should be noted that both studies included relatively small cohorts. 
Nevertheless, chronic pancreatitis is regarded as an established risk factor for the 
development of PDAC. 
Several mechanisms for the role of chronic pancreatic inflammation in the causation of 
PDAC have been proposed. Pancreatic carcinogenesis has been described as a series of 
specific molecular and cellular changes. Such changes are described later in this work and 
include alterations to certain oncogenes and tumour suppressor genes, which give rise to 
the development of cellular atypia. Mutations in the proto-oncogene, K-RAS2, are well 
described in pre-cursor lesions and have been consistently identified in PDAC [120]. 
However, work undertaken by a number of groups, including our own, have also recorded 
alterations in K-RAS2 in association with chronic pancreatitis [121]. This has led to the 
proposal of chronic inflammation as a predisposing factor to the development of pancreatic 
dysplasia [122]. 
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Explanation for the cellular atypia resulting from inflammation has been proposed by 
several authors, and centres on the role of free radicals.  The influx of leucocytes at the site 
of inflammation results in increased oxygen uptake, and subsequently, the release of free 
oxygenated species. Examples of such products include hydroxyl radicals and nitric oxide 
(NO). Furthermore, NO, may react with nitrate (NO-3) and nitrite groups (NO
-
2) to form 
peroxynitrite (ONOO-) [123, 124]. These products display oncogenic potential inducing DNA 
damage through impairment of cellular repair mechanisms and promotion of angiogenesis.   
 
1.2.8 ABO group and cancer risk 
 
ABO blood group antigen expression has long been associated with cancer development and 
risk. In 1953, Aird et al identified a positive association between blood group A and 
protective effect of blood group O in gastric cancer [125].  
The antigenic structure of the ABO group is derived from the ABO gene encoding for 
glycosyltransferase. Glycosyltransferase catalyses transfer of different amino acids onto the 
H antigen. A and B alleles differ in amino acid sequence, and so will catalyse the transfer of 
different proteins onto the H antigen, resulting in blood groups A and B. In the case of blood 
group O, there is no antigenic expression due to the presence of a single base deletion. The 
absence of any AB antigens has been demonstrated to confer a protective effect against 
cancer. Early work into such an association between the AB antigen and pancreatic cancer 
found that there was an increased frequency of deletions in A,B and H antigens and 
increased incompatible expression of A and B antigens seen in association with this 
malignancy [126].  
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It has been hypothesized that expression of the different ABO groups may confer variable 
risk for cancer development due to an observed effect upon tumour necrosis factor α 
(TNFα). In a genome analysis encompassing 496,032 SNPs across 1200 individuals, 
polymorphisms in the ABO gene were found to correlate with serum TNFα levels. Those of 
blood group O were found to have higher serum TNFα. It was proposed that this 
phenomenon may explain the potential protective effect seen in blood group O. However, 
this association was only consistently demonstrated using one assay [127]. 
A genome wide association study (GWAS) in 2009 undertook genotyping of 558, 542 SNPs in 
1896 individuals with pancreatic cancer and 1939 controls [128]. An association between 
the first intron of the ABO gene, located on the q arm of chromosome 9, and pancreatic 
cancer was reported. Analysis across different blood groups identified an increased risk for 
the development of pancreatic cancer associated with blood groups A and B, as compared 
to O [128, 129]. It is again hypothesized that this association may be attributable to the 
apparent relationship between this locus and circulating TNF-α level. 
1.3  Molecular pathogenesis in PDAC 
 
Carcinogenesis is a multistep process in which a number of genetic aberrations occur 
through damage incurred during DNA replication, or following exposure to a chemical 
carcinogen. Mutations in protooncogenes, oncogenes, tumour suppressor and DNA repair 
genes accumulate within a cell and result in uncontrolled cell proliferation [130]. 
 1.3.1 Molecular pathogenesis – K-RAS2 in PDAC 
 
There is evidence to suggest that K-RAS2 mutations occur early in the pathway of 
carcinogenesis. In one study from the Johns Hopkins group, mutations in the K-RAS2 
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protooncogene have been identified in 36%, 44% and 87% of pancreatic intraepithelial 
neoplasia (PanIN) I, II and III lesions respectively [120]. 
1.3.2 Molecular pathogenesis – CDKN2A and CDKN2A methylation in PDAC 
 
CDKN2A (the gene encoding p16 protein) is a cell cycle regulatory gene which may be 
inactivated by mutations or deletions, or through methylation of CDKN2A promotor gene. 
Inactivation of CDKN2A is seen in approximately 85-90% of pancreatic cancers [131, 132], 
via homozygous deletion of both alleles in 40%, by intragenic mutation in a further 40%, and 
by hypermethylation of CDKN2A promoter in 15% [120]. Evidence for its inactivation at an 
early stage in the process of carcinogenesis, is provided in the frequency at which it is seen 
in PanIN precursor lesions. Loss of p16 has been identified in approximately 31% of PanIN Ia 
and 44% of PanIN Ib lesions [133], so suggesting that it is a relatively common and early 
event in the stepwise progression of pancreatic carcinogenesis [133, 134]. 
 
1.3.3 Molecular pathogenesis – TP53 in PDAC 
 
TP53 is a tumour suppressor gene which is mutated in 50-75% of pancreatic 
adenocarcinomas [133]. TP53 mutation has been found to occur relatively late in the 
pancreatic carcinogenesis pathway. Evidence from the Johns Hopkins group, determining 
the frequency of TP53 mutations in PanIN lesions, reported that 57% of 7 PanIN II lesions 
demonstrated a mutation of the TP53 tumour suppressor, whilst none of the 48 PanIN I and 
II lesions included in the analysis demonstrated a TP53 mutation [133]. 
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1.3.4 Molecular pathogenesis – SMAD4/DPC4 in PDAC 
 
Similarly, mutations in the SMAD/DPC4 tumour suppressor gene and BRCA2 DNA repair 
gene occur as a late event in the progression of molecular changes towards pancreatic 
cancer [133]. SMAD/DPC4 is a tumour suppressor gene which is a member of the 
transforming-growth factor ß family. SMAD/DPC4 becomes inactivated by homozygous 
deletions or through somatic mutation, with subsequent loss of heterozygosity in 
approximately 55% of pancreatic adenocarcinomas [133]. 
1.4 Precursor lesions in PDAC 
 
A number of specific precursor lesions have been identified in the progression to pancreatic 
carcinogenesis, and present a similar theory to that of the adenoma-carcinoma sequence 
established in colorectal carcinoma [135]. Recognised premalignant lesions of the pancreas 
were recently formally classified by the World Health Organisation (WHO) [136]. These 
include established precursor entities such as PanIN, intraductal papillary mucinous 
neoplasms (IPMN) and mucinous cystic neoplasm (MCN) lesions [137]. In addition, the WHO 
classification detailed a new premalignant entity: intraductal tubular papillary neoplasms 
(ITPN)[137]. Attention has focused upon the recognition and treatment of these four non-
invasive precursors, in an effort to prevent progression to the development of PDAC and the 
conferred poor prognosis. 
1.4.1 Pancreatic Intraepithelial Neoplasia (PanIN) 
 
PanIN lesions, graded I-III, are recognised as PDAC precursor lesions and increasing grade 
signifies progression of the cell towards carcinogenesis [138]. Evidence supporting this 
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theory is demonstrated by the appearance of PanINs around invasive cancers on histological 
reporting. In addition, the morphological changes exhibited in PanIN lesions of increasing 
grade are mirrored by specific molecular genetic changes, which further substantiates the 
role of PanINs as premalignant lesions [138]. Each grade of PanIN, and their associated 
cellular atypia, is associated with inactivation or activation of specific tumour suppressor 
genes, or oncogenes, respectively. PanIN I lesions are characterised morphologically by the 
presence of elongated mucin producing cells. Progression of this cellular atypia leads to the 
formation of PanIN II lesions. PanIN II lesions exhibit increased nuclear size and loss of 
polarity. The progression of these features indicates inactivation of the tumour suppressor 
gene CDKN2A [134]. PanIN III lesions are characterised by the budding off of cells into the 
ductal lumen and are associated with mutations in K-RAS2, CDKN2A and TP53 genes [139]. 
1.4.2 Intraductal Papillary Mucinous Neoplasms (IPMN) 
 
IPMN has been defined in the recent WHO classification as: ‘an intraductal grossly visible 
(typically > 1.0cm) epithelial neoplasm of mucin-producing cells’ [136]. The incidence of 
IPMN is difficult to quantify as they are frequently asymptomatic and present as an 
incidental finding following radiological investigation for unrelated symptoms or conditions. 
Alternatively, they may present with pain in association with pancreatitis, jaundice, weight 
loss or pancreatic insufficiency [140, 141]. IPMN predominantly affect males and occur at a 
mean age of 66-68 years [135, 141].  
It is estimated that 70% of IPMNs occur in the head of the pancreas and account for 
approximately 20% of resected cystic lesions [135]. Macroscopically, IPMN are characterised 
by segmental dilatation of the affected ductal branch by 5mm or greater. There are 2 main 
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recognised subtypes; namely: main branch, which arise from the main pancreatic duct, and 
side branch IPMN. There may be both subtypes present indicating a ‘mixed’ type [137]. 
Histologically, IPMN are composed of an intraductal proliferation of mucin-producing 
columnar cells and can be categorised as gastric, intestinal, pancreaticobiliary or oncocytic 
in type [140]. IPMN are further characterised as having features of low, intermediate or high 
grade dysplasia. Each of which is associated with specific cellular changes. Low grade 
dysplasia is typified by a single layer of columnar epithelial cells, with minimal cellular 
atypia. Intermediate grade demonstrate nuclear aberrances including enlargement and 
nuclear pleomorphism and high grade dysplasia is characterised by marked atypia. This 
encompasses significant nuclear polymorphism, loss of cellular polarity and budding off of 
neoplastic cell clusters [64]. 
IPMN are established precursor lesions to PDAC and the prevalence of invasive malignancy 
varies dependent upon site. In their series of 208 resected IPMN, the Johns Hopkins centre 
identified that 64% of main branch IPMN were seen in association with invasive malignancy, 
compared to 38% of mixed and 18% of side branch lesions (p=0.001) [141]. The variable risk 
of invasive malignancy associated with different subtypes is reflected in the International 
consensus guidelines for the management of IPMN published in 2006 [142]. In their review 
of data, Tanaka et al reported the frequency of malignancy in main branch IPMN to range 
from 60-92% compared to 0-31% side branch IPMN [142]. In light of the significant increase 
in associated malignancy, the consensus view was that resection should be offered to 
individuals with main branch IPMN who are deemed fit to undergo surgical intervention. It 
was concluded that resection of side branch IPMN is indicated in lesions greater than 30mm 
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and in those who are symptomatic, as these factors were associated with an increased 
likelihood of malignancy [142].  
The cellular atypia seen in IPMN reflects underlying molecular changes across all grades of 
dysplasia. The molecular changes seen in the development of PDAC have been identified in 
IPMN. K-RAS2 mutations have been reported in up to 80% of IPMN, with increasing 
frequency in association with high grade dysplasia [137]. More specifically, in their sequence 
of 52 IPMN, through the application of laser capture microdissection, Chadwick et al 
reported K-RAS2 mutations in 86% (6/7 cases) of IPMN of pancreaticobiliary type and 84% 
(16/19 cases) of gastric type [143]. These represented the lesions with the highest 
frequency of K-RAS2 mutations.  These findings have been substantiated by other groups 
[144]. Different subtypes of IPMN in the pancreas have distinct pathways to pancreatic 
cancer progression. Mutations in CDKN2A and TP53 have also been described in IPMN of 
high grade dysplasia [137]. 
1.4.3 Mucinous cystic neoplasms (MCN) 
 
The 2010 WHO classification defined MCN as ‘a cyst forming epithelial neoplasm which does 
not communicate with the pancreatic ductal system and is composed of columnar mucin-
producing epithelium associated with ovarian type subepithelial stroma’ [136]. MCN 
account for 2-5% of pancreatic neoplasms and occur exclusively in perimenopausal women 
of mean age 40-50 years [145-147]. Such lesions are almost universally located in body or 
tail of the pancreas and typically present at a large size. In their series of 130 cases, 
Thompson et al recorded an average size of greater than 10cm at presentation [146]. The 
large size of MCN at presentation was further confirmed by Yamao et al  in their later series 
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of 156 cases which reported an average size of 65.3mm [145].  In view of their size at 
presentation, the commonest presenting symptoms are of abdominal pain, weight loss, 
vomiting and diarrhoea [137, 146]. This symptomatology is associated with a palpable 
abdominal mass in 5-10% [137, 146]. Despite the large size commonly seen at presentation 
causing the clinical features listed; approximately 10-30% of MCN present as incidental 
findings on imaging undertaken for an unrelated clinical indication in the absence of any 
signs or symptoms [137]. MCN may be seen in association with other pancreatic or biliary 
conditions, such as pancreatitis; cholelithiasis; diabetes mellitus and neuroendocrine 
tumours [137, 145]. 
Macroscopically, MCN are typically characterised by multiple loculations within a thick 
capsule. Foci of calcification may be seen within the capsule [135, 137, 146]. One important 
characteristic in differentiating MCN from IPMN, is communication with the pancreatic duct. 
IPMN, by definition, are in communication with either the main duct or side branch. It has 
been proposed by some authors that the presence of such communication between cystic 
lesions and ductal structures is not consistent with MCN [147]. More recent series have, 
however, concluded that a proportion of MCN may communicate with the pancreatic duct. 
In their series of 156 cases, Yamao et al reported communication with the pancreatic duct in 
18.1% of MCN assessed [145]. It has been proposed that the phenomenon of apparent 
communication with the pancreatic duct may occur as a result of erosion of the cyst wall 
into an adjacent ductal structure; thus, forming a fistula rather than a lesion of true 
intraductal origin [135, 137, 145]. 
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1.4.4 Screening for precursor lesions 
  
The role of precursor lesions in the development of pancreatic carcinogenesis is established. 
Specific molecular changes are recognised in association with precursor lesions as discussed 
above. Those individuals with recognised precursor lesions, in the presence of specific 
molecular changes, are at high risk for the development of PDAC. Techniques which allow 
diagnosis and sampling of cyst content have been utilised to identify those at high risk. 
Molecular analyses, in association with specific imaging modalities, have proved useful in 
identifying those precursor lesions at highest risk for malignant potential. The most sensitive 
imaging modality for the detection of pancreatic precursor lesions, which also allows cyst 
fluid sampling to be undertaken, is endoscopic ultrasound (EUS). EUS involves the 
transmission of high frequency sound waves via an endoscopically placed probe in the 
stomach or duodenum [148]. It is established that certain precursor lesions may be too 
small to be identified using cross-sectional imaging techniques such as computed 
tomography (CT) or magnetic resonance imaging (MRI) [149, 150]. Of 6874 individuals 
undergoing EUS at the Johns Hopkins centre between 2006 and 2010, 486 patients were 
identified as having pancreatic cysts [150]. In the diagnosis of cystic lesions of the pancreas, 
EUS was found to confer an increase in diagnostic yield for the prediction of neoplasia in 
36% and 54% of individuals compared to CT and MRI respectively [150].   
In the specific case of IPMN lesions, the International consensus guidelines on the 
management of IPMN as outlined by Tanaka et al [142] and discussed in an earlier sub-
chapter of this thesis; EUS criteria of location, size and nodule involvement determine the 
indication for surgical intervention. More specifically, findings of a main pancreatic duct 
diameter greater than 10mm; branch duct diameter greater than 30mm, and the presence 
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of nodules, are all indicative of malignant IPMN [142]. In a series of 310 resected IPMN, 
Shimizu et al reported that branch diameter was a weaker indicator of malignancy than 
main duct diameter or the presence of nodules [151]. More specifically, the presence of 
nodules greater than 5mm in branch IPMN was found to have sensitivity and specificity of 
74.3% and 72.7% respectively [151].  
In addition to the improved diagnostic yield of EUS versus cross-sectional imaging in cystic 
precursor lesions, there is some evidence that changes seen at EUS may correlate to non-
cystic, flat PanIN lesions. The recognition of PanIN lesions has been difficult using 
conventional imaging techniques. In a series of 24 patients undergoing surgical resection of 
IPMN, Maire et al compared the histological occurrence of PanIN lesions with pre-operative 
EUS findings, independent of the diagnostic features of IPMN. As opposed to IPMN and 
MCN, PanIN lesions are more typically characterised as flat, non-invasive lesions which are 
not necessarily associated with ductal dilatation. The absence of cystic change or ductal 
dilatation in PanIN lesions has meant that their diagnosis through imaging techniques has 
proven difficult. Maire et al reported that of 24 patients with EUS changes, independent of 
concurrent IPMN, 20 had histological evidence of PanIN (83%) [149]. EUS abnormalities, 
characterised as hyperechogenic foci and microcysts, occurred in 19 (51%) and 5 (13%) of 
the cohort of 24. 20 of the individuals were identified as having PanIN lesions as described 
above. In the remaining 4 individuals in whom PanIN lesions were not identified, chronic 
pancreatitis was reported following post-operative examination of the resected specimen 
[149]. EUS also confers the advantage of obtaining samples of cyst content for cytological 
and molecular analyses to further ascertain the risk for malignant potential [149, 150]. The 
PANDA study involving centres across the US, performed molecular analyses of cyst fluid 
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across a cohort of 113 individuals with confirmed malignant and benign pancreatic cysts 
[152]. Cyst fluid obtained via EUS fine-needle aspiration (FNA) underwent molecular 
analyses. Of the 113 individuals included, 25 cysts were classified as benign, non-mucinous 
and 88 mucinous, of which 40 were found to be malignant. On DNA analysis of cyst content 
aspirated at EUS, a higher number of overall mutations were identified in the mucinous 
group. K-RAS2 mutations were associated with mucinous lesions with a specificity of 96% 
and OR of 20.9 compared to non-mucinous lesions [152]. In a smaller series of 38 mucinous 
lesions (35 IPMN and 3 MCN lesions), Al-Haddad et al defined their molecular analysis as 
total DNA quantity of greater or less than 40 nanograms per litre (ng/l) and the presence or 
absence of K-RAS2 mutations. They reported a sensitivity of 50%, specificity of 80% and 
accuracy of 56.3% of molecular analysis in the diagnosis of mucinous lesions i.e. DNA 
quantity greater than 40 ng/l and the presence of K-RAS2 mutation [153]. With specific 
regard to K-RAS2, mutation was absent in 22 of the 38 mucinous lesions assessed (58%). 
In addition to the reported diagnostic advantage conferred by analysis of DNA quantity and 
K-RAS2 mutations from cyst content aspirated at EUS, other markers have yielded promising 
results. In a multicentre series of 341 mucinous neoplasms, EUS imaging, plus analysis of 
cyst cytology and tumour markers, was undertaken by the Cooperative Pancreatic Cyst 
Study [154]. In the identification of mucinous versus non-mucinous cystic lesions, EUS 
morphology reported a sensitivity of 56.1% and specificity of 45.4% (accuracy 50.9%), and 
cyst cytology of 34.5% and 83.3% respectively (accuracy 58.7%). However, carcinoembryonic 
antigen (CEA) levels were found to have the highest accuracy of the measures evaluated 
with sensitivity of 75%, specificity of 83.6% and accuracy of 79.2% in the diagnosis of 
mucinous versus non-mucinous cystic lesions [154]. Furthermore, no combinations of the 
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measures assessed were found to confer any diagnostic advantage over CEA levels alone 
(p=< 0.0001). Further analyses of cyst CEA levels have reported similar findings. In their 
series of 38 mucinous lesions, Al-Haddad et al recorded an accuracy of 62.5% of CEA level 
[153]. In contrast to the Cooperative Pancreatic Cyst Study group, Al-Haddad et al found 
that the diagnostic accuracy of CEA levels was improved in combination with cytology and 
molecular analyses at 73% [153].  
 
1.5 PDAC: rationale for screening 
 
A diagnosis of PDAC confers a dismal prognosis. However, early detection and treatment of 
small asymptomatic tumours has been proven to yield five year survival rates of 60% [9]. A 
significant proportion of individuals diagnosed with PDAC present with metastatic disease. 
This is largely refractory to chemotherapy. It remains unclear as to whether the frequent 
advanced presentation of PDAC is attributable to early dissemination of the disease or late 
presentation. Yachida et al of the Johns Hopkins group have quantified the timing of 
pancreatic carcinogenesis. Through genome sequencing in seven PDAC patients, Yachida 
suggests an interval of at least ten years from the initiating mutation to evolution of the 
non-metastatic founder cell. Moreover, it is reported that a further 5 years are required for 
the acquisition of metastatic potential with death occurring following an additional 2 years 
[155]. This paper provides compelling evidence for a significant window of opportunity for 
the detection of pancreatic adenocarcinoma at a potentially curable stage. Therefore 
targeted screening, to individuals at elevated risk, has the potential to improve survival. 
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1.5.1 Identifying screening populations 
 
It is established that early detection and treatment of small asymptomatic pancreatic 
tumours has been proven to yield five year survival rates of 60% [9]. Therefore, targeted 
screening to individuals at elevated risk has the potential to improve survival. In order to 
identify a potential screening population, we need to define those at an elevated risk for the 
development of pancreatic cancer. Evidence supporting the role of various environmental 
and disease derived risk factors has been discussed above. Table 1 demonstrates the 
expected sensitivity (true positive rate) and specificity (false positive rate) that screening in 
smokers or those with chronic pancreatitis or diabetes would yield. Screening within these 
populations is not feasible due to the high false positive rates seen. Major surgical resection 
with significant associated post-operative morbidity is to be considered in those in whom 
screening is positive. It is therefore imperative that benign disease, or “normal” pancreata, 
is recognised as such. It appears that those with a positive family history are the most 
feasible to screen, but further risk stratification in this group is required to ensure targeted 
screening with maximum yield and minimal harm. 
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Table 1: Relative true and false positive rates expected from undertaking screening in defined at-risk populations; 
assuming sensitivity and specificity of 98% of the screening modality 
 
Smoking
Type II Diabetes (late onset)
Chronic pancreatitis
Genetic predisposition
Population
(aged over 40) Cases True +ve False +ve
If screening was 98% 
sensitive and specific
9 million 3,000 2,940 180,000
6,000 10 10 120
167,000 1600 1568 3340
? 700 686 ?200,000 4,000
 
 
1.6 Genetic predisposition to PDAC 
 
Several genetic alterations and syndromes are recognised as conferring a significantly 
increased risk for the development of PDAC. Hereditary Pancreatitis; Familial Atypical 
Multiple Mole Melanoma (FAMMM); Peutz-Jeghers; Hereditary Non-Polyposis Colorectal 
Cancer (HNPCC or Lynch syndrome) and Li Fraumeni syndromes all confer variable elevated 
risk along with certain BRCA2 mutations. FPC is characterised by an autosomal dominant 
pattern of inheritance of PDAC. The underlying genetic aberrations in FPC are not yet fully 
understood. Attempts to further understanding of FPC have led to the identification of 
additional novel genes, which confer an increase in risk, but do not sufficiently explain the 
phenomenon fully.  
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1.6.1 Familial Pancreatic Cancer (FPC) 
 
The phenomenon of autosomal dominant inheritance in pancreatic cancer was initially 
recorded anecdotally, prior to an analysis of 18 families (76 individuals), by Lynch et al in 
1990. Lynch reported a family history of PDAC in 6.7% of cases compared to 0.7% of controls 
(p=<0.001) [156]. Further quantification of risk in those with a positive family history was 
undertaken in later work by Klein et al from the National Familial Pancreas Tumor Registry 
(NFPTR). In a series of 5179 individuals from 838 kindreds, a significant elevation in risk was 
identified with increasing numbers of affected family members [157]. Those individuals with 
2 affected first degree relatives were found to have a 6.4 fold increase in risk, compared 
with SEER data. However, in those with 3 or more affected first degree relatives this risk 
increased exponentially to represent a 35 fold increase compared with expected values 
from SEER data [157]. 
1.6.2 Aetiological factors implicated in FPC 
 
FPC demonstrates incomplete penetrance. Factors influencing cancer development in FPC 
have yet to be formally recognised. The phenomenon of anticipation has been described in 
FPC. In a series of 1223 individuals from 106 FPC kindreds with 2 or more affected 
individuals, McFaul et al concluded that anticipation for the development of pancreatic 
cancer between the oldest and intermediate generations was 6 years [158]. The factors 
which influence penetrance and anticipation in FPC are not fully understood. Limited 
evidence exists as to the significance of environmental and disease exposures in the onset 
of disease in members of FPC kindreds.  
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1.6.3 Smoking and FPC 
 
Early evidence from Schenk et al in 2001, in a case-control study including 247 cases and 
1816 of their first degree relatives (FDR), identified a greatly increased risk for the 
development of pancreatic cancer in those FDR who were ever smokers, with an OR of 8.23 
(95% CI 2.18-31.07) [159]. When the risk factors of ever smoking and positive family history 
were analysed independently, results suggested that smoking may precipitate earlier age of 
onset of pancreatic cancer in those with an apparent inherited predisposition. These 
findings have been replicated in later work by a number of groups [159, 160]. However, this 
is potentially a result of recall bias and, in previous reports from EUROPAC, no influence of 
smoking was recorded [158]. Furthermore, it is notable that given autosomal dominance, 
previous reports indicating 100% smoking habit in affected individuals and less than 50% 
habit in their unaffected FDR would suggest that carriers are characterised by a 
predisposition for smoking, rather than a greater susceptibility for cancer if they smoke 
[161]. Evidence from the University of Washington group, from 251 members of 28 FPC 
families, suggested that unaffected members of FPC kindreds who smoke develop 
pancreatic cancer 10 years earlier than their non-smoking counterparts (mean age of onset 
59.6 years versus 69.1 years respectively [p=0.01]) [161]. A history of ever smoking was of 
particular significance in the male subgroup of patients (OR 5.2 [95% CI 2.0-13.2]) compared 
to females (OR 2.0 [95% CI 0.8-5.2]) [161]. Furthermore, 85% of those members of FPC 
kindreds who developed pancreatic cancer below the age of 50 were smokers. There was a 
gross increase in smoking associated risk in those below the age of 50 (OR 7.6 [95% CI 1.3-
43.0]). The trend for increased risk among members of FPC families who smoked was 
evident across all age ranges [161]. The most recent evidence, published in 2009, by the 
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Johns Hopkins Group concluded that smokers from FPC kindreds, who had also been 
exposed to environmental tobacco smoke below the age of 21, were diagnosed at a 
significantly younger age than non-smokers without any environmental tobacco smoke 
exposure (63.7 years versus 66.6 years respectively [p=0.05]) [162]. This trend was also 
apparent in an Ashkenazi Jewish FPC patient subgroup, in whom diagnoses in smokers were 
made 5.9 years earlier than non-smokers [162]. It can therefore be seen that, although 
evidence is limited, tobacco smoke may play a significant role in the onset of pancreatic 
cancer in members of FPC kindreds. This knowledge has important implications for health 
education and risk stratification in this high risk patient group.  
1.6.4 Diabetes and FPC  
 
There is no current evidence to support a causal relationship between diabetes and 
penetrance or anticipation in FPC kindreds. Limited evidence from the Johns Hopkins group 
has suggested an association between diabetes and pancreatic dysplasia in 10 cases from 4 
families [161]. However, it should be noted that 5 of the 10 cases with co-existing diabetes 
and pancreatic dysplasia which were included for analysis, were members of the same 
kindred, so leading to difficulty in establishing any firm conclusions for such a link [161]. 
 
1.6.5 Hereditary Pancreatitis  
 
Approximately 1% of all cases of pancreatitis have an underlying inherited cause. A number 
of genetic mutations are recognised in their association with Hereditary Pancreatitis (HP) 
and idiopathic pancreatitis. HP arises through mutations in the Protease Serine 1 (PRSS1) 
gene which transcribes for cationic trypsinogen. HP is characterised by the development of 
pancreatitis in childhood, with symptoms commonly affecting multiple generations. 
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Typically, symptoms of malabsorption and diabetes mellitus commence at a younger age in 
HP than other causes of chronic pancreatitis, and the cumulative rate of both endocrine and 
exocrine failure is higher [163]. 
In addition to the cancer syndromes which have been outlined, a significant lifetime risk of 
pancreatic cancer, estimated at 35-40% [163], is associated with HP. HP exhibits an 
autosomal dominant pattern of inheritance, with high penetrance of approximately 80% 
[164]. Localisation of the disease mutation in HP to the q arm of chromosome 7 was first 
reported by Claude Ferec and his group [164]. Later the same year, a mutation was 
identified in the PRSS1 gene by Whitcomb et al [165]. The commonest mutation of PRSS1 is 
p.R122H and constitutes a single guanine (G-) to adenine (A-) transition mutation in exon 3 
of PRSS1 which results in an Arginine (Arg) to Histidine (His) substitution at amino acid 
position 122 [165, 166]. This was initially described as R117H, in concordance with the 
chymotrypsinogen consensus numeration. The p.N29I mutation of PRSS1 is recognised as 
the second most frequent alteration of the gene. This mutation is characterised by a single 
adenine (A-) to thymine (T-) transversion in exon 2 of PRSS1. This results in a change from 
asparagine (AAC) to isoleucine (ATC) at amino acid 29 [166]. Evidence suggests that p.N29I 
and p.R122H mutations of PRSS1 are mechanistically and phenotypically similar. However, 
the third most frequently identified mutation in PRSS1, p.A16V, appears to exert a very 
variable phenotype. The p.A16V mutation is characterised by a missense mutation in exon 2 
with replacement of cytosine (C) to thymine (T), and subsequent substitution of alanine 
(GCC) to valine (GTC) at amino acid position 16 [167, 168]. 
In addition to the recognised p.R122H, p.N29I and p.A16V mutations, there are a number of 
less common alterations which have been described in association with idiopathic 
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pancreatitis. The following mutations are not considered to confer an elevated lifetime risk 
for the development of pancreatic cancer. Examples include p.R122C [169], p.N29T [169], 
p.D22G [170] and p.K23R [171] mutations. The mechanism by which mutations in the PRSS1 
gene result in the phenotype of HP is open to debate. However, it is hypothesized that 
increased activation of trypsinogen, or inactivation of protective buffers, plays a key role in 
the pathophysiology of HP [172]. Trypsinogen, the inactive proenzyme precursor of trypsin, 
is synthesized by pancreatic acinar cells, prior to secretion and activation in the small 
intestine. It is known that intrapancreatic trypsinogen activation contributes to the pattern 
of increased proteolytic activity and acinar cell damage which characterises pancreatitis 
[172, 173]. Three trypsinogen isoforms have been identified in the human pancreas; 
cationic, anionic and meso-trypsinogen. These isoforms are encoded for by the PRSS1 and 
PRSS2 genes [168, 172]. It has been hypothesised that PRSS1 mutations confer an increase 
in trypsinogen function and cause increased activation within the acinar cell [172, 173].  It is 
suggested that increased activation of trypsinogen would then trigger proteolytic activity 
and subsequent acinar cell damage [172, 173]. Whitcomb et al propose that excess trypsin 
activation within the normal pancreas causes hydrolysis of trypsinogen and trypsin so 
resulting in inactivation of trypsin [173]. This, in turn, will create a safety mechanism 
whereby the pancreas is protected from the effects of autodigestion. Whitcomb’s group 
hypothesise that, in HP, this cleavage (proposed to occur at position R117H/p.R122H – 
corresponding to the commonest site of mutation within the gene) is prevented by a 
mutation at this locus, and so there is loss of the mechanism for trypsin and trypsinogen 
deactivation [173]. Hence, those with HP may be prone to persistent pancreatic 
autodigestion and recurrent pancreatitis.  However, other groups refute this, Sahin-Toth has 
demonstrated that although rat trypsinogen, which naturally has a histidine substitution for 
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arginine at the presumed trypsin cleavage site (equivalent to p.R122H), was more resistant 
to trypsin digestion [174], the human form was not [175]. Sahin-Toth and his group went on 
to suggest that the human p.R122H and the p.N29I mutation were more likely to cause 
increased autoactivation [176].  Lerch, supported by Sahin-Toth, went on to suggest that if 
other autosomal dominant conditions are used as a model to hypothesize the effect of a 
PRSS1 mutation; alterations within the specific causative gene usually confer a loss of 
function through inheritance of a defective protein, or impairment of its intracellular 
processing. If this were the case, it would be envisaged that a mutation in PRSS1 would lead 
to a decrease in trypsinogen function, rather than the increased activation seen in 
pancreatitis [177]. Lerch identified that the multiple mutations in PRSS1 which have been 
described, occur at distinct regions of the PRSS1 gene, and hence, it is likely that each 
mutation exerts a different structural effect on trypsinogen [177]. Furthermore, Lerch and 
co-workers highlight evidence, using in vivo models, which has identified that activation of 
digestive proteases occurs independently of trypsin activity. These groups have in the past 
proposed a protective role of trypsin in defence against other, potentially more harmful, 
proteases [177].  As a caveat to this, Sahin-Toth has proposed a model whereby 
chymotrypsinogen C (caldecrin) inactivates trypsin via digestion at Leu81-Glu82, exposing 
the Arg122-Val123 cleavage site for tryptic digestion, and that p.R122H might therefore be 
of significance in reducing autodeactivation of trypsin after all [178]. Furthermore, Lerch 
and Sahin-Toth have convincingly shown that at least one PRSS1 mutation (R116C) may be 
related to pancreatitis due to induction of the misfolded protein response, and not due to 
its trypsin activity at all! [179] It can therefore be seen that the specific mechanism by which 
PRSS1 mutations lead to HP remain conjectural. However, regardless of how the mutations 
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convey their variable phenotypes, all appear to be characterised by an increased pancreatic 
adenocarcinoma lifetime risk in the region of 40% as highlighted above [163].   
1.6.6 BRCA2 mutations 
 
BRCA2 is a DNA repair gene, aberrations in which are often associated with familial 
aggregation of pancreatic cancer cases. In a study of FPC families from the European 
Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer, BRCA2 mutations were 
identified in 5 of 26 (19%) of kindreds included in the analysis by Hahn et al [180]. These 
aberrations consisted of 3 previously reported frameshift mutations, and 2 families with 
novel BRCA2 variants [180]. In a large series of 245 reportedly sporadic pancreatic cancer 
cases, Goggins et al identified 15 (27%) that had allelic loss at the 13q12 BRCA2 locus, of 
which 3 were germline mutations (6174delT and 6158insT). These mutations were identified 
in individuals with no family history of pancreatic adenocarcinoma [181]. The frequency of 
BRCA2 mutations has been found to be particularly elevated in PDAC patients of Ashkenazi 
Jewish origin. In their series of 145 patients, Ferrone et al identified BRCA2 founder 
mutations in 4.4% of an Ashkenazi Jewish cohort with pancreatic cancer, as opposed to 1.1% 
of cancer free, non-Jewish controls. This corresponds to an OR of 3.85 (95% CI 2.1-10.8 
p=0.007) [182]. It is possible that the increased risk conferred by BRCA2 mutations may be 
further augmented by co-existent low penetrance polymorphisms. Such polymorphisms in 
isolation may not confer any increased in PDAC risk, but may result in carcinogenesis in 
combination with BRCA mutations. 
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1.6.7 CDKN2A mutations – Familial Atypical Multiple Mole Melanoma (FAMMM) 
 
Germline mutations in the CDKN2A tumour suppressor gene are associated with the 
phenotype FAMMM. An increased risk for the development of PDAC as part of the spectrum 
of FAMMM was first described by Lynch and Krush in 1968 [183]. Quantitative evidence for 
the increased risk of PDAC in FAMMM was provided in later work by Lynch et al following 
segregation analysis in 4 kindreds [184]. This work identified an overall five-fold increase in 
risk for all cancers within the 4 kindreds described. In addition, an increased risk of PDAC 
was identified, but in too small a sample size to definitively prove an association. More 
substantive evidence was provided by Lynch et al in their analysis of 159 families, with an 
apparent increased risk for the development of PDAC [185]. 12% of the families analysed 
demonstrated a phenotype consistent with FAMMM. This led the authors to propose a new 
variant of the FAMMM syndrome; the FAMMM-Pancreatic Carcinoma (FAMMM-PC) 
syndrome. In a more recent series of 18 families, Bartsch et al reported a varied phenotype 
across proposed FAMMM-PC families. This has led to the suggestion that a number of 
distinct hereditary cancer syndromes may be encompassed within the umbrella of FAMMM-
PC [186]. 
1.6.8 Peutz-Jeghers syndrome 
 
Peutz-Jeghers syndrome is characterised by the development of hamartomatous polyps 
throughout the gastrointestinal tract and is associated with mutations in the STK11 tumour 
suppressor gene. Such mutations confer a lifetime cancer risk of 93% [187]. More 
specifically, risk for the development of PDAC in Peutz-Jeghers, has been estimated at 11-
32% [187]. In the case of a confirmed STK11 mutation consistent with Peutz-Jeghers, PDAC 
risk has been estimated to be as high as 132-fold increase compared to expected rates 
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[188]. However, this risk is difficult to quantify, as such individuals may often develop 
carcinoma of other gastrointestinal origin prior to their presentation with a pancreatic 
malignancy. 
There is established evidence that mutations in STK11 can predispose to the development of 
IPMN lesions. In a series of 22 IPMN, Goggins et al of Johns Hopkins, identified STK11 
mutations in 100% (2/2) individuals with phenotypic features of Peutz-Jeghers, and in 25% 
(5/20) of those without [189]. Therefore, mutations in STK11 may, in part, confer an 
increase in risk of PDAC through a predisposition to the development of precursor IPMN 
lesions. 
 
1.6.9 Hereditary Non-Polyposis Colorectal Cancer or Lynch syndrome 
 
The syndrome of Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is associated with 
germline mutations in DNA mismatch repair (MMR) genes. In addition to the established risk 
of colorectal and endometrial carcinomas, it has been proposed that HNPCC confers an 
elevated risk for the development of PDAC. Some argue that this is only true of a subtype of 
HNPCC and as a result HNPCC is subdivided into two syndromes, Lynch Syndrome I 
(colorectal and endometrial only) and Lynch syndrome II which includes other cancers [190].  
This risk has been difficult to quantify until recent evidence from Kastrinos et al [189]. In a 
series of 6342 individuals from 157 families with MMR mutations, an 8.6-fold increase in 
PDAC risk compared to the general population was reported. 
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1.6.10 TP53 mutations – Li Fraumeni syndrome 
 
Germline TP53 mutations have been found to be associated with PDAC carcinogenesis. In a 
UK series of 28 Li Fraumeni families, Birch et al recorded a moderately elevated risk of PDAC 
which reached significance (p=0.007) [191]. In an earlier analysis of 475 tumours in 91 
families, Kleihues et al recorded a frequency of PDAC of 1.3% [192]. 
1.6.11 Novel mutations – PALB2/Palladin 
 
In the quest to identify the causative gene in FPC, a number of candidates have been 
identified. Most notably, mutations in Palladin and PALB2 have been proposed as playing a 
significant role in FPC. However, consistent evidence definitively associating either gene 
with FPC remains elusive. 
A significant role for Palladin in FPC was initially proposed by the University of Washington 
group. It is hypothesised that Palladin exerts proto-oncogene characteristics; and mutations 
thereof were identified in sporadic PDAC cell lines, and tissue from one FPC kindred [193]. 
However, such an association has not been replicated in other FPC cohorts. Following 
sequencing of the coding region of Palladin in 48 FPC individuals, the Johns Hopkins group 
refuted any association with FPC [194]. Similarly, our group, through sequencing of the locus 
in 74 individuals from FPC kindreds, did not identify Palladin mutations in any of those 
analysed [195].  
More compelling evidence exists as to the role of PALB2 in carcinogenesis in FPC. PALB2 is a 
binding partner for BRCA2 and has been implicated in breast cancer families. Its association 
with FPC was initially proposed following the identification of truncating mutations in 3 of 
96 individuals from US FPC kindreds [196].  During my work towards this thesis, families I 
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recruited were included in the analysis of a European series of kindreds, furthering our 
understanding of PALB2 as a potential candidate gene. In our series of 81 European FPC 
families, sequencing of the 13 exons of PALB2 also identified 3 truncating mutations (3.7%). 
Significantly, all 3 mutations were identified in kindreds with a history of breast cancer, 
proposing a causative role for PALB2 in this particular subset of families [197]. A number of 
smaller studies in sporadic and familial pancreatic cancer individuals have not demonstrated 
any role for PALB2 [198, 199]. Despite this, PALB2 is gaining more widespread acceptance 
for its role in pancreatic carcinogenesis in a certain subset of FPC families. 
 
1.7 Secondary screening for early pancreatic cancer in high risk groups 
1.7.1 Screening centres and recruitment strategies 
 
Strategies for screening for PDAC in high risk groups have been established by a number of 
worldwide groups. Two of the first groups to offer screening in the US and Europe were the 
NFPTR of the Johns Hopkins Medical Institute, and the European Registry of Familial 
Pancreatic Cancer and Hereditary Pancreatitis (EUROPAC). In this section of my thesis, I shall 
outline the different screening techniques employed by different worldwide groups and the 
underlying rationale behind the differing strategies. Identification and recruitment of 
participants is a key determinant in ensuring that only those deemed at highest risk for the 
development of PDAC will be exposed to screening techniques, and the potential 
complications thereof. The potential risks and complications of different screening 
modalities will be discussed in detail later in this thesis. The NFPTR and EUROPAC vary in 
their recruitment approaches. The NFPTR of the Johns Hopkins Medical Institute recruit 
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families following an individual’s diagnosis of PDAC; this individual is the proband for that 
family. Inclusion on the registry requires recognition of a positive family history; family 
history in this sense meaning a FDR with pancreatic cancer. This approach is cross-sectional, 
i.e. the probands must have cancer during the very small window of the registry 
recruitment. Previous reports from the NFPTR show a highly elevated risk of prospective 
pancreatic cancer in such families [200]. However, this risk was overwhelmingly due to a 
very small number of families with a very strong family history. Only one out of 98 families 
with 2 existing cases of pancreatic cancer had a prospective cancer, in contrast one out of 
just 4 families with 5 or more cases had a prospective cancer. Clearly, family classification is 
dependent on the observer, if 2 out of 5 cases of cancer are known originally, and 3 new 
cases are subsequently identified, there has not been any change to actual cancer risk, 
merely a change to assumed cancer risk. If we accept that there are families with equivalent 
biologically defined risk in the group with 2 cases, and the group of families with 5 cases, 
this would strongly suggest that most families are random clusters, but there are fewer 
random clusters in the families with more cases [200]. EUROPAC tries to reduce the number 
of random clusters by adopting a longitudinal approach to recruiting families. This is based 
mostly on concerned healthy individuals with multiple (two or more) pancreatic cancer 
cases in their family approaching the registry. The rationale being that, recruitment on the 
basis of an affected proband can only include families where a cancer case is current. This 
will represent only a very small proportion of genuine families in any catchment zone, given 
the unfortunately short life expectancy of people diagnosed with PDAC. Clearly, if the 
proband is defined as being a pancreatic cancer patient, at least one case is already 
guaranteed in that family. The proband will know the cause of death of a certain number of 
individuals in their family (n). A conservative estimate of the probability of a second cancer, 
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assuming the null hypothesis of no genetic predisposition, will be the probability of dying 
from pancreatic cancer (in the general population) multiplied by n. In fact it will be slightly 
higher than this, bearing in mind that the proband will be highly motivated and sensitised to 
cancer compared to other causes of death. In contrast, concerned healthy individuals 
reporting to EUROPAC will be describing cancer cases dating back over a potentially 
extensive period. We believe this helps to reduce random clusters and extend the 
proportion of true FPC pedigrees that will be sampled.   
Since the advent of screening for early pancreatic cancer in high risk individuals, further 
groups have adopted differing recruitment and surveillance strategies, with variable yields 
in cancer diagnosis [201-207]. Most registries recruit participants following referral by 
Clinical Genetics departments upon confirmation of their status as high risk, or self-referral 
of concerned individuals in the knowledge of their affected family members. The 
recruitment strategy of referral, or self-presentation, of high risk families is adopted by most 
groups, rather than enrolling affected probands [201, 203-207]. 
1.8 Screening strategies in high risk groups 
 
Once a screening population has been defined and identified, strategies as to how to 
perform screening for early PDAC need to be developed. Screening centres worldwide adopt 
different protocols to optimise potential for detection of early lesions, and minimise 
potential adverse effects of any screening modality employed. Various biochemical 
parameters and imaging modalities are used in combination, in an attempt to maximise 
diagnostic accuracy.  However, such investigations will only identify detectable lesions, and 
do not confer any benefit in risk stratification, or recognition of specific individual molecular 
markers which are recognised in the pathway of carcinogenesis. Hence, more invasive 
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surveillance techniques are advocated by some groups to allow for more targeted 
stratification of individual risk. The biochemical and imaging modalities, and their relative 
sensitivity and specificity, will be considered in more detail. The International Cancer of the 
Pancreas Screening Consortium recently published data summarising screening programmes 
across a number of groups [208]. The imaging modalities utilised by each group, along with 
their diagnostic yield were summarised. A total of 12 programmes were outlined across the 
US and Europe [201-207, 209, 210]. All except two surveillance protocols have adopted EUS, 
alongside either CT or MRI, as their primary imaging modality. These two groups advocate 
the role of MRI screening as an initial imaging modality, with a view to further imaging in the 
event of a detected abnormality [206, 207]. More definitive risk stratification can be offered 
by ERCP, with the collection of pancreatic juice for analysis of molecular markers. This 
technique is offered to high risk screening cohorts by our group, and through the 
surveillance regime adopted by the University of Washington [201]. In this context, ERCP is 
undertaken with the specific aim of analysis of molecular markers to achieve more targeted 
risk stratification on an individual basis. Other worldwide groups offer ERCP, but only in the 
event of an abnormality detected at EUS [202, 207]. In this eventuality, ERCP or EUS is 
undertaken with a view to confirmation of cytological diagnosis, rather than risk 
stratification through molecular analyses.  
Variable yields of PDAC and precursor lesion diagnoses have been reported across differing 
worldwide surveillance cohorts and protocols. A technique of annual MRI is adopted by two 
groups; in a cohort of FPC individuals, with a yield of 3 PDAC and 15 cystic lesions after 
screening in 262 individuals [207]; and in 79 FAMMM patients, yielding 7 (9%) PDAC 
diagnoses and detection of 9 (11%) precursor lesions [206]. In those groups advocating EUS 
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as the first-line imaging modality [202-205], the yield of cancer diagnoses has been reported 
as 7/38 in a cohort of FPC and Peutz-Jeghers individuals [202], and 6/51 in a further US FPC 
screening group [205]. In their series of 76 FPC individuals, a German EUROPAC 
collaborating group reported the detection of abnormalities at EUS of 33% [204]. 
The technical considerations and potential complications of the biochemical, radiological 
and more invasive molecular screening modalities, used across the surveillance protocols 
reviewed above will be discussed in the following sub-chapters. 
1.8.1 CA19.9 
 
Carbohydrate antigen (CA) CA19.9 is a sialylated Lewis blood group carbohydrate antigen, 
which is elevated in over 80% of pancreatic cancers [211]. However, if used as a screening 
tool in isolation, CA19.9 lacks specificity [212, 213], and is not produced by those who are 
Lewis a and b negative [214, 215].  
 
1.8.2 Fasting glucose 
 
The measurement of serum glucose is utilised in the early detection of pancreatic cancer. A 
number of different techniques may be performed. In a case-control study analysing the 
prevalence of pancreatic cancer associated diabetes mellitus, Pannala et al defined 5.5 
millimoles per litre (mmol/l) as the upper limit of the normal reference range [216].  
Alternative screening tools for the detection of diabetes mellitus have been used by other 
groups. Two large US cohort studies identified a trend in increased development of 
pancreatic cancer in those with an elevated post prandial, or post load, glucose [64, 106]. 
Post prandial glucose measurement involves the administration of a glucose load, for 
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example, 50g oral glucose load, and drawing of blood at a specified interval following this 
challenge. This may be one or two hours in most cases. The resultant plasma glucose level is 
measured in mmol/l. A result of greater than 11.1 mmol/l is generally considered as 
diagnostic of diabetes mellitus [64, 106]. 
1.8.3 Imaging modalities utilised in screening for PDAC 
 
Much evidence exists as to the sensitivity and specificity of various imaging modalities in the 
detection of pancreatic precursor, or early malignant, lesions.  A discussion of the 
comparative diagnostic yield of precursor lesions when utilising EUS versus CT and MRI has 
been undertaken earlier in this thesis. In this subchapter, the imaging modalities of CT, MRI 
and EUS, and their role in the diagnosis of early PDAC in varying clinical contexts, will be 
reviewed. 
CT as a screening modality 
CT scanning involves the projection of x-rays from several angles in order to achieve cross 
sectional images. The specificity of CT in reliably distinguishing between malignant and 
benign pancreatic disease has been estimated at 59-93% [206-209]. With specific regard to 
screening, the use of CT has recently been evaluated by the International Cancer of the 
Pancreas Screening Consortium [208]. In a series of 216 high risk individuals screened across 
4 US centres, the group evaluated the use of CT in the detection of asymptomatic pancreatic 
lesions [217]. A total of 283 solid and cystic pancreatic lesions were identified in the cohort 
of 216 individuals using three imaging modalities i.e. CT, MRI and EUS. CT detected 39 
(13.8%) of the lesions. With specific regard to potential precursor cystic lesions, CT 
visualised fewer cysts greater than 1cm than MRI and EUS. Of those lesions less than 1cm, 
the CT detection rate fell to 11% [217].   
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MRI as a screening modality  
MRI involves the application of an oscillating magnetic field at a resonant frequency, and 
subsequent detection of the resultant specific frequency radio waves emitted from 
hydrogen atoms. This technique confers an advantage in the avoidance of exposure to 
ionising radiation. Several series have evaluated the use of MRI techniques in the screening 
of high risk groups [205, 206, 218]. In a series of 51 patients from 43 kindreds, Verna et al 
undertook MRI and EUS screening over a period of 3 years. A total of 2 pancreatic masses 
and 3 cystic lesions were detected by both modalities. In a larger series of 109 high risk 
individuals, Ludwig et al employed a single cycle screening technique of magnetic resonance 
cholangiopancreatography (MRCP). The overall diagnostic yield of MRCP was reported at 
8.3% (9/109 patients) and was concluded to be a safe screening technique. Following 
identification of an abnormality at MRCP, individuals underwent further imaging with EUS 
[218]. Further evidence for the diagnostic yield of MRI was reported by Vasen et al in their 
Dutch series of 79 FAMMM patients [206]. Annual screening MRI scans, undertaken over a 
median follow-up period of 4 years, detected PDAC in 7(9%) individuals [206]. The use of 
MRI as an effective screening tool was also evaluated, alongside CT and EUS, in the larger US 
series by Canto et al [217]. In their analysis of 283 lesions in 216 high risk individuals, MRI 
visualised 218 (77%) of the detected abnormalities [217]. With specific regard to cystic 
precursor lesions, MRI detected 33% of sub-1cm abnormalities, and 90% greater than 1cm 
in size [217]. 
EUS as a screening modality  
Evidence pertaining to the role of EUS in the detection of precursor lesions of the pancreas 
has been discussed earlier in this thesis. The International Cancer of the Pancreas Screening 
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Consortium has advocated EUS, and/or MRI, in the initial screening of high risk individuals 
[208]. This followed work by Canto, which has been summarised in the above subchapters, 
discussing CT and MRI techniques [217]. The effectiveness of EUS as a screening technique 
was assessed in the cohort of 216 high risk individuals. EUS conferred the highest detection 
rate of 229 (79%) of the total 283 visualised lesions [217]. In the detection of precursor 
cystic lesions, EUS detected 100% of cysts greater than 1cm in size, a significantly higher 
rate than CT (62.5%) and MRI (90%) [p=0.007][217]. Further support for the use of EUS in 
screening of unaffected members of FPC kindreds, was provided in earlier work by Poley et 
al in 2009. This group reported results from first-time EUS screening in a series of 44 high 
risk individuals, from families with a variety of cancer syndromes [218]. The high risk cohort 
was recruited prospectively and undertook screening between April 2005 and October 2007. 
In this period, 3 asymptomatic pancreatic mass lesions which were subsequently 
demonstrated to be ductal adenocarcinomas were identified. In addition, 7 (15.9%) cystic 
abnormalities suggestive of IPMN were diagnosed [218]. This evidence would appear to 
suggest a high pick up of asymptomatic cancers in high risk individuals via EUS. However, 
evidence from a different established screening group refutes this finding. In their 5 year 
follow-up of 76 high risk individuals, undertaking screening including EUS and MRI, Langer et 
al concluded that, although screening led to the identification of precursor lesions in 25 
(33%) of high risk individuals via EUS alone, undertaking long term surveillance in all high 
risk individuals delivers a relatively low yield [219] . This evidence from the Marburg group 
suggests that risk stratification, even in those deemed at high risk for the development of 
pancreatic cancer, is required in order to target secondary screening to improve the yield of 
abnormalities.  
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1.8.4 CT versus EUS in the detection of PDAC 
 
The main imaging modalities undertaken by EUROPAC in screening for early pancreatic 
cancer are CT and EUS. These techniques are summarised earlier in this thesis. Defining 
sensitivity of these imaging techniques depends upon the stage of the cancer, and definition 
of specificity depends on the control group used. Therefore, these estimates vary greatly in 
the literature. CT and EUS have been found to exhibit a sensitivity of 69-90% [219-222] and 
>90% respectively [223, 224]. EUS has not been demonstrated to be as specific in the 
presence of pancreatitis, with poor specificity of 64%. However, in the absence of 
pancreatitis, the specificity of EUS has been demonstrated to be 96% [225]. Hence, EUS is 
primarily utilised in the screening of eligible unaffected members of FPC kindreds with 
expected ‘normal’ pancreata, whereas CT is used as the follow-up imaging modality of 
choice in those with HP. 
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2 Thesis aims and objectives 
 
2.1 Thesis Aims 
 
In this thesis I aimed to identify subpopulations of high risk families who are at the greatest 
risk of pancreatic cancer in order to target them for screening. 
2.2 Thesis Objectives 
 
To achieve the aims of my thesis I had several objectives, notably: 
1. Registering families with multiple cases of pancreatic cancer and/or pancreatitis and 
obtaining full epidemiological data stratified by kindred. I achieved this objective 
through recruitment of individuals and families eligible as high risk kindreds either 
through self-referral or via a collaborating clinician. Confirmation of the family as 
having a genuine predisposition to PDAC was obtained and familial and individual 
demographic, lifestyle and disease related data was obtained at the time of 
registration through completion of questionnaires. Completion of corroborating 
medical questionnaires was also sought from the referring clinician.  
2. Comparison of age of onset in sporadic pancreatic cancer with age of onset of cancer 
in high risk kindreds. This analysis was achieved through data collection and Kaplan 
Meier survival analysis in high risk family groups following their registration. 
3. Comparing lifestyle characteristics and other demographics in cancer patients on the 
registry with sporadic pancreatic cancer patients (prospectively identified and as 
recorded in the literature). This thesis objective was achieved through collection of 
individual and familial lifestyle and disease related data at registration and Kaplan 
Meier survival analyses. 
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4. Investigation of genetic factors that could be used in stratification of risk within 
kindreds and in sporadic pancreatic cancer. This objective was achieved through 
registration of high risk families, in the confirmation of diagnoses and construction of 
pedigrees and in the collection of DNA and cell line blood samples for storage and 
analysis. 
5. Parallel pilot screening of high risk individuals and comparing outcomes with 
predictions based on the previous objectives. Achieved through recruitment of high 
risk individuals to the EUROPAC secondary screening study. Through collection of 
pancreatic juice samples for the analysis of molecular markers to stratify risk based 
on previous work by our group and discussed further in the later Materials and 
Methods section of this thesis. 
6. Evaluating the risks of screening compared to outcome measures, and optimising the      
screening process. This objective was achieved through the recording of 
complications and morbidity encountered as a result of the EUROPAC secondary 
screening study and in the implementation of techniques to minimise harm, with 
particular reference to amendment of the screening protocol for the collection 
pancreatic juice. 
3 Materials and Methods 
3.1 Introduction to the European Registry of Familial Pancreatic Cancer 
and Hereditary Pancreatitis (EUROPAC) - Background to registry, 
eligibility criteria and recruitment of families. 
 
EUROPAC has been working on the genetic and clinical characterisation of Hereditary 
Pancreatic Diseases since it was established in 1997. EUROPAC is the largest European 
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registry of FPC and HP kindreds, both of which are associated with an increased risk for the 
development of pancreatic cancer as discussed above. A major part of this thesis has 
involved the expansion of this registry, as will be described later.  
Registration with EUROPAC as either an FPC or HP kindred, was achieved either through 
self-referral following consultation of our internet website, or via referral from a clinician or 
Clinical Geneticist. Registration with EUROPAC as an FPC kindred requires confirmation of 
multiple cases of pancreatic cancer affecting multiple generations. A minimum of two cases 
suggesting an autosomal dominant mode of inheritance, was the minimum criterion for 
registration. My key role was in the recruitment of individuals either through self-referral or 
via a collaborating clinician or geneticist. I provided information regarding the registry and 
eligibility for participation in the secondary screening study to interested individuals. I was 
responsible for collecting and collating individual and family data using questionnaires at the 
time of registration. I undertook consent and collection of blood samples for DNA storage 
and research as part of the recruitment process. The specific parameters of data collected 
and mode of storage are discussed in more detail later in this chapter. 
The probability of a family carrying a genetic predisposition for the development of 
pancreatic cancer is increased with increasing numbers of affected first degree relatives. 
This phenomenon was established by research undertaken by Klein et al from the US NFPTR 
and has been discussed earlier in this thesis [157]. Those individuals with 2 affected first 
degree relatives were found to have a 6.4 fold increase in risk compared to SEER data. 
However, in those with 3 or more affected first degree relatives this risk increased 
exponentially to represent a 35 fold increase compared with expected values from SEER 
data[157]. 
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The FPC registry also includes families of additional cancer syndromes which confer an 
increased risk for the development of pancreatic cancer. Such syndromes include Peutz-
Jeghers, Breast-Ovarian, FAMMM, Neurofibromatosis, Li Fraumeni and HNPCC syndromes. 
Many Breast-Ovarian families carry BRCA2 mutations. BRCA2 has a very variable phenotype 
which may include a preponderance for pancreatic adenocarcinoma. Although a number of 
candidate genes have been identified [195, 197], the gene loci which is responsible for FPC 
has yet to be formally described. Through familial based association testing, EUROPAC has 
identified a haplotype and is continuing to sequence candidates in this region. I was 
involved in the recruitment of such families and in the collection of blood samples from 
affected and unaffected individuals from high risk families to work towards achieving this 
aim. 
3.1.1 Research Ethics Committee approvals 
 
The EUROPAC registries of FPC and HP were founded in 1997 following Research Ethics 
Committee (REC) approval for the collection and analysis of data and blood samples from 
these high risk groups. Ethical approval for the FPC registry was obtained via consultation 
with the North West Multi-Centre Research Ethics Committee (REC reference: 03/8/069). 
Similar approval was sought for the HP registry from the Scotland A Research Ethics 
Committee (REC reference: 04/0/010). The favourable ethical approval obtained for the FPC 
and HP registries encompasses collection and collation of data for research purposes in 
these high risk groups. Our ethical approval also encompasses the collection and storage of 
blood for research purposes and DNA storage from consenting individuals.  
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Screening ethics 
 
EUROPAC has ethical approval to undertake screening on a research basis in those 
individuals who fulfil criteria as high risk (REC refs: 07/H1008/153 Central Manchester REC;  
07/H1211 Warwickshire REC). A key part of my work towards this thesis was in the 
authorship of a significant amendment to the screening protocol and associated ethical 
application and approval. I was responsible for counselling and consenting eligible 
individuals wishing to participate in the secondary screening study as well as co-ordinating 
the investigations which comprise the screening protocol. 
 
3.1.2 Identification and referral of participants 
 
Families which may be suitable for recruitment to the EUROPAC FPC and HP registries were 
identified through self-referral by an individual, or referral by a collaborating clinician. In the 
case of the former, individuals may be alerted to the possibility of an underlying inherited 
increased risk for the development of pancreatic cancer within their family and seek further 
information and advice. EUROPAC operates and maintains a website (www.europac-org.eu), 
which individuals concerned about their risk may refer to. The website contains information 
regarding the FPC and HP registries, and contact information. We receive enquiries via email 
and telephone from individuals concerned about their pancreatic cancer risk seeking advice.  
EUROPAC works closely with Clinical Genetics Departments and Hepatobiliary physicians 
and surgeons across the UK and Europe. Individuals seeking advice regarding the possibility 
of a familial predisposition to pancreatic cancer may often be referred to a local Clinical 
Geneticist for advice by their primary care physician. The Clinical Geneticist may then refer 
the individual to EUROPAC for further advice, and possible inclusion on the FPC or HP 
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registries. In this case, it was usual to receive a letter of referral from the clinician involved 
which indicates that the individual has consented to receive the relevant registry participant 
information sheet. This was then duly sent to the potential participant for consideration 
prior to completion of the registry questionnaires and consent. 
EUROPAC maintains links with Pancreatic Cancer UK and the Pancreatic Cancer Research 
Fund and attends scientific meetings across the UK and Europe. This provides education and 
awareness of the registries to both patient, and professional, groups.  
Individuals with pancreatitis or pancreatic cancer suitable for inclusion on the HP or FPC 
registries were regularly reviewed in the regional Hepatopancreatobiliary specialist clinic. 
The clinicians who form the Professorial Hepatopancreatobiliary unit were all involved in 
recruitment to EUROPAC in the identification and education of participants. I was 
responsible for liaising with interested eligible individuals and orchestrated their clinic 
attendance and consent prior to registration. 
In addition to the active and passive method of recruitment discussed, EUROPAC works 
alongside further studies in the recruitment of eligible individuals and families. This process 
is reciprocal and applies to a number of studies currently being undertaken within the 
Professorial Hepatopancreatobiliary unit at the Royal Liverpool University Hospital National 
Health Service (NHS) Trust. I worked in liaison with other members of the research team in 
this recruitment process. 
3.1.3 Data acquisition  
 
The EUROPAC HP and FPC registries acquire information from registering eligible individuals 
via the use of ethically approved personal and family history questionnaires. The “EUROPAC 
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Study Questionnaire of Familial Pancreatic Cancer (FPC)/ Hereditary Pancreatitis (HP)” 
contains questions relating to personal identifiable information, such as full name, address 
and contact details. This initial demographics section also includes questions about GP 
contact details, occupation, brief educational background, ethnicity, religious origin, height 
and weight. The questionnaire also comprises questions relating to exposure to specific risk 
factors which may be implicated in risk stratification in FPC and HP. The “Smoking” section 
of the questionnaire asks for the participant to indicate whether they are a current, ex or 
never smoker and to provide quantitative information regarding their exposure. Similar 
information was sought for alcohol intake. Dietary factors were quantified to some degree 
by the inclusion of questions relating to the average weekly consumption of meat, fish, fresh 
fruit, greasy or fried food and dairy products.  
The registering individual was also asked to provide information regarding any history of 
specific medical conditions which may be relevant; such as cystic fibrosis, diabetes, 
pancreatitis and other specified intra-abdominal conditions. A further section of the 
questionnaire asked participants to provide information regarding their past surgical history. 
The information received from the questionnaires was entered into the high risk database 
under the corresponding fields described above. I was responsible for issuing the 
appropriate questionnaires prior to registration and in the collection and entry of data into 
the databases described below. 
Confirmation of the pancreatic, and significant other, cancer diagnoses within each 
potential FPC family being considered for addition to the registry was sought via a variety of 
methods. Histological reports concerning each of the affected family members were sought, 
where possible, through liaison with clinicians and hospital trusts involved in the provision 
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of their care. In the absence of histological confirmation, information regarding an affected 
family member’s diagnosis was sought from the regional Cancer Registry organisation. This 
requires consent to be provided by the registering individual. This consent was indicated on 
a specific form which requests details of the deceased family member, in order for us to 
approach the relevant Cancer Registry for information. Finally, in the event that such 
information was not available, or the date of death of an affected relative predates the 
registration of all known cancer deaths, then a copy of their death certificate was sought 
from the registering individual.  
In addition to the personal and family history questionnaires detailed above, each 
participant was required to complete a consent form which contains clauses relating to the 
holding and use of their data for research purposes; access to relevant medical records by 
the research team; storage of DNA and blood for research purposes and molecular analysis 
of such samples. Participants indicated their consent for each of these clauses and 
contributed a voluntary blood sample at their discretion. The provision of a blood sample 
for research purposes was not a prerequisite for inclusion on the respective registry. 
Working alongside the EUROPAC database co-ordinator, I was responsible for ensuring 
appropriate informed consent was obtained and that diagnoses of affected individuals 
within the kindred was confirmed prior to inclusion on the EUROPAC registry. 
In the event of a participant consenting to provide a blood sample for research purposes, 
this sample was processed for two purposes. An EDTA sample was processed for purposes 
of DNA storage within the Regional Molecular Genetics Laboratory based at the Liverpool 
Women’s Hospital. A second sample obtained within a sodium-heparin vial underwent 
lymphocyte preparation for cell line storage in liquid nitrogen at the Division of Surgery and 
81 
 
Oncology at the University of Liverpool. I was responsible for obtaining informed consent 
from individuals wishing to provide a blood sample for research purposes and involved in 
the collection and processing of such samples for storage. I worked in liaison with other 
members of the research team who were principally involved in the preparation and 
analysis of blood samples from participating individuals. 
The EUROPAC registries work in collaboration with, and handle data from, The European 
study into Digestive Illnesses and Genetics (PanGen-EU). PanGen-EU is a large, European 
wide epidemiological study recruiting individuals with a diagnosis of pancreatic 
adenocarcinoma and matched controls. The study involved a structured questionnaire 
which was completed by a research interviewer by directly questioning eligible participants. 
The questions within the questionnaire related to epidemiological factors which may be 
implicated in the development of pancreatic adenocarcinoma. The questionnaire was 
structured and featured questions pertaining to different dietary intakes; smoking; alcohol; 
water consumption; exercise habits and occupations over a participant’s lifetime. Samples 
for DNA extraction and SNP analysis were taken in parallel to the questionnaire. Buccal 
(salivary), urine and blood samples were collected from consenting participants. I worked in 
liaison with other members of the research team in the identification of individuals who 
were eligible for recruitment to PenGen-EU and other studies undertaken within our unit. 
Data obtained from patient notes 
 
It can be necessary to obtain specific clinical data from a participant’s clinical notes and the 
EUROPAC registry consent includes a specific clause to this effect. Only researchers directly 
involved with EUROPAC, who hold either a full or honorary NHS Trust contract, were 
entitled to have access to such participant information.  
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Participation in the EUROPAC secondary screening study requires each individual’s details to 
be entered onto the NHS trust computer system for recording of patient results and records. 
The NHS Trust databases involved were only accessible by individuals who held full or 
honorary NHS contracts, following training by the NHS Trust Computer Services department 
who issued access usernames and passwords to eligible researchers. 
Access to the NHS Trust computerised records provided data regarding the results of 
screening investigations undertaken, as well as access to demographic data if required. 
Screening reports were included in the research records of study participants and stored 
within a secure locked filing cabinet within the NHS Trust building. 
Data obtained as part of the screening program 
 
Data obtained from the NHS Trust computerised records and patient notes were accessed 
by researchers involved in co-ordination of the secondary screening study, as detailed in the 
participant consent. Such data may be entered into the high risk database to the relevant 
fields outlined previously. It was necessary to include clinical data on the high risk database 
in order to track progress with each participant’s involvement with the study. Clinical data, 
such as results from screening investigations, were held on the high risk database to allow 
for data analysis of the screening study. 
 
3.2 EUROPAC Databases 
 
Three databases have been established and are maintained as part of the EUROPAC registry. 
The databases each fulfil a different role in the storage of specific information regarding 
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family data and samples collected. These three databases will be described in detail and are 
referred to as: 
1. The high risk database 
2. The anonymous tissue database 
3. The names database 
In the construction and maintenance of the databases, our group apply specific principles 
which will be discussed in more detail. In work undertaken towards this thesis I was involved 
in the input of data and maintenance of the databases described below. 
3.2.1 Guiding principle 
 
It is imperative that the storage of personal and demographic data referring to individual 
study participants is held on secure systems to maintain confidentiality. Furthermore, in 
order to minimise researcher bias, it is good practice for research data to be held separately 
from identifiable information. Thus researchers can access a bank of research data for 
analysis, without unnecessary exposure to participant identifiable information. 
In addition to this principle, a further key aim when considering the storage of participant 
information is that the systems in place for the storage of such information should be secure 
to ensure that access by an unauthorised individual, by accident or intent, is virtually 
impossible. The systems in place should act to ensure that clinical and research data cannot 
be linked by unauthorised individuals. 
3.2.2 Definitions: 
 
Coded:  
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‘Coded’ refers to data which may be traced to a specific study participant. This may include 
follow-up data for which referral to medical case notes may be required. 
Anonymous:  
 
‘Anonymous’ refers to data which cannot be traced to an individual study participant. One 
example is in the event that multiple samples were obtained with data that cannot be 
traced to the specific study participant and the samples were then randomised prior to 
storage of data. e.g. if multiple samples were obtained with data that cannot be traced back 
to the participant, and the samples were then randomised before storage of data. 
Participant: 
 
This refers to any individual donating a sample or information for research having given 
informed consent.  
3.2.3 The high risk database 
 
Information regarding those high risk individuals registered with EUROPAC was held on a 
Progeny database. Progeny is a family tree based database with a spreadsheet format for 
individual participants (individual spreadsheet), and a spreadsheet format for pedigrees 
(pedigree spreadsheet). The database was created to have 316 fields in the individual 
spreadsheet, and 30 fields in the pedigree spreadsheet.  
As discussed in our guiding principles regarding the maintenance of databases; it is 
preferable to maintain databases as two separate entities; one containing demographic 
information that could be linked to a participant and the other confidential information. 
However, it was impractical to keep two databases of family based information 
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synchronised and so, under this exceptional circumstance, it was considered acceptable to 
have a single database with separate hierarchical password access for demographic 
information and clinical or research data. 
Researcher access to fields was in accordance with a user hierarchy which was set at 3 
levels: “Co-ordinator” (DCO), “Geneticist” (G) and “Molecular” (M). DCO is the only level 
able to fully access information regarding participant contact data, such as telephone 
number and home address. The DCO user password does not allow access to confidential 
research data on participants or risk estimates.  G gives access to data related to familial 
information and clinically relevant data (risk estimates, genetic tests etc.) but, in contrast to 
the DCO user password, level G access does not provide any of the information which would 
be required to contact the specific participant. Username M gives access to all research 
data, but in a coded format.  
The security levels necessitated some redundancy of field, in most cases redundant fields 
were populated from other fields (e.g. “Year of Birth” can be populated automatically from 
“Date of Birth”). The reason for the hierarchy was to preserve anonymity of participants 
from unauthorised access, and multiple passwords were not routinely held by any one 
individual. The level of appropriate access was determined by each research team member’s 
role in the addition of data.  Necessary members of the research team were given access 
during separate sessions to different levels of the hierarchy.  
Most nominal data were entered via dropdown options. Where appropriate, calculations 
were automatically carried out on the basis of entered data to populate other fields. One 
example is “BMI” which was calculated from height and weight entry, where weight in 
kilograms was calculated automatically if weight was entered in stones. Additional comment 
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fields were also available to add further information in the form of free text where 
appropriate.  
Data entry onto the high risk Progeny database was usually via forms linked to individuals 
on a family tree presentation, although direct entry into spreadsheets was also possible. 
Individual/Global spreadsheet fields 
 
The entry of data into the Individual spreadsheet fields was governed by user access. As 
discussed above, use of the G username password allowed access to specific data which 
differs from that accessed via the DCO username and accompanying password. Use of the 
‘All’ username allowed access to all fields encompassing the DCO, G and M passwords. 
System fields 
 
These fields were populated on the basis of the family tree and were accessible to all users. 
They are summarised as follows: 
“Pedigree name” - this is a coded number referring to the specific family tree; “UPN” or 
“Unique Personal Number” – refers to a specific individual within the family tree; “Adopted” 
– refers to adoptive status of a registered individual; “Deceased status”; “Degree of 
relation” – refers to that how that specific individual was related to the proband; “Father 
ID”; “Folder name” – which refers to groupings of particular families with common 
mutations, this field does not specify the family diagnosis; “G:P” or “Generation: Position” – 
refers to that generation and position of the individual relative to the proband; “Gender”; 
“Gender Unknown”; “Global ID”; “Individual name” – refers to a code allocated to that 
specific family member; “Marked By”; “Mother ID”; “No Issue”; “Proband status” – referring 
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to whether the proband was affected or not; “SAB” or spontaneous abortion; “Twin status”; 
“Twin relationship”. These data fields were accessible by all users. 
Personal Details 
 
These fields were entered directly or populated on the basis of other fields, an example 
being the calculation of computed age from the entry of dates of birth. 
All user passwords included access to information within the fields: 
“Date registered; Computed Age; Age of Death; Age at last contact; Affected; Cause of 
death; Nationality; Other diagnosis; Individual Number; Study Number; User global ID; Year 
of Birth, Year of Death”. 
Patient identifiable information, such as held in the forename and surname fields, was 
accessible only via the DCO password. Similarly, the fields entitled “Date of Birth; Date of 
Death; Hospital Unit Number; NHS Number” and “Tissue Database code”, which refers to 
the location of stored participant samples, were also accessible via the DCO access level. 
Other fields such as the “age difference of affected parent; average age of affected; family 
number” and free text comments fields were accessible via the G and M user names. 
Address 
 
Participant identifiable contact information held within the fields of “E-mail; Telephone 
Number; Postcode; Street; Town” were accessible via the DCO password only. 
All levels of access include more general information regarding the “City; Country; County; 
Family UK region; UK Region” of study participants. These specific data fields contain generic 
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information concerning the region of origin of a participant and their family with no 
inclusion of information which may result in the identification of the particular individual. 
Clinician Details 
 
Information regarding the Clinical Genetics Department involved in each family was 
accessed via the DCO and G user name passwords. These data include “Clinical Geneticist E-
mail; Clinical Geneticist Forename; Clinical Geneticist Hospital; Clinical Geneticist Surname; 
Clinical Geneticist Telephone”. In certain cases, the Clinical Geneticist was also included in 
the Referrer fields if the family were recruited to EUROPAC as a result of their referral for 
inclusion on the registry. 
Additional clinician details including “GP Address City; GP Address Country; GP Address 
County; GP Address Postcode; GP Address Street; GP Address Town; GP Surname; Ordered 
Referrer Surname; Referral; Referrer Address City; Referrer Address Country; Referrer 
Address County; Referrer Address Part 1; Referrer Address Part 2; Referrer Address Part 3; 
Referrer Address Post Code; Referrer Address Town; Referrer E-mail; Referrer Surname;    
GP Address Telephone; Month referred; Referrer Address Telephone” were accessible via 
the DCO user name. 
Lifestyle 
 
Information regarding risk factors such as “Alcohol; Smoking;  Age started drinking (alcohol); 
Age started smoking; Age stopped drinking (alcohol); Age stopped smoking; Age variable for 
smoking; Alcohol amount; Estimated smoking amount; Estimated Stop Smoking; Pack Years; 
Smoking amount; Years Smoking; Lifestyle notes” (free text) were accessible by those using 
the G user name. 
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Linkage 
 
Further characterisation of the genetic mutations associated with FPC is obviously a key 
area of our on-going work. In view of this, the linkage folder includes an extensive number 
of fields pertaining to specific genetic regions of interest, as well as mutations in BRCA2 and 
other genes relating to established familial cancer syndromes. These fields were accessible 
to those with M level of entry to the database and are entitled: “1539 Standardised-a1; 
1539 Standardised-a2; 1596 Standardised-a1; 1596 Standardised-a2; 1597 Standardised-a1; 
1597 Standardised-a2; 1603 Standardised-a1; 1603 Standardised-a2; 1617 Standardised-a1; 
1617 Standardised-a2; 2952 Standardised-a1; 2952 Standardised-a2; 393 Standardised-a1; 
393 Standardised-a2; 413 Standardised-a1; 413 Standardised-a2; 415 Standardised-a1; 415 
Standardised-a2; 1539 allele1; 1539 allele2; 1596 allele1; 1596 allele2; 1597 allele1; 1597 
allele2; 1603 allele1; 1603 allele2; 1617 allele1; 1617 allele2; 2952 allele1; 2952 allele2; 393 
allele1; 393 allele2; 413 allele1; 413 allele2; 415 allele1; 415 allele2; Chance of exclusion; 
Disease Allele; Disease Allele?; Exclusion criteria; Standardisation 377/ABI-a1; 
Standardisation 377/ABI-a2; Used on array; Consistent with Linkage; Hi risk allele;   PPID 
Polymorphism; Palladin Mutation; Palladin SNP;  ; 4q Class; D3S1277-a1; D3S1277-a2; 
D3S1289-a1; D3S1289-a2; D3S1297-a1; D3S1297-a2; D3S1304-a1; D3S1304-a2; D4S1539-a1; 
D4S1539-a2; D4S1596-a1; D4S1596-a2; D4S1597-a1; D4S1597-a2; D4S1603-a1; D4S1603-a2; 
D4S1617-a1; D4S1617-a2; D4S2952-a1; D4S2952-a2; D4S393-a1; D4S393-a2; D4S413-a1; 
D4S413-a2; D4S415-a1; D4S415-a2; D5S424-a1; D5S424-a2; D5S641-a1; D5S641-a2; 
D8S260-a1; D8S260-a2; D8S505-a1; D8S505-a2; DXS1001-a1; DXS1001-a2; DXS1047-a1; 
DXS1047-a2; Li's Codes; Linkage analysis; Number used in 4q; Pseudo” and “sequencer 
type”. In addition to the listed association loci of interest, information regarding the 
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presence or absence of a familial BRCA2 Mutation, or CDKN2A Mutation, were also entered 
via the G and M levels of access. 
Risk calculation 
 
In the absence of a recognised underlying attributable mutation in FPC, the risk to 
individuals from each specific kindred was approximated from the following fields, which 
relate to risk calculation. The combination of these factors will help to determine the 
probability of the individual being a carrier of the familial mutation. These data fields are 
entitled: “Affected code; Affected Siblings; Calculate affected 1; Calculated affected 2; 
Difference in age with affected parent; Difference in age with sibling; High adjusted risk; 
High Risk; LH1 probability; LH2 probability; Low adjusted risk; Low risk; Medium risk 
probability; Penetrance High risk Calc; Penetrance low calc; Penetrance Not calculated; 
Probability sib; Probability based on cohort; Probability based on parent unadjusted; 
Probability by parent; Probability of being a carrier; Probability on age; Probability on age 
unadjusted; Probability risk adjusted; Probability sibling unadjusted; Sum of Cohort 1 
adjusted risk; Unaffected Siblings”. Risk calculation in each participant was the key in 
determining which individuals were at highest risk and would benefit from targeted 
secondary screening. Information regarding these risk calculation parameters were read and 
entered by researchers with G user name access to the database. 
1901 Census 
 
The folder entitled 1901 census is self-explanatory, and contains the fields: “Age in 1901; 
City 1901; Civil Parish 1901; County 1901”. Such information could be accessed by all user 
names. More detailed information localising an individual to a specific location or street was 
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accessible only by the DCO. Such fields comprise: “1901 Ident; Town 1901 and Street in 
1901”. 
Details of cancer 
 
The DCO may enter specific data regarding an individual’s specific “Cancer Registry Number” 
and “Date of diagnosis of cancer”. Fields detailing “Histological confirmation; Year of 
diagnosis” and specific “Histological Reports” were available to all levels of access. 
EUROPAC screening 
 
After appropriate risk estimation, the decision that screening was indicated for a particular 
individual was made. Information regarding the process of instigating, and continued 
participation, in the screening study was maintained on the database. All levels of access 
entered data in the fields of “Interested in Screening; Referred for screening; Followed up 
and Date of last screen”. More specific information regarding results of screening 
investigations and molecular analyses was entered by the M user name under the fields 
listed: “Notes on screening; ERCP complication; ERCP complications Amylase; ERCP CRP 
Level; K-RAS2; K-RAS2 in tumour; methylation (in pancreatic juice); methylation in tissue; 
Molecular Test of Tissue; Somatic mutation results; Nature of BRCA2 test; CDKN2A 
Mutation; CDKN2A Test; TP53; TP53 in tumour; Peutz-Jegher Test; Type of screening; CA19-
9; Date of CA19-9; Molecular Screen; Year of Latest CT; Year of Latest ERCP; Year of Latest 
EUS; CT; ERCP; EUS; Latest CT Report; Latest EUS report; MRCP; Hospital; Summary of Scans; 
Transabdominal Ultrasound”.  
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Non-clinical details regarding the screening clinicians involved in delivering a secondary 
screening study participant’s care i.e. “Radiologist Forename; Radiologist Surname” were 
entered by the DCO. 
Family history 
 
All levels of access to the Progeny high risk database allowed the fields of “Age of affected 
parent; Age of oldest affected sibling; Age of Parent; Age of parent 2” and “Transmission” to 
be read and entered.  Access to clinical information and further risk stratification 
information within the fields “Known causes of death; Anticipation; Bias in transmission; 
Calculate affected; Cohort Individual; Cohort Parent; Generations; Li Hsu Generation; New 
Average age; Sum of cohort based probability; Sum of maternal; Sum of paternal; Total FPC; 
Coeliac Disease; Crohns Disease; Total Diabetes; Total gastric; Total other cancers; Total 
pancreas related; Year of diabetes diagnosed; Parents with data; Penetrance; Siblings with 
data; Family Diagnosis; Proband affected” and “Risk Category” was withheld from those 
with DCO and M levels of access and was only accessible via the G user name. 
Samples 
 
As part of the registration process, as detailed above; each registering individual was asked 
to provide a voluntary blood sample for research purposes and DNA storage. These data 
were entered into the appropriate fields on the Progeny website via the M user name. The 
specific fields comprise: “DNA Stored; Location of additional Sample; Location of Blood; 
Location of Blood DNA; Location of Cell Line; Location of Tissue Block; Type of tissue; Any 
other samples; Blood DNA; Blood Sample; Cell Line; Date when sample was taken; DNA from 
Tissue; Number of samples” and “Tissue Block”. This enabled the location all of the samples 
93 
 
taken from a study participant and stored in the University of Liverpool Division of Surgery 
and Oncology freezer and liquid nitrogen facilities to be accurately recorded, and hence 
obtained readily for linkage and association analyses where appropriate.  
Weight and Height 
 
Clinical information regarding a study participant’s weight and height were recorded in the 
fields of “BMI; Computed Kg; Computed Metres; Feet; Height in m; Inches; Pounds; Stones; 
Weight in Kg; Obesity” and “Record of weight changes”. As these data are clinical and may 
relate to risk they were accessible via the G user password. 
Actions required 
 
The fields detailing specific actions to be undertaken relate to the logistical process of 
recruiting an individual who has expressed an interest in the registry and was suitable for 
inclusion. In view of this, the DCO entered information under the fields “Date action 
required; Date (registration) pack sent; Description of action; DNA needed” and “Pack 
details”, as all of these parameters do not contain any clinical information but provided an 
overview of the participant’s progress in the registration process. 
Health 
 
The clinical data fields relating to a study participant’s relevant personal medical history 
were entered by the G user name. The following parameters were included and represent 
medical conditions which may affect risk for cancer development, specifically: “Age diabetes 
diagnosed; Date diabetes diagnosed; Diabetes; General Health Notes; Neurofibromatosis; 
Other Cancers; Pancreas related cancer; Pancreatitis; Type of Diabetes; Operation”. 
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Participant consent 
 
Recording of each study participant’s informed consent for their data to be included on the 
EUROPAC registry was obviously of great importance. In view of this, data regarding 
appropriate consent was included in the fields “Consent for access to Information; Consent 
for blood sample; Consent for Deceased Relatives Notes and Consent for Deceased Relatives 
Tissue”, which was accessible by all users. 
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Pedigree spreadsheet fields 
 
System fields 
 
In addition to the coded data relating to each individual from a registered family, the system 
fields folder within the pedigree spreadsheet fields details the coded name, or Pedigree 
Number, given to the pedigree, as well as the grouping to which the family belong. This 
grouping is referred to as the “Folder” to which the family belongs and did not provide 
specific details of a family’s diagnosis.  
Statistical analysis 
 
Within the fields included in the statistical analysis folder, data concerning risk stratification 
in a family was held. For example, the phenomenon of anticipation has been described in 
FPC and “Average Anticipation; Average age of onset; Consistent with anticipation” were 
specific fields accessible via the G user name along with “Transmission characteristic” and 
“Descriptive Statistics”. All of these fields were utilised in risk calculation when considering 
screening in an unaffected FPC family member. 
Family details 
 
The G user name allowed access to specific details regarding the familial diagnosis, namely, 
“Family Diagnosis; Family Number; Nationality; UK region; Other Cancers; Number of 
affected; Total Diabetes; Total other cancer types; Total Pancreatic related cancers; Notes” 
(which allows the addition of free text). In their primary role in the construction of the 
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family pedigrees, the DCO had access to indicate the status of the proband of each family 
via the Proband field. 
Linkage fields 
 
 As described in the Individual/ Global spreadsheet fields, any association of linkage of the 
family to a particular loci was added in the following fields “4q32-34; Chance of Distribution 
(linked); Chance of Distribution (Unlinked); Chr 3 1297-1304; Chr 5 424-641; Chr 8 505-260; 
Chr3 1277-1289; Notes on linkage; Probability of Elimination; X Chr 1001-1047; Eliminated”. 
These fields were accessed via the M user name. 
Clinician 
 
Similar to the Individual/ Global spreadsheet, a specific referrer sometimes alerted a 
number of family members to the EUROPAC registry, and so represented the referring 
clinician for the family. This data was registered by the DCO under the field “Referring 
Clinician”. 
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3.2.4 The anonymous tissue database 
 
The anonymous tissue database is a Microsoft Access database which stores 
pseudonymised study participant data via a series of linked tables, which refer to the 
location of stored samples from study participants within the Division of Surgery and 
Oncology, plus relevant clinical and research data. No participant identifiable data was held 
on this database. All study participants were pseudonymised using a specific code. 
Clinical fields which were of relevance to the study are included in this database and the 
fields comprise: “P Number” which is the pseudonymised code allocated to each study 
participant; “P Link” refers to the linking “Unique Personal Number” or “UPN” field of the 
high risk database thus allowing participant information to be linked across the two 
databases; “Author” of the database entry; “Paired” includes details of the type of samples 
stored for a participant; more specifically, blood, pancreatic juice or tissue; furthermore the 
time and date of the taking and processing of the samples was also recorded. Participant 
identifiable information was entered into fields entitled “Hospital Number”; “Hospital 
(name)”; “Gender”; “Age”; “Date of birth”; “Year of birth”; as well as the date and year of 
entry of the participant onto the database. Details regarding the vital status were also 
included under the field headings “Alive/ Deceased”; “Date of Death”; “Year of death”. Last 
contact and event time data were also entered under similar parameters. Clinical 
information was entered within the fields “Diagnosis” and “Aetiology”. Furthermore, details 
regarding the diagnosis of specific relevant conditions, notably diabetes, malabsorption and 
pancreatitis were entered into fields including “Date of Diagnosis”; “Year of Diagnosis” and 
“Treatment” (specific to the relevant condition). Exposure to risk factors which are 
implicated in pancreatic disease were entered under the following field headings “Smoking 
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Y/N/Ex”; “Alcohol Y/N/Ex”, along with quantitative data fields detailing lifetime exposure i.e. 
“Age started/ stopped”; “Light/Moderate/Severe” intake/ exposure. Information regarding 
the surgical history of each participant, where relevant, was also entered onto the 
anonymous database. Clinical parameters including blood test results for pancreatic and 
other tumour markers, in addition to other specified tests were also entered under the 
corresponding fields where appropriate. In addition to blood test results, different imaging 
modalities were recorded on the anonymous database, under the appropriate field 
headings “Transabdominal ultrasound”; “Laparoscopic ultrasound”; “Magnetic Resonance 
Imaging”; “Endoscopic ultrasound”; “Endoscopic retrograde cholangiopancreatography 
(ERCP)” along with the corresponding dates of each investigation. In the event of a 
participant involved in a specific cancer related or chemotherapy trial being added to the 
database, fields such as “Chemotherapy” and specific trial information was recorded along 
with any histological reports and prognostic information following surgical intervention.  
One of the most important aspects of the anonymous database was in the recording of data 
relating to the location of participant samples within the Division of Surgery and Oncology at 
the University of Liverpool. The “P number” allocated to each participant on the “Names” 
database was applied to all samples derived from that individual. The appropriate location 
within the freezer room or liquid nitrogen storage facilities was entered for the 
corresponding “P Number” under the fields “Urine”; “Serum”; “Plasma”; “Cell Line”; 
“Pancreatic juice”; “Duodenal juice”; “Bile”. Similarly, any tissue samples obtained from 
resected specimens, for example, normal pancreas, pancreatic tumour, duodenum, 
common bile duct etc had their locations entered. In certain cases, the method of collection 
of samples was recorded. In the case of pancreatic juice, the method of collection i.e. via 
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ERCP or per operatively, holds significance, as the presence of radiological contrast or blood 
within the sample influenced subsequent DNA extraction or analysis. The dates of all 
samples collected were entered accordingly. 
 
3.2.5 The names database 
 
The “Names” database is a separate Microsoft Access database, which is comprised of a 
single table, which records the allocated pseudonymised code with identifiable participant 
information. In view of the sensitive nature of the data held, the “Names” database is held 
on a secure, password protected disk which is stored in a locked fireproof safe. The fields 
incorporated in the “Names” database comprise “Surname”; “Forename”; “Hospital 
Number”; “Gender”;“Date of birth”; “Year of birth”; “Age”; “Date of registration”, “Year of 
registration”; “Last contact”; “Referring clinician”; “Consent taken by” to include the name 
of the clinician who consented the patient for inclusion on the database and taking of any 
samples for storage; “Code for consent form” refers to the version code, number and date 
of the consent form completed by the participant and finally; “P Link” refers to whether an 
individual included on the database has a registration code for the high risk Progeny 
database, more specifically, this refers to the “Unique Personal Number” or “UPN” entered 
in the “System Fields” folder of the Individual/ Global spreadsheet on the high risk Progeny 
database discussed earlier. 
3.2.6 Statistical analysis 
 
Data from our databases, follow-up questionnaires and clinical tests were analysed using a 
variety of statistical methods. Descriptive statistics, including graphical methods, were used 
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to determine the distribution of the data. From this information, summary measures of the 
data can be determined for use in further analyses. Continuous and categorical data were 
collected as part of the registry and secondary screening studies and were analysed using 
parametric tests, for example, t-test and paired t-test, or, in the case of data which was not 
normally distributed, non-parametric tests such as chi-squared (χ2) or Fisher’s exact test. 
Regression describes the relationship between two random variables. Linear regression was 
undertaken to analyse the relationship between one continuous response and one 
explanatory variable. Linear regression can only be applied to data which appears to follow 
a linear trend. In the case of there being multiple explanatory variables for a response, 
multiple linear regression techniques may be employed after identification of the most 
significant explanatory variables using simple linear regression methods.  
A logistic regression method of analysis is used more commonly in survival analysis as it 
pertains to the (log) odds or probability of an event (response variable), commonly, death, 
occurring. Survival analysis, or ‘time-to-event’ analysis, methods were used in the analysis of 
follow-up data. In this type of analysis, the response variable was the time from a specific 
trigger to subsequent event. For example, time interval between exposure versus non-
exposure to a specific risk factor, and subsequent death. A Kaplan Meier curve was used to 
give an estimate of the proportion of individuals still alive at different points in the study.  
In order to gain a better understanding of the relationship between multiple specific 
variables of interest upon survival, Cox’s proportional hazards model was used. This model 
can adjust for the confounding effect of extrinsic variables upon the explanatory variables 
included in the analysis. 
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In the analysis of sensitivity and specificity of, for example, a specific screening method, 
receiver operator characteristic (ROC) curves were used. ROC curves plot sensitivity i.e. 
number of true positives (x axis) versus 1-specificity i.e. false positives (y axis). This allows 
for the calculation of the area under the curve (AUC) which can be used as a comparator 
between different diagnostic tests.  
3.2.7 Sample collection and processing 
 
In addition to the acquisition of data from participants at the time of registration via the 
questionnaires discussed above; EUROPAC requests the voluntary provision of blood for the 
purposes of DNA storage and analysis. This was undertaken in conjunction with the Regional 
Genetics Service at the Liverpool Women’s Hospital where storage of participant samples 
was undertaken on an anonymised basis. I consented individuals prior to research samples 
being obtained and was involved in taking, preparing and storing such samples. Upon 
completion of this process, samples taken were recorded on the databases described above. 
3.3 EUROPAC secondary screening study for early pancreatic cancer in 
FPC and HP 
 
Upon registration with EUROPAC, eligible participants were offered information regarding 
participation in the secondary screening study for the detection of PDAC.  I counselled and 
consented all individuals prior to their registration. Participation in the secondary screening 
study was offered to those who fulfilled criteria as high risk, following registration with 
EUROPAC as outlined above. Those individuals who wished to be considered for screening 
were invited to attend our specialist Hepatobiliary clinic to discuss the protocol in detail 
prior to participation. Secondary screening was offered from the age of 40 in most 
circumstances. However, previous work by EUROPAC has established the phenomenon of 
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anticipation in FPC i.e. the development of PDAC at progressively younger ages in successive 
generations [158]. Hence, eligibility for participation in the secondary screening study was 
considered below the age of 40 in kindreds demonstrating a strong trend of anticipation. I 
arranged attendance at Hepatobiliary clinic for counselling of all individuals prior to 
obtaining informed consent for participation in the secondary screening study. Following an 
individual’s inclusion in the study I then instigated their relevant screening investigations 
according to the EUROPAC secondary screening protocol. The protocol is outlined later in 
this work. 
3.3.1 Phenomenon of anticipation in FPC 
 
Evidence from EUROPAC data has found that the onset of disease occurs a median of 10 
years earlier in successive generations [158]. On initial inspection, it may appear that such a 
phenomenon could be attributable to ascertainment bias. However, statistical correction of 
such bias has been undertaken via the equation outlined in Figure 2. This equation decrees 
that no anticipation can predict cancer death in second and third generation FPC kindreds 
from survival data in the first generation. Figure 2 demonstrates low risk calculation 
regression analysis of uncensored Kaplan Meier survival in first generation of FPC kindreds 
and risk in successive second (G2) and third generations (G3) [158].  
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Figure 2: The phenomenon of anticipation in FPC 
Kaplan Meier survival analysis of cohorts of EUROPAC FPC individuals from different generations and dates of birth. The 
numbers below the graph show the number of family members from each group at each time point who were considered 
in the survival analysis. It can be seen that age of death of individuals was significantly different between generations G1, 
G2 and G3 (989 at risk, 261 affected; p>0.001) [158]. The Low Risk equation is calculated from survival data in G1.  
Application of the Low Risk equation to G2 and G3 demonstrates a significant increase in the observed rate of PDAC versus 
the expected according to the survival seen in G1 (p<10
-6
). The High Risk equation is derived from survival data as seen in 
G3. Application of this equation to individuals in G1 demonstrates a significant reduction in observed versus expected 
survival (p=0.003) which is the reverse of the trend seen in G3.  
 
3.3.2 Positive family history risk and false positive rate – need for further stratification  
of risk. 
 
EUROPAC currently offers screening on a research basis to those high risk individuals with a 
defined genetic predisposition who meet certain eligibility criteria. Those who may be 
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eligible to participate include unaffected members of FPC kindreds, those from families with 
recognised high risk cancer syndromes and affected HP patients with p.R122H/C, p.N29I/T 
and p.A16V mutations of their PRSS1 gene, or those with an apparent autosomal dominant 
mode of inheritance of idiopathic pancreatitis, even in the absence of a known PRSS1 
mutation. Secondary screening for pancreatic cancer is offered on a research basis to high 
risk individuals by a number of groups across Europe and the US.  Within these populations, 
defined as having a genetic predisposition to pancreatic cancer, further risk stratification is 
required. FPC individuals are at a significantly elevated risk for the development of 
pancreatic adenocarcinoma as demonstrated by the earlier comparison with SEER data, and 
so provide a potentially attractive screening group. However, further stratification of risk is 
required before consideration of screening. If all those individuals in the UK with one 
affected FDR were to be screened, then this would identify a cohort numbering 
approximately 200,000 (Table 1). This figure was derived from the probability of having a 
FDR who has died from pancreatic cancer multiplied by the number of people within the UK 
population aged over 40 (approximately 30 million). The probability of having a FDR who has 
died from pancreatic cancer can be estimated by multiplying the average number of 
deceased FDR an individual in the UK has, by the proportion of deaths attributable to 
pancreatic cancer.  This calculation was used to determine the 200,000 cohort. If a 98% 
sensitive and specific screening test were to be applied to this group, although 686 of the 
700 expected cases would be positively identified, there would also be a high number of 
false positives wrongly detected, approximately 4000. In a worked example assuming a 0.1% 
risk of pancreatic cancer within a population, application of a screening test with 98% 
sensitivity and specificity to a cohort of 1000 participants would identify one true positive 
cancer case. However, in assuming a 0.1% risk in this population and applying a 98% specific 
105 
 
test, although 980 true negatives would be correctly excluded, 20 false positives would be 
wrongly identified as having cancer. It would therefore be unethical to apply such screening 
in a population with such low risk, as in the detection of one true cancer case, 20 people 
would be wrongly diagnosed and potentially harmed through unnecessary treatment. In a 
second example considering a population of 1000 participants at 10% risk for the 
development of cancer, assuming a 98% sensitive and specific test, 98 individuals would be 
correctly diagnosed with cancer. In the same test, one would expect to positively exclude 
882 individuals with a false positive result in 18. This equates to 98 individuals being 
correctly diagnosed with 18 participants being wrongly diagnosed as having cancer. 
Although the risk of 10% in this theoretical screening population is elevated compared to 
that seen in our screening cohort, the anticipated risk of pancreatic cancer development 
falls between these two worked examples, and such risk should be stratified with the aim of 
yielding maximal benefit to those at highest risk whilst minimising harm to those who are at 
lowest risk for the development of pancreatic cancer. In view of this, the current screening 
criteria for participation in the EUROPAC secondary screening study are individuals over the 
age of 40 from FPC kindreds with confirmation of two or more affected relatives. Despite 
this, in the absence of any genetic testing for the, as yet unknown mutation responsible for 
FPC, any screening programme may expect to identify a number of false positives, 
particularly when only 50% of individuals will be expected to carry the mutation. In order to 
gain higher specificity rates from screening, further aetiological factors which may influence 
the penetrance of pancreatic cancer in genetically predisposed individuals should be 
identified and incorporated into the risk stratification process. 
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3.3.3 Risk stratification model and clinical interface 
 
We can use the phenomenon of anticipation and other risk factors in a model for risk 
stratification in FPC kindreds. My thesis centred on determining factors which influence the 
age dependent risk. The combination of this risk which was determined by age, anticipation 
and various environmental and disease exposures can be combined with estimation that the 
family was a true FPC family, and that the individual was a carrier of the mutation 
concerned, to determine the probability that the individual will develop cancer. Obviously 
this approach to screening will change in the advent of further characterisation of the 
underlying genetic alteration. Previous work undertaken by our group formulated the risk 
stratification interface as outlined in Figure 3. Risk stratification through determination of 
the probability of the family as a true FPC kindred and the individual as a carrier, along with 
the age dependent risk, allowing for the phenomenon of anticipation, will enable clinicians 
to target screening to those at highest risk. The principle of the risk stratification model is 
outlined in Figure 3. Work undertaken towards this thesis has specifically aimed to quantify 
age dependent risk, according to lifestyle factors, which influence penetrance in FPC, so 
contributing to the risk model and targeted screening of those at highest risk. 
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Estimate that an individual is a 
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+ve LR2
Age dependent risk if a carrier
Regression based on family structure, lifestyle and gender
+ve LR3
Odds that an individual will develop cancer in next 5 years
 
Figure 3 EUROPAC risk stratification model 
The model assumes that individuals can be put into groups with a mean time to event determined by a selection of critical 
co-variates. The co-variates examined included gender, smoking, age and parental history of cancer. 
 
3.3.4 Overview of EUROPAC screening protocol 
 
EUROPAC, along with other registries worldwide have developed multi-modality screening 
protocols. The screening protocols adopted by other registries have been summarised 
earlier in this thesis. Throughout the period of this work, the screening programme evolved 
in various ways, partly as a direct result of the data presented later, and partly due to 
evaluation of data from other centres. The secondary screening protocol, as employed in 
2010 is outlined in Figure 4. A chief part of the work towards this thesis was centred upon 
the recruitment of individuals to the secondary screening study and orchestration of 
screening investigations according to our protocol. Data collected from our screening cohort 
will be presented later. A significant part of this work was in the amendment of the 
EUROPAC screening protocol with the aim of improved participant safety as stated in my 
thesis aims and objectives. The protocol comprises a combination of blood tests, imaging 
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modalities and molecular analyses. Initial baseline fasting glucose and CA19.9 were 
measured and repeated on an annual basis. A 5 millilitre (ml) serum sample was obtained 
from our screening participants for measurement of CA19.9. In the EUROPAC secondary 
screening study for early pancreatic cancer, plasma fasting glucose, measured in mmol/l, 
was used as a screening tool for diabetes mellitus. Plasma analysis of fasting glucose 
required the patient to have fasted for a minimum of 8 hours. The sample was taken using a 
EDTA tube and 3ml volume was required for the analysis. The reference range, as stated by 
the Royal Liverpool University Hospital Trust Department of Biochemistry, was 3.5-6.0 
mmol/l. This reference range may vary between groups. Alternative plasma glucose 
measurements were utilised by other screening centres as previously discussed. 
Baseline imaging of the pancreas was sought via a single CT scan upon entry into the 
screening program. In addition, EUS was undertaken at baseline and on a repeated basis. 
 
109 
 
 
 
Figure 4: EUROPAC secondary screening protocol 
Schematic representation of the EUROPAC secondary screening protocol incorporating primary screening, baseline 
imaging, pancreatic juice collection for molecular analysis and resultant risk-dependent screening schedule. 
 
3.3.5 ERCP and pancreatic juice collection  
 
In addition to the blood tests and imaging modalities described, EUROPAC undertook ERCP 
and pancreatic juice collection for analysis of molecular markers. These molecular markers, 
namely, K-RAS2 mutations, CDKN2A methylation and TP53 mutations aid in risk 
stratification and identification of pre-cancerous, or early malignant, lesions. The role of K-
RAS2, CDKN2A and TP53 in pancreatic carcinogenesis has been described earlier. I was 
responsible for collection, preparation and storage of juice samples for further analysis by 
another member of our team. 
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ERCP procedures were undertaken on a day case basis for high risk individuals participating 
in the EUROPAC secondary screening study. All procedures were undertaken by a 
Consultant Endoscopist under sedation with 1-5mg intravenous Midazolam plus an opiate 
analgesic, Fentanyl 50-100mg or Pethidine 50mg, dependent upon endoscopist preference, 
and an anti-peristaltic agent. Selective cannulation of the pancreatic duct, in order to 
aspirate pancreatic juice for analysis, was confirmed by fluoroscopy prior to aspiration. 
Pancreatic juice aspiration was then undertaken following the administration of intravenous 
secretin, this aspect of the screening study will be discussed in more detail in a subsequent 
sub-chapter. A maximum of 10 ml of pancreatic juice was then aspirated for analysis. Upon 
completion of the procedure, the endoscopist deployed a 5 French gauge stent. The stent 
utilised was plastic and self-expelling. Follow-up abdominal x-ray was undertaken at 6 weeks 
to ensure expulsion of the stent. In addition to the deployment of prophylactic pancreatic 
stents at ERCP, participants also received 50mg of the anti-inflammatory Diclofenac per 
rectally within 30 minutes of completion of the procedure. The use of prophylactic stents 
and per rectal Diclofenac was instigated following an amendment to the EUROPAC 
screening protocol undertaken by me with the aim of improved participant safety. 
 
Molecular analysis of pancreatic juice  
The use of molecular techniques for the detection of key mutations in pancreatic 
carcinogenesis is an attractive strategy for screening patients at risk of pancreatic cancer. 
Following my collection, preparation and storage of pancreatic juice samples, another 
member of the research team undertook analyses according to the standard operating 
procedure described later in this chapter. Point mutations of K-RAS2 occur in around 80% of 
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tissue samples taken from sporadic PDAC [226]. K-RAS2 oncogene activation appears to 
occur in preinvasive pancreatic cancer [227] and is also mutated in various types of ductal 
hyperplasia [226-228]. K-RAS2 mutations have been detected in pancreatic juice samples of 
patients with pancreatic cancer with a sensitivity of between 67%-100% [229, 230]. They 
have also been detected in patients with chronic pancreatitis, and in patients with normal 
pancreata [231-234]. This suggests that K-RAS2 is a sensitive marker for the presence of 
malignancy, but lacks specificity, particularly in the presence of chronic pancreatitis.  
The tumour suppressor gene CDKN2A is deleted or mutated in 85% of tissue samples from 
PDAC [131, 235]. A subset of FAMMM kindreds that carry CDKN2A mutations, have a 
significantly increased risk of pancreatic cancer [236]. Aberrant methylation of cytosine 
residues in the promoter region of CDKN2A is an important mechanism of gene inactivation 
in the molecular pathogenesis of pancreatic cancer [237, 238]. Detection of CDKN2A 
promoter CpG island methylation has been examined as a screening modality for PDAC 
[239-241] but only on the basis of detection or non-detection. Reported sensitivity was low 
(<20% to 40%), and although specificity was reported to be high in pancreatic juice, this 
could have been because of the low sensitivity of the test, and the authors confirm the 
presence of methylated sequences in normal tissue. In the analysis of CDKN2A methylation 
utilised in the EUROPAC secondary screening study, we used a sensitive polymerase chain 
reaction (PCR) modality combined with quantification to improve specificity. 
TP53 gene mutations occur in approximately 50% of pancreatic cancers [242] and mutations 
have also been detected in pancreatic juice using a technique called single stranded 
conformation polymorphism (SSCP). Of 26 patients with PDAC, 11 (42%) carried a TP53 
mutation, whilst none of the 16 patients with chronic pancreatitis had a detectable TP53 
mutation [243].  It is believed that TP53 mutations are more likely to arise relatively late 
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during pancreatic carcinogenesis and are rare in chronic pancreatitis [243, 244]. The 
presence of mutant TP53 in combination with K-RAS2 mutations in pancreatic juice has also 
been described. In their analysis, Wang et al recorded TP53 and K-RAS2 mutations in 
pancreatic juice in 42.9% (9 of 21) and 81.0% (17 of 21) of cancer cases respectively. No 
TP53 mutations were seen in 25 patients with chronic pancreatitis, whilst K-RAS2 mutations 
were detected at an incidence of 28% (7 of 25)[245]. 
The specificity (percentage of chronic pancreatitis controls or benign biliary disease controls 
correctly identified by each of the three screening tests) and sensitivity (percentage of 
pancreatic cancer correctly identified by the screening tests) of the molecular tests have 
already been evaluated. Mutations of TP53 were detected in 20 of 48 cases (42%) of PDAC, 
none in 49 biliary controls and 2 (4%) in 49 patients with chronic pancreatitis. K-RAS2 
mutations were seen in 31/57 (54%) cancer patients, but also in 13/61 (21%) biliary 
controls, and 23/67 (34%) with chronic pancreatitis. 26 out of 42 (62%) cancer patients had 
CDKN2A promoter methylation levels >12% compared to 1/22 (5%) biliary controls and 2/20 
(10%) individuals with chronic pancreatitis. The specificities and sensitivities based on these 
results are given in Table 2 below.  Combination of TP53 results with CDKN2A promoter 
methylation increased the discrimination between patients with malignant and benign 
disease of the pancreas: 27 (79%) out of 34 cancer patients had a TP53 mutation or high 
level CDKN2A promoter methylation compared to 1/18 (6%) controls and (28%) 5/18 with 
chronic pancreatitis.  The analysis of molecular markers in pancreatic juice, as undertaken 
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by our group, is summarised by the Bayesian approach depicted below [121] 
 
Figure 5: Bayesian model for molecular screening of pancreatic juice 
Molecular analyses (p16 methylation, K-Ras mutation and p53 mutation) were carried out on pancreatic juice DNA from 
patients recruited with PDAC and benign biliary disease. This allowed a calculation of sensitivity and specificity for each 
marker (for detection of PDAC). Each marker was tested in each group for independence and on the basis of independence 
a Bayesian approach was adopted. Briefly, odds and likelihood ratios of having cancer were calculated on the basis of the 
specificities and sensitivities for each marker and the likelihood ratios used sequentially to calculate probability of cancer 
(the combination obviously having the same value in whichever order the markers are used). The data is also presented in 
table 2 below [121]. 
 
Table 2: Sensitivity and specificity of analysis of TP53, K-RAS2 and CDKN2A methylation in pancreatic juice [121] 
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3.3.6 Preparation of pancreatic juice aspirate samples taken at ERCP prior to 
DNA extraction 
 
A maximum of 10ml of pancreatic juice was taken during cannulation of the pancreatic duct 
at ERCP. Within two hours of collection, the chilled juice was transferred to a sterile 1.5ml 
Eppendorf tube and spun at 4000g for ten minutes. The supernatant was aspirated and 
immediately stored at –80ºC. I undertook this process of collection, preparation and storage 
of pancreatic juice samples prior to further analyses by another member of our research 
team according to the standard operating procedure outlined below. 
 
Pancreatic juice aspirate DNA extraction 
 
To 200 microlitres (µl) of pancreatic juice aspirate, equal volumes of sterile water and 
Phenol: Chloroform: Isoamyl Alcohol 25:24:1 were added. The aqueous and organic phases 
were separated by centrifugation. DNA was precipitated overnight at 4ºC using 2.5 volumes 
of 100% ethanol and 20µl 3M sodium acetate pH 6.8. The DNA was dissolved in 200µl of 
molecular grade water.  
 
Functional assay of TP53  
 
The TP53 assay is based on the principles of a yeast functional assay system designed by 
Flaman et al. [246]. The most important modification was the use of genomic DNA, rather 
than RNA. Exons five to eight, which contain the mutation hotspots 42, were chosen, as 
these exons code for the DNA binding domain of the TP53 protein. 
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Polymerase Chain Reaction (PCR)  Amplification and linkage of TP53 exons 5,6 
and 7  
Genomic DNA was amplified by PCR; the conditions were 95ºC for 12 minutes, followed by 
40 cycles of 94ºC for 30 seconds, 60ºC for 30 seconds and 72ºC for 1 minute. The PCR 
mixture contained 0.25 units of pfu DNA polymerase, 1x pfu buffer (Promega) with 2mM 
Magnesium Sulphate, 20 µmol of each primer and 0.2 mm dntps. Primers were designed to 
allow PCR linkage of exons 5-6 and exons 7-8 and then to link 6 to 7, where possible the 
overlapping primers were used to amplify the exons directly from genomic DNA, otherwise 
an external (intronic) primer was used to give product followed by a second nested PCR. 
 
Strains, vector, media and yeast functional assay  
  
The reporter yeast strain yig-397 was co-transformed with the PCR product of TP53 exons 5 
to 8 and a circular expression vector carrying full length TP53 (pls76). The vector TP53 
sequences were replaced by PCR amplified sequence in vivo by homologous recombination. 
Wild type TP53 allows expression of ADE2 and consequently white yeast colonies, whilst 
mutant TP53 sequences result in no expression of ADE2 and so red colonies. White and red 
transformants appear following 48 hours incubation on selective plates lacking leucine and 
with a low adenine concentration (10mg/l). The uncut circular vector was used rather than 
gap repair. Although this dramatically decreases the ratio of red to white colonies, it also 
decreases the number of false positive colonies. Previous studies [246, 247] have shown 
that the TP53 functional assay of tissue containing wild-type TP53 gave 5-10 % red colonies 
with the gap repair vector. The background resulted from PCR-induced error, alternative 
splicing of intron 44 and self-ligated vector with gap repair 41 (this latter problem was 
avoided by the use of undigested vector). To identify mutations, plasmids were rescued 
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from three red yeast colonies by alkaline lysis and transformed into E coli DH5α and 
sequenced. If two sequences from different yeast carried the same TP53 mutation the 
sample was classified as mutant.  
 
Amplification Refractory Mutation System (ARMS) analysis for K-RAS2 
mutations 
 
ARMS is a mutation specific PCR assay controlled with amplification of an overlapping 
sequence with mutation independent primers. Real-time PCR was performed using the 
Roche lightcycler (Roche Diagnostics) and detection was via SYBR Green I. In practice, there 
was normally a degree of amplification of the wild type sequence even with mutation 
specific primers, hence control primers were used for comparison, that amplify wild type 
and mutant sequences with equal efficiency. Threshold cycles with mutant specific primers 
were plotted against threshold cycles using the control primers. The assay had been 
calibrated using varying concentrations of normal blood DNA, at least 100 pairs of PCR 
reactions for each mutation specific primer. This allowed 98% confidence intervals to be 
produced on a linear regression curve. Samples were analysed in triplicate for each K-RAS2 
mutation, and threshold cycles plotted. If all three points were below the 98% confidence 
limit for the regression the sample was considered to contain mutant sequences, otherwise  
it was classified as wild type. 
 
Reaction conditions for ARMS 
  
Primers specific for the six recognised point mutations at codon 12 were used (aspartate, 
arginine, valine, serine, alanine and cysteine). Real time PCR was performed with an initial 
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denaturation step of 10 minutes at 95ºc. This was followed by 60 cycles of: 2 seconds at 
95ºc, 20 seconds at the annealing temperature of 61ºc, 20 seconds at 72ºc and 10 seconds 
at 81ºc. This was followed by a melting curve ramp from 72 to 95ºc over 10 minutes. 
Quantification analysis was performed on each sample using the lightcycler software 
(Version 5.32). Melting curve analysis was performed to verify that pure PCR products were 
produced.  
 
Real-time PCR measurement of CDKN2A promoter methylation in pancreatic 
juice aspirate 
 
DNA from pancreatic juice aspirate was subjected to sodium bisulfite modification as 
described previously [248]. Real-time PCR amplification was carried out in a 20 µl of volume 
with 2 µl Light Cycle DNA Mastermix, with a primer concentration of 1µm. PCR reactions 
were carried out on the lightcycler amplification and detection system. Pre-incubation was 
performed for 10 minutes at 95 ºC. DNA was amplified for 60 cycles of 20 seconds at 95ºC, 
10 seconds at 67ºC for methylated primer (65ºC for unmethylated primer), and 10 seconds 
at 72ºC.  Data were analyzed by the quantification program software. The methylation index 
(%) in a sample was calculated using the following equation: Methylation index = [M/(M+U)] 
x 100%, where ‘M’ is the quantity of methylated CDKN2A sequences measured by MSP 
following bisulfite conversion, and ‘U’ is the quantity of unmethylated CDKN2A sequences 
measured by real-time MSP following bisulfite conversion [249]. 
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3.3.7 Reduction of ERCP pancreatitis in FPC screening using PR Diclofenac and 
temporary self-expelling pancreatic stents 
 
Despite the advantages in risk stratification achieved through the collection and analysis of 
pancreatic juice via ERCP; cannulation of the pancreatic duct poses a significant risk of 
pancreatitis. The procedure associated risk of pancreatitis following ERCP varies greatly 
from 1% to in excess of 30% [250, 251] [252]. This risk varies in accordance with exposure to 
certain risk factors, which may be technical or patient derived. Young age has been 
consistently demonstrated to confer a significantly increased risk of the development of 
post-ERCP pancreatitis [251-253]. This is a risk factor which is of particular concern, as those 
unaffected family members belonging to confirmed FPC kindreds were invited to commence 
screening from the age of 40, and so fall into this category of elevated risk. In order to 
minimise the risk of pancreatitis in the EUROPAC screening cohort, an amendment to the 
protocol was undertaken as part of my work towards this thesis. The advent of the anti-
inflammatory agent Diclofenac, administered per rectally, and the deployment of temporary 
self-expelling pancreatic stents resulted in significantly reduced ERCP pancreatitis in our 
screening cohort. 
 
3.4 The use of intravenous Secretin for duodenal juice collection for 
analysis of molecular markers 
 
 A mechanism of collection of genetic material derived from pancreatic juice for 
stratification via molecular analysis; whilst avoiding pancreatic duct cannulation, and the 
resultant risk of pancreatitis, would be preferable to minimise risk exposure in the screening 
population. In view of this, the technique of juice collection has been modified with the 
119 
 
objective of improving safety, and reducing procedure related risks, in our screening cohort. 
The modification involves hormonal stimulation of secretion of pancreatic juice and 
collection within the duodenum (first part of the small bowel). This technique has been used 
successfully in the analysis of biochemical markers in chronic pancreatitis [254] and in two 
previous studies similar to that which was proposed i.e. analysing molecular markers for 
pancreatic cancer [250, 251]. This method involves the use of a synthetic gut hormone, 
secretin, which is administered intravenously and stimulates production and secretion of 
pancreatic juice. The stimulated juice is then collected within the duodenum, with the 
ultimate aim of avoiding cannulation of the pancreatic duct, and hence the associated risk of 
pancreatitis. 
The techniques of ERCP and EUS are employed in those with suspected malignant or benign 
disease for a variety of diagnostic and therapeutic interventions. ERCP may be undertaken in 
patients with obstruction of the biliary tree secondary to a mass lesion in the head of the 
pancreas, or due to intraductal stones. In the event of a probable malignant mass affecting 
the head of the pancreas, stent deployment is undertaken via ERCP in patients pre-
operatively or as a palliative procedure. ERCP and EUS are also undertaken to obtain 
samples for cytological or histological analysis of a suspected pancreatic adenocarcinoma. 
We recruited patients with benign or malignant disease attending for either ERCP or EUS for 
a prescribed clinical indication. 
We have previously demonstrated that the analysis of molecular markers in pancreatic juice 
can enable discrimination between malignant and benign disease [121]. We have ethical 
approval to perform the technique of pancreatic juice collection via ERCP for molecular 
analyses of K-RAS2 and TP53 mutations plus CDKN2A methylation in order to stratify risk in 
a number of defined high risk screening populations (REC refs: 07/H1008/153 Central 
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Manchester REC;  07/H1211 Warwickshire REC). Similar studies have been performed 
analysing the sensitivity and specificity of duodenal fluid for the detection of molecular 
markers which may indicate early pancreatic adenocarcinoma. These studies have been 
undertaken in small sample groups and have yielded inconsistent results [239, 255, 256]. 
We aimed to evaluate the sensitivity and specificity of molecular markers within duodenal 
fluid as an indicator of pancreatic carcinogenesis by comparing analyses from malignant and 
benign patient groups. It was envisaged that the results of such analyses could be 
interpreted as a surrogate for the presence of molecular markers in pancreatic juice in high 
risk screening patients. A significant part of my work towards this thesis was in the ethical 
approval for a prospective cohort study for the collection and analysis of duodenal juice in 
the screening of high risk individuals for pancreatic cancer (REC Reference: 10/H1010/19 
NRES Committee North West Haydock).  
 
3.4.1 Historical use of Secretin for duodenal juice sampling and rational for use 
in screening for early pancreatic cancer 
 
 It is hypothesised that the sensitivity and specificity of molecular markers in pancreatic 
juice will be replicated in similar analyses of duodenal aspirate. The collection of duodenal 
fluid does not require cannulation of the pancreatic duct, which is the event that 
precipitates procedure related pancreatitis during ERCP. Thus, this technique is likely to be 
safer in our cohort of screening patients, provided that the sensitivity and specificity are 
comparable to that seen in pancreatic juice. 
Post-ERCP pancreatitis may affect 2-15% of those undertaking the procedure depending 
upon technical and patient derived risk factors. Of particular relevance to the EUROPAC 
cohort of screening patients is the increased risk which has been consistently identified in 
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patients below the age of 50 [251, 253, 257, 258]. In a study of 2444 procedures, a large 
multicentre trial performed in Italy recorded a significantly increased risk of ERCP related 
pancreatitis in patients below the age of 60 (OR 1.53 [95% CI 1.06-2.20] p=<0.001)[258]. The 
reported severity of post-ERCP pancreatitis varies across different cohorts and may be 
classified as mild, moderate or severe. The majority of post-ERCP pancreatitis is classed as 
mild and characterised by the onset of abdominal pain within 24 hours following the 
procedure. This is associated with a threefold elevation in serum amylase; a human enzyme 
which exhibits grossly elevated levels in the presence of pancreatic inflammation i.e.in acute 
pancreatitis. In a large multicentre US trial examining outcomes in 11,497 ERCP procedures, 
75% of the 304 reported cases of post procedure pancreatitis were mild in severity. There 
was an associated mortality rate of 0.06% with ERCP induced pancreatitis in this large 
cohort [250]. This demonstrates that, although post-ERCP pancreatitis is mild in the majority 
of cases, it may be a cause of significant morbidity, and in severe cases, with the associated 
onset of multi-organ failure, may be fatal. A number of studies have examined the influence 
of certain procedure and patient related risk factors in the development of post-ERCP 
pancreatitis. Among the factors most consistently demonstrated as conferring an increased 
risk of post-procedure pancreatitis is age. A number of large cohort studies have identified a 
significantly increased risk in individuals undertaking ERCP below the age of 50-60 years 
[253, 257, 258]. As EUROPAC commences screening in eligible individuals from the age of 
40, and they may undertake ERCP for juice collection at a maximum of every 18 months, the 
evidence suggesting an increase in risk of ERCP-pancreatitis within this age group is an 
important consideration. It should be noted that, although the highest risk of ERCP 
pancreatitis is conferred through therapeutic procedures including sphincterotomy and 
multiple contrast injections into the pancreatic duct [250, 251, 257, 258], certain other 
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patient related factors bear significance when considering the risk to a screening cohort. The 
majority of patients involved in the EUROPAC secondary screening study for early pancreatic 
cancer have not undertaken any ERCP intervention prior to their participation in the 
screening programme. One study has identified an increased complication rate in such 
individuals who underwent ERCP with cannulation via a native papilla i.e. in those who have 
not undertaken any previous therapeutic ERCP [259]. In order to reduce the risk of 
procedure related pancreatitis in our screening cohort we administered a synthetic gut 
hormone, secretin, to enable collection of pancreatic juice within duodenal aspirate, so 
avoiding cannulation of the pancreatic duct and the inherent risk of procedure related 
pancreatitis. Secretin is a 27 amino-acid polypeptide hormone secreted in an inactive form, 
prosecretin, by the S cells of the duodenal mucosa in response to acidity (low pH) within the 
duodenal lumen. The acidic conditions which stimulate the release of prosecretin occur 
through the presence of gastric contents entering the duodenum during the digestive 
process. Secretin exerts a number of effects within the digestive process. It targets the 
pancreas where it stimulates the secretion of bicarbonate rich pancreatic juice from 
pancreatic acinar cells. The alkaline bicarbonate rich juice is secreted into the duodenum so 
increasing the pH within the duodenal lumen. This process serves as an aid to digestion and 
protective mechanism. Lowering of the intraluminal pH within the duodenum enables 
activation of other digestive enzymes, and buffering the acidity of the gastric contents 
prevents damage to the small bowel mucosa. Secretin also relaxes the sphincter of Oddi and 
may facilitate pancreatic duct cannulation at ERCP, as a result of widening of the orifice 
[260]. Secretin has other functions, in stimulating release of bile from the liver and inhibiting 
pepsin production from G cells within the gastric antrum, so further increasing the pH within 
the duodenum by reducing acid production within the stomach. Secrelux® is a purely 
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synthetically derived porcine secretin which is available for investigational clinical use to aid 
diagnosis at MRCP and ERCP in a number of clinical conditions including sphincter of Oddi 
dysfunction and chronic pancreatitis [254, 261]. Biologically derived porcine secretin was 
originally extracted by Jorpes and Mutt in 1961 [262] and has been used for clinical 
diagnostic purposes in the US since 1981 [260]. Research into the pharmacological efficacy 
of synthetically derived porcine secretin compared to a biological derivative has 
demonstrated identical effects [263]. The active ingredient within synthetic porcine secretin 
is secretin pentachloride, and the manufacturer’s (Sanochemia Diagnostics International) 
guidelines recommend intravenous administration at a dose of 1 CU (international unit) per 
kilogram over a period of 1-2 minutes for juice collection in the diagnosis of exocrine 
pancreatic function. Previous pharmacokinetic analysis in 15 volunteers has recorded a half-
life of porcine secretin of 2.84 (+ 0.62) minutes in humans [264]. From the manufacturer’s 
data, reported undesired effects include occasional diarrhoea resulting from a frequently 
observed increase in secretion of pancreatic amylases, lipases and trypsin. This may be 
associated with abdominal pain and nausea or vomiting. Rapid infusion may result in 
flushing or faintness. Other reported effects include urinary urgency and a transient fall in 
blood glucose, which may be observed in diabetics. Synthetic secretin is licensed for patient 
use in a variety of clinical scenarios. Secretin stimulated EUS and MRCP are performed in 
individuals with recurrent pancreatitis of uncertain aetiology [265]. There is limited evidence 
to suggest that secretin stimulated EUS and MRCP achieve a higher diagnostic yield than 
ERCP in this patient group [265]. The administration of synthetic secretin at MRCP has been 
found to improve pancreatic duct delineation [265, 266]. This effect occurs as a result of 
stimulation of the exocrine pancreas to secrete bicarbonate rich fluid which causes transient 
dilatation of the pancreatic duct [261].  In the context of screening for early PDAC, recent 
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evidence has highlighted an important potential advantage in the use of intravenous 
secretin. A recent randomised, double-blind, placebo-controlled trail by Jowell et al 
reported a significant reduction in post-ERCP pancreatitis following the use of intravenous 
secretin. In their series of 889 participants, the incidence of post-ERCP pancreatitis in the 
secretin cohort was 8.7%, versus 15.1% in the placebo group (p=0.004).  
In addition to its use in various imaging modalities, secretin is also administered to stimulate 
pancreatic juice secretion for collection for biochemical analyses, including bicarbonate 
measurement [267-269]. There is a limited body of evidence regarding molecular analysis of 
duodenal fluid as a surrogate marker for pancreatic juice, and its potential role in the 
detection of early pancreatic cancer [255, 256].  
3.4.2 Molecular analysis of secretin stimulated duodenal aspirate 
 
Secretin stimulated duodenal aspirate was taken at screening ERCP, the process of which 
has been described earlier in this work. Prior to cannulation of the ampulla and pancreatic 
duct, the endoscopist undertook suction aspiration of existing gastric debris in order to 
mimimise contamination of the collected duodenal sample with junk DNA. The researcher 
then administered secretin in accordance with the manufacturer’s guidance as outlined 
above. The endoscopist then employed continuous aspiration of the resultant ampullary 
secretions for a maximal 10 minute collection period, or at such time that 10ml of aspirate 
was obtained. Larger volumes of duodenal aspirate were collected, compared to that of 
pancreatic juice, in order to maximise the diagnostic yield in subsequent molecular analyses. 
The endoscopist then proceeded on to cannulate the ampulla and pancreatic duct to obtain 
pancreatic juice samples for comparative analyses. The ERCP and recovery were then 
managed as previously detailed. 
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3.4.3 Duodenal juice analysis protocol  
 
EUROPAC has ethical approval for the collection of pancreatic juice for the analysis of 
molecular markers. The collection, analysis and storage of duodenal aspirate was 
undertaken according to this protocol. My role was in authorship of the protocol for ethical 
approval and in recruitment and sample collection. Collection and analysis of K-RAS2, 
CDKN2A methylation and TP53 mutation was performed in accordance with the techniques 
previously validated by our group and discussed earlier in this work [121].  
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Sample collection was undertaken in individuals attending for clinically indicated ERCP or 
EUS. No procedure was undertaken in the absence of clinical need for the sole objective of 
sample collection.  The comparative sensitivity and specificity of molecular markers in 
duodenal aspirate versus pancreatic juice, from individuals with pancreatic cancer and 
chronic pancreatitis, plus a control cohort with benign biliary disease, determined the 
feasibility of this technique in effective screening of high risk groups. It was proposed that 
the collection of duodenal aspirate as a surrogate marker for pancreatic juice may enable 
risk stratification, while minimising the morbidity of ERCP-associated pancreatitis. The 
results of this analysis will be discussed later in this thesis. 
4. RESULTS: Registries 
4.1 FPC registry: Demographics 
 
The EUROPAC FPC and HP registries were established in 1997 and, at the time of writing, we 
had recruited 1000 families who appear to exhibit an underlying genetic predisposition to 
the development of pancreatic adenocarcinoma. This included 401 families who were 
registered with the EUROPAC FPC registry. Of these, there were 273 kindreds who displayed 
an autosomal dominant pattern of inheritance consistent with FPC. This encompassed 16 
families in whom there appeared to be an inherited predisposition to gastric cancer in 
conjunction with an elevated pancreatic cancer risk.  Of those families demonstrating a clear 
autosomal pattern of inheritance, 184 kindreds had 2 affected cases and 89 had 3 or more 
affected family members. Table 3 provides an overview of the FPC registry during the period 
of work towards this thesis:  
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Table 3: Summary of FPC database 
Table 3a: Summary of FPC database 
 
 
Country 
 
Total number of 
families 
 
Family diagnosis 
 
Family diagnosis FPC/FPC? 
 
Number of affected at registration 
FPC/FPC?  Other inc. 
BRCA2 
2 affected 
 
>2 affected 
UK 327 216 111 146 70 
France 22 14 8 11 3 
Germany 12 11 1 9 2 
Greece 6 6 0 4 2 
Italy 6 5 1 2 3 
Latvia 6 6 0 5 1 
Hungary 4 4 0 3 1 
Eire 4 1 3 0 1 
Sweden 3 1 2 0 1 
Belgium 3 3 0 2 1 
Denmark 2 2 0 0 2 
Spain 2 2 0 1 1 
Netherlands 1 1 0 1 0 
Portugal 1 0 1 0 0 
Switzerland 1 0 1 0 0 
Japan 1 1 0 0 1 
TOTAL 401 273 128 184 89 
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Table 3b: Summary of UK FPC families  
Histological confirmation includes cases where pathology reports and/or cancer registry and/or good medical records 
confirm the diagnosis of PDAC. 
 
No families 
registered 
Total no. 
individuals 
registered 
Pancreatic 
cancer cases 
Histologically 
confirmed 
cases 
DNA stored 
 
Cell line 
Affected Unaffected Affected Unaffected 
390 11737 857 442 111 509 48 240 
 
The EUROPAC FPC registry also encompasses those families with hereditary cancer 
syndromes which confer an increased risk for the development of pancreatic 
adenocarcinoma. Examples include kindreds with mutations in BRCA2, Peutz-Jeghers, 
Breast-Ovarian, FAMMM and HNPCC syndromes. A summary of families registered with 
specific cancer syndromes and an associated increased risk for the development of 
pancreatic cancer is given in Table 4. 
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Table 4: Summary of specific cancer syndrome families registered with EUROPAC 
Encompassing families with the following diagnoses: BRCA2 Breast Ovarian; BRCA2 FPC; HNPCC; FAMMM; Breast Ovarian; 
Peutz-Jeghers; Neurofibromatosis. 
 
 
 
No. of Families 
 
Diagnosis 
8 BRCA2 BOv 
5 BRCA2 FPC 
4 HNPCC 
5 FAMMM 
24 BOv 
3 PJS 
2 NF 
 
 
4.2 HP registry – updated figures and breakdown/ demographics 
 
At the time of completion of the work towards this thesis, the EUROPAC HP registry had 540 
registered families, which represents the largest series across Europe. As described earlier, 
the criteria for registration as an HP kindred are either an apparent autosomal dominant 
pattern in inheritance for pancreatitis of early onset in the absence of other causative 
factors; or a confirmed mutation of the PRSS1 gene. Table 5a summarises kindreds 
registered with the EUROPAC HP registry from across Europe during the time of writing of 
this thesis. 
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Table 5: Summary of HP database 
Table 5a: Summary of HP database  
 
Country p.R122H 
families 
p.N29I 
families 
A16V 
families 
NEG 
ALL HP 
families 
Copy 
number 
variance 
Other 
mutation 
Familial 
Idiopathic 
Pancreatitis 
(FIP) 
Possible 
HP 
CFTR 
families 
SPORADIC TOTAL 
UK 30 24 3 19 1 1 28 45 15 139 305 
France 29 9 1 3 5 10 6 4 0 1 68 
Germany 19 4 0 5 0 1 0 1 0 3 33 
Eire 5 2 0 1 0 0 2 4 1 12 27 
Denmark 2 0 3 1 0 0 4 1 1 12 24 
Belgium 2 1 1 1 0 0 2 1 0 6 14 
Italy 3 1 0 4 1 1 2 1 1 0 14 
Netherlands 2 1 0 1 0 0 1 0 0 0 5 
Finland 1 0 0 0 0 0 0 0 0 1 2 
Greece 0 0 0 0 0 0 0 0 0 1 1 
Sweden 2 0 0 0 0 0 0 3 0 8 13 
Switzerland 3 0 1 2 0 0 0 1 0 1 8 
Hungary 2 0 0 1 0 0 0 0 0 4 7 
Czech 0 2 0 1 0 0 3 0 0 0 6 
Spain 0 0 0 0 0 0 0 1 1 1 3 
Turkey 0 1 0 0 0 1 1 0 0 0 3 
Norway 0 0 1 0 0 0 0 0 0 0 1 
Poland 2 0 0 0 0 0 0 0 0 0 2 
Portugal 0 0 0 0 0 0 0 0 0 1 1 
Sri Lanka 0 0 0 0 0 0 0 0 0 1 1 
USA 0 0 1 0 0 1 0 0 0 0 2 
TOTAL 102 45 11 39 7 15 49 62 19 191 540 
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A summary of the mutations present within those families registered with EUROPAC HP 
registry is presented in Table 5b. 
 
Table 5b: Summary of PRSS1 mutations identified in individuals registered with the EUROPAC HP registry. 
 
Mutation Families Affected individuals Pancreatic cancer cases 
(in affected individuals) 
True HP 212 839 49(46) 
p.R122H 102 462 25 (22) 
p.N29I 45 185 11 (11) 
p.A16V 11 25 1 (1) 
Neg All 39 145 11 (11) 
Other mutation 15 22 1(1) 
 
4.3 RESULTS: Epidemiological factors implicated in cancer 
development in HP 
 
In previous work undertaken by EUROPAC, in the largest series of HP individuals in Europe 
to date, Howes et al identified cumulative risk for pancreatic cancer development with age. 
In a cohort of 233 individuals, cumulative cancer risk increased with advancing age from 
0.5% (95% confidence interval [CI]: 0.0 – 1.3%) at 40 years to 33.3% (95% CI: 19.0 - 47.5%) at 
80 years of age [163]. When considering cumulative risk from onset of symptoms, at 70 
years from onset, the risk for cancer development was 44% (95% CI: 8.0 – 80%)[158]. 
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4.3.1 Risk according to PRSS1 mutation  
 
The risk of pancreatic cancer conferred by the p.A16V mutation of PRSS1 is difficult to 
quantify. In the largest series of p.A16V individuals to date, previous work by Grocock et al 
[167] using data from the EUROPAC HP registry, has revealed that p.A16V exerts a very 
variable phenotype. The cancer risk associated with the p.A16V genotype is difficult to 
characterise [167], the cumulative lifetime risk of pancreatic adenocarcinoma conferred 
with p.R122H and p.N29I mutations is widely accepted. In the largest series of p.A16V 
families to date, our group characterised the phenotypic variation seen in p.A16V [167]. The 
phenotypic and clinical features of the p.A16V families described in this series are outlined 
in Table 6 [167]. 
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Table 6: Summary of EUROPAC p.A16V families 
 
 
 
 
  
 
Family 
 
Classification 
 
Number 
testing 
positive for 
p.A16V*  
(with 
pancreatitis) 
 
Median age of 
onset (IQR) 
All patients 
testing positive 
for p.A16V* 
 
Median age 
of onset (IQR) 
Patients with 
pancreatitis 
 
Endocrine 
pancreatic 
failure  
(with 
pancreatitis) 
 
Exocrine 
pancreatic 
failure  
(with 
pancreatitis) 
 
Pancreatic 
cancer cases  
(with 
pancreatitis) 
A HP 7(3) 
 
18 years 
(7-53) 
 
10 years 
(5-21) 
4(0)† 1(1) 0 
B HP 2(2) 2(1) 2(2) 0 
C HP 2(2) 0 0 0 
D HP 4(4) 0 0 0 
E HP 5(2) 0 0 1(0) 
F HP 3(2) 2(2) 2(2) 1(0) 
G Idiopathic 3(1) 
Not reached 
(5-Not reached) 
2 
(1-5) 
1(0)† 0 0 
H Idiopathic 3(1) 1(1) 1(1) 0 
I Idiopathic 4(1) 0 0 0 
J 
Single 
Generation 
4(4) 
27 
(25-28) 
27 
(25-28) 
0 2(2) 1(1) 
Totals  37(22) 26 (7-54) 10 (5-26) 10(4) 8(8) 3(1) 
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In light of this evidence, it was concluded that cancer risk should be considered within the 
context of each kindred. In the event of a single case of idiopathic disease, then risk for the 
development of cancer should be considered as per any individual with idiopathic 
pancreatitis. However, in those families which exhibit a pattern of inheritance consistent 
with true HP, then the cancer risk should be considered as that of true HP. As summarised 
above, a number of PRSS1 mutations have been described and are associated with a 
variable clinical picture and cancer risk. p.R122H, p.N29I and p.A16V have been found to 
confer a significantly increased lifetime risk for the development of pancreatic cancer, in 
addition to the earlier age of onset of exocrine and endocrine failure. Other mutations in 
PRSS1 have been described in association with idiopathic disease and have been 
summarised earlier. For the purposes of discussion of those mutations which confer an 
elevated pancreatic cancer risk, these mutations will not be mentioned further. 
4.3.2 Age – SEER data and EUROPAC HP data demonstrating 28 fold 
increase in risk 
 
Data pertaining to the lifetime risk for development of pancreatic adenocarcinoma in 
certain PRSS1 mutations associated with HP, have identified a constant increase in risk with 
progressive age. Comparison of EUROPAC HP survival data with SEER statistics 
demonstrated an approximate 28-fold increased risk in the HP cohort when comparison to 
US SEER data is made. This trend appears constant with increasing age as detailed in Figure 
6. 
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Figure 6: Kaplan-Meier curve demonstrating EUROPAC HP risk compared to 28 fold increase on SEER data. 
SEER data (from the US) provides cross-sectional analyses of cancer incidence and survival across 5 year age ranges. I used 
SEER data to extrapolate survival by utilising the incidence (/10,000 population) to determine the percentage (%) risk of 
PDAC within each 5 year age range (red continuous line). Kaplan Meier analysis was applied to HP individuals to give the 
continuous blue line. Comparison of HP risk in age brackets (from Kaplan Meier) to the equivalent SEER data gave an 
average ratio of 28 (EUROPAC:SEER). The SEER risks were multiplied by 28 and applied as above to produce a pseudo 
Kaplan Meier curve (discontinuous pink line).  
 
4.3.3 Cancer risk in HP according to smoking and diabetes status 
 
From EUROPAC HP data, we have analysed the influence of smoking status and diabetes 
mellitus on cancer risk in HP. In Figures 7-10 the relationship between diabetes onset, 
smoking status and cancer development can be seen. The data reveal that although there is 
evidence that diabetes influences age of death from cancer in HP; that this effect is 
overwhelmed by the effect of smoking.  
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Figure 7: Age of onset of diabetes and age of cancer death in the EUROPAC HP cohort (just non-smokers) 
Date of death denotes age of death in years from a confirmed diagnosis of PDAC or the age of last contact, which is 
denoted as the point at which the data for that individual is ‘censored’ and analysed. The blue squares are all patients with 
diabetes. 
 
Figure 7 demonstrates the age of onset of diabetes and cancer death in our HP cohort. The 
following figure demonstrates age of onset of diabetes in a cohort of non-smoking HP 
individuals. It can be seen that diagnosis of diabetes demonstrates a proportional 
relationship to age of death from cancer as evidenced by the clustering of cases at the 
trend-line. 
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Figure 8: Age of onset of diabetes and age of death from cancer in HP non-smokers 
Date of death denotes age of death in years from a confirmed diagnosis of PDAC or the age of last contact, which is 
denoted as the point at which the data for that individual is ‘censored’ and analysed. Cancers are marked on in red the line 
indicates a linear regression for the cancer patients. 
 
Evidence from the EUROPAC HP registry therefore appears to suggest a trend in age of 
onset of diabetes and age of death from cancer. However, Figure 9 details the same data in 
a subgroup of HP smokers. The effect of age of onset of diabetes has been superseded by 
the influence of smoking on cancer risk. 
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Figure 9: Plot of age of onset of diabetes and age of cancer death in a cohort of HP smokers 
The trend in aggregation of cancer cases seen in the non-smoker HP cohort is not replicated in the smoking group. The 
assumption made is that of smoking causing cancer. The trend seen in the EUROPAC HP cohort is that of smoking as 
causative of both diabetes and cancer. The line represents a proposed screening age of 20 years after diabetes diagnosis, 
this misses most cancers in smokers but would have missed none in the non-smoking cohort. 
 
It can be seen that the relationship between age of onset of diabetes and death from cancer 
which is apparent in non-smoking HP individuals, has been confounded by the influence of 
smoking on cancer risk in HP. The effect of smoking upon cancer risk in the EUROPAC HP 
cohort is further evident when ex-smokers are considered (Figure 10). 
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Figure 10: Plot of age of onset of diabetes and age of death from cancer in HP ex-smokers 
In analysis incorporating ex-smokers, it can be seen that the proposed screening age at 20 years post onset of diabetes 
would be too late to identify the majority of cancers in ex-smokers with HP. 
4.4 RESULTS: Epidemiological factors implicated in cancer 
development in FPC 
4.4.1 Influence of age of onset in FPC 
 
Previous analysis of survival data from the EUROPAC FPC Registry has identified a 100-fold 
increased risk when compared to SEER data [32] at progressive age ranges (Figure 11); this 
will be further addressed in this thesis. 
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Figure 11: Survival data from EUROPAC FPC individuals and 100-fold increase in risk from US SEER data 
SEER data was used as a basis for calculation of % risk and applied to the EUROPAC FPC cohort as described in Figure 6 
 
4.4.2 Age of onset in FPC 
 
It has been proposed that families with an autosomal dominant predisposition for 
pancreatic cancer also have an earlier age of onset than individuals with no clear genetic 
predisposition. This is consistent with observations in other cancer syndromes and was 
systematically addressed by Brune [270] et al based on families recruited by the NFPTR. In 
their paper entitled “Importance of Age of Onset in Familial Pancreatic Cancer kindreds”, 
Brune et al reported a significantly elevated risk in kindreds with younger age of onset for 
existing affected individuals. This was based on a comparison of families where affected 
relatives were above or below 50 years of age. Being a member of a younger onset family 
conferred a standardised incidence ratio (SIR) of 9.31 (95% CI 3.42-20.28, p=<0.001) 
compared to an SIR of just 6.34 (95% CI 4.02-9.51, p =<0.001) in the older onset families 
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[270].  However, in this thesis I propose that this apparent trend is attributable to 
ascertainment bias.  Previous reports from the NFPTR show a highly elevated risk of 
prospective pancreatic cancer in such families [157]. However, this risk was overwhelmingly 
due to a very small number of families with a very strong family history. Only one out of 98 
families with 2 existing cases of pancreatic cancer had a prospective cancer, in contrast one 
out of just 4 families with 5 or more cases had a prospective cancer. Clearly, family 
classification is dependent on the observer, if 2 out of 5 cases of cancer are known originally 
and 3 new cases are subsequently identified there has not been any change to actual cancer 
risk, merely a change to assumed cancer risk. If we accept that there are families with 
equivalent biologically defined risk in the group with 2 cases and the group of families with 5 
cases, this would strongly suggest that most families are random clusters, but there are 
fewer random clusters in the families with more cases [157]. EUROPAC tries to reduce the 
number of random clusters by adopting a longitudinal approach to recruiting families as 
explained earlier in this work. To ascertain whether bias through variation in recruitment 
strategy could explain the young age of onset reported by Brune et al, we have compared 
the characteristics of families recruited to our registry on the basis of an affected versus an 
unaffected proband, including the estimated cancer risk in FDR. For the purposes of this 
analysis, the total number of affected individuals within a family included probands in 
addition to FDR. It is surmised that the greater the number of PDAC cases confirmed within 
a kindred, the greater the likelihood of a genuine familial predisposition to PDAC. Brune et 
al proposed that there is a lower age of onset in FPC versus sporadic PDAC, therefore the 
age of onset should be lower in kindreds with greater numbers of affected relatives. 
Kindreds included for analysis were divided depending upon the number of confirmed PDAC 
cases in the family i.e. 2 and 3 or more (Figure 12). Families were recruited via probands 
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who, following informed consent, completed family and personal health questionnaires. 
Where appropriate, clinicians also completed parallel questionnaires, which were used for 
confirmation of clinical details and hospital and pathology notes were also obtained. Clinics 
were arranged and family members were invited to attend via the proband. Individuals 
were classified as affected based on histological confirmation of PDAC where available. 
Where histology was not available good quality medical notes or reliable cancer registry 
information were used. FPC was defined as families with two or more affected individuals 
not fulfilling criteria for any other familial cancer syndrome. We assessed 289 families (706 
affected) of which 91 families had 3 or more affected cases (310 in total).  As was reported 
by Brune et al, there was a trend for earlier onset in families with greater number of 
affected individuals but despite large numbers of individuals included this does not reach 
significance (Figure 12). 
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Figure 12: Cumulative survival for all on kindred individuals including probands 
Kaplan-Meier curve demonstrating survival in on-kindred FPC in families with 2 versus 3 or more affected individuals. There 
is a non-significant trend of earlier age of onset in those families with 3 or more cancer cases i.e. those more likely to 
reflect ‘true’ FPC kindreds with a genuine predisposition to PDAC (p=0.24).   
 
Figure 12 highlights a trend for earlier onset in families with greater number of cancers but 
this did not reach significance (Mantel Cox Log rank, p=0.24). Furthermore, removal of 
probands from the analysis reverses the apparent trend for apparent earlier onset in 
families most likely to have an autosomal dominant predisposition to PDAC. 
If the family is identified because of an affected individual appearing in clinic, there is a 
tendency for younger cases to be followed up more rigorously. This will be equally true if 
the individual chosen actually comes from a genuine family, or if they come from a random 
cluster. Therefore, there may be a tendency to identify a younger age of onset in registered 
families because of bias, rather than in any genuine younger age of onset in legitimate FPC. 
To address ascertainment bias, we excluded all probands (whether affected or not), and 
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only included the FDR of these probands. As seen in Figure 13, this gave a small but 
significant apparent survival benefit for families with more cancer cases; thus not 
demonstrating earlier onset for those families with more than 2 affected individuals, but the 
opposite. Clearly this is in direct contradiction to the data obtained by Brune et al. This 
cannot be explained merely by the form of analysis and must reflect some fundamental 
difference between the EUROPAC and NFPTR cohorts. 
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Figure 13: Cumulative survival for first degree relatives of probands 
Exclusion of probands from survival analysis (FDR only) demonstrates an apparent significant improvement in survival in 
those FDR from families with 3 or more affected individuals versus only 2, contrary to the trend expected in the presence 
of a genuine autosomal dominant predisposition (p=0.021). 
 
Figure 13 demonstrates a significant survival advantage for those families with 3 or more 
affected individuals (Mantel Cox Log Rank p=0.021). 
Ascertainment bias in registries ensures that registered individuals will have at least one 
case of pancreatic cancer in an FDR, regardless of whether cancer is genetically predisposed 
or not. Consider the family in Figure 14, which illustrates a typical registered family where 
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two generations are affected. Consider two hypothetical cases with identical family 
structures: Where the proband is in generation 2 (G2, individual A), or where the proband is 
in G3 (individual B). By definition, proband B will have FDR who are comparatively young i.e. 
offspring will be in G4 rather than G3. Ascertainment bias will ensure that there will be at 
least one affected FDR individual, regardless of which generation the proband is in. In 
calculating SIR, the numerator is the number of affected individuals and the denominator is 
mainly unaffected individuals. In Kaplan-Meier survival analysis, any individual who has not 
reached an outcome event is said to be censored. Whichever way age of onset is considered 
there is a bias defined by the nature of the proband. Neither the numerator in SIR or the 
event times in a Kaplan-Meier analysis will be unchanged (as the number of affected FDR is 
fundamental to family selection), but the denominator in calculating an SIR and the age of 
censorship in a Kaplan-Meier analysis will both be younger if the proband is in G3 as 
compared to G2.  
 
Figure 14: Typical FPC pedigree demonstrating 2 affected individuals in successive generations. 3 possible probands are 
marked, A and B affected and C not affected with PDAC. 
This figure provides an illustration of the variable age in potential onset of PDAC in an FPC kindred dependent upon the 
proband. The NFPTR recruit families by presentation of an affected proband while EUROPAC mainly recruits from probands 
who are not affected. The families must have at least two affected individuals. If A is an affected proband then, for 
recruitment B must have also developed PDAC; and as B is a descendant of A she must have developed the cancer earlier 
than A. In the event of B presenting to the registry as an affected proband, both A + B must be affected, but A may have 
developed PDAC at a younger age than B. C cannot be recruited under the NFPTR system as a proband but would be a 
typical proband for EUROPAC. If C is the proband, then A + B must have PDAC and age of onset may be earlier or later than 
the present age of C. Therefore, a bias in age of onset can be introduced dependent upon which generation is recruited as 
proband. 
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If the family is selected on the basis of a non-affected individual reporting two cases of 
cancer in their family, then the report will almost certainly come from an individual in G3 or 
G4 (such as C in Figure 14), simply because by the time an individual in G3 develops cancer, 
most individuals in G1 and G2 will be over 60. There can also be a considerable delay 
between an individual in G2 developing cancer and the family being recruited. 
To further investigate this, our group undertook survival analyses for families with affected 
and unaffected probands. The Kaplan-Meier curve in Figure 15 compares event time in FDR 
of affected probands with the FDR of unaffected probands. A significant earlier onset was 
seen with the unaffected probands. This can be explained by ascertainment bias which 
dictates that the “proband affected” cohort of individuals will contain a greater number of 
older censored FDRs as compared to the “proband unaffected” group. Hence, the 
appearance of an apparent earlier age of onset.  
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Figure 15: Cumulative survival for all FDR in proband (Pb) affected (Af) and not affected (not A) groups. 
Referring to the example in Figure 14, the Kaplan Meier curve above compares FDR with proband affected (proband A 
when B is affected and vice versa; and proband C (unaffected) when A + B are affected). There appears to be a significant 
earlier age of onset in FDR whose probands were unaffected as compared to affected. 
 
This figure demonstrates an apparent earlier age of onset in FDR of unaffected probands 
(Mantel Cox Log Rank p=<0.0001). However, in the analysis of a more stringent selection of 
families, this effect is confounded (Figure 16). Our group propose that the apparent 
significant influence of proband status on age of onset is due to the phenomenon of 
ascertainment bias. If the effect seen in Figure 15 is due to ascertainment bias, then it 
should be reduced or eliminated if the proportion of random clusters is minimised. The 
Kaplan-Meier curve in Figure 16 compares survival, dependent upon proband affected 
status, in FDR of families with 3 or more cases i.e. those families more likely to represent 
‘true’ FPC, rather than an effect of random clustering. 
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Figure 16: Cumulative survival for FDR of families with 3 or more affected individuals according to proband status. 
Survival in more ‘genuine’ FPC families with 3 or more affected family members where proband is affected versus 
unaffected demonstrating a trend for improved survival in those with an affected proband. This reflects the NFPTR 
recruitment policy. 
 
In analysis of individuals from perceived “genuine” FPC families, with three or more cancer 
cases, according to affected proband status; there is a trend for improved survival in those 
FDR from families where the proband is affected, but this is less marked (Mantel Cox Log 
Rank p=0.05). In contrast, the evidence for ascertainment bias on the basis of the nature of 
the proband is accentuated in families with a less stringent selection i.e. two cases or less 
(see Figure 17). 
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Figure 17: Survival in FDR of families with 2 or less affected individuals 
The above Kaplan-Meier curve is the same analysis as in figure 16, but applied to those families with 2 affected family 
members, thus representing those less likely to have a genuine genetic predisposition to FPC. There is an apparent 
significant trend in survival in FDR where the proband is affected.  
 
The families included in the survival analysis demonstrated in Figure 17 are more likely to 
represent random clusters rather than a genuine predisposition to PDAC. A significant 
survival advantage is seen in those individuals from families with an affected proband 
(Mantel-Cox Log Rank p=<0.0001). It can therefore be seen that ascertainment bias can 
change apparent age of onset. If the results from Brune et al. are, indeed, due to 
ascertainment bias then it should be possible to generate a similar effect with EUROPAC 
families simply by restricting family selection to kindreds with an affected proband. This is 
demonstrated in Figure 18. 
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Figure 18: Kaplan-Meier plot for all families in whom the proband was affected at the time of registration split by the 
total number of confirmed PDAC cases i.e. less than 3 versus 3 or more. 
Survival analysis of EUROPAC families limited to those with proband affected. There is an apparent survival advantage seen 
in those with 2 affected family members compared to those with 3 or more (‘genuine’ FPC) which reflects the observation 
of the NFPTR and reflects the recruitment policy of the NFPTR. 
 
Analysis of FDR from families with an affected proband demonstrates an apparently 
significant increased survival in those individuals from families with less than 3 cases 
(Mantel-Cox Log Rank p=0.007). By limiting survival analysis to those families with an 
affected proband, in accordance with the selection criteria applied by the NFPTR; an 
apparent trend for decreased survival with increasing number of affected family members 
can be seen (Figure 18). Similarly, if the effect is due to bias then it should be minimised or 
reversed in families with unaffected probands, as seen in Figure 19 (Mantel-Cox Log Rank 
p=0.007). 
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Figure 19: Cumulative survival in FDR of families with unaffected probands. 
In survival analysis in EUROPAC families with unaffected probands, the reverse of the trend demonstrated in Figure 18 can 
be seen (p=0.007). Thus the NFPTR observation is dependent on their recruitment policy. 
 
The recruitment policies of the NFPTR and EUROPAC both produce biases which can lead to 
an impression of younger age of onset in particular families. In the case of EUROPAC, this 
can give the impression of younger onset in families with fewer affected family members. 
While recruitment by the NFPTR, gives the impression of younger onset with more affected 
family members. The observations from the NFPTR published by Brune et al can be 
duplicated in the EUROPAC cohort, by restricting family inclusion to only those families 
where the proband is affected. As families reported by unaffected individuals are at least as 
legitimate as families encountered on the basis of affected individuals recruited in clinic, and 
arguably will include less  falsely identified families; it is not reasonable to assume an earlier 
age of onset for familial pancreatic cancer (in comparison with sporadic disease). This is in 
contrast to reports from other cancer syndromes and may appear counterintuitive, 
particularly as we have previously argued that anticipation is a characteristic of FPC. 
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However, nothing we or others have published previously excludes late onset in FPC 
individuals, indeed, that is exactly the feature we previously described for earlier 
generations.  
 
4.5 Smoking and risk in FPC 
 
Evidence discussed earlier in this work has demonstrated a causative role for smoking in the 
onset of sporadic PDAC. Analysis of our data has identified an apparent phenomenon of 
recall bias with no definitive evidence of smoking as significantly influencing PDAC risk.  
Figure 20 demonstrates survival in the EUROPAC FPC cohort according to smoking status as 
reported by the proband, whether affected or unaffected. The data suggest an apparent 
trend in poorer survival associated with smoking; a trend which has been reported in 
sporadic cases and has been discussed earlier in this work. 
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Figure 20: Survival in EUROPAC FPC cohort according to smoking status 
Survival analyses in the EUROPAC cohort dependent upon status as a current, ex or never smoker. This data suggests an 
increase in incidence in the smoking group. However, there appears to be an increase in non-smokers versus ex-smokers 
which conflicts with established data for sporadic disease.  
 
Smoking data taken at the time of a participant’s registration with EUROPAC is taken for the 
registering individual and affected family members, through use of the individual and family 
history questionnaires. Accuracy of the data recorded by the registering individual is subject 
to recall bias. An individual reporting their own smoking status will recall with accuracy 
whether they are a current or ex-smoker. On recalling the smoking status of affected 
relatives, particularly in the context being sensitised to their family cancer risk, an individual 
is more likely to report a relative as a smoker or non-, rather than ex-. This introduction of 
bias can be seen in the survival analysis of ever (encompassing current and ex-smokers) 
versus non-smokers. It can be seen from the following survival analysis, that there is no 
At Risk   
Ex  238  212  115  16 
Non  367  311  136  11 
Smoker  206  163  74  7 
 Ex smoker 34 events (PDAC) 
 Non smoker 60 events (PDAC) 
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significant relationship between smoking and cancer risk in the EUROPAC FPC cohort. This is 
explained by the over-reporting of smoking status in affected family members by sensitised 
unaffected probands. 
 
 
 
 
Figure 21: Survival data in the EUROPAC FPC cohort according to ever versus non-smoking status 
Upon classification of smoking history as ever versus non, there is no significant difference in survival, the original 
difference in survival could be explained by recall bias.  
 
4.6 Obesity and cancer risk in FPC 
 
Research into the effect of obesity on the development of sporadic pancreatic cancer has 
suggested a trend in cancer risk with increasing BMI [88-94]. BMI data are poorly reported  
in the EUROPAC FPC cohort. In addition, BMI is a dynamic measurement with considerable 
variation in an individual over time. Hence, an isolated BMI taken at the time of an 
individual’s registration is unlikely to yield any benefit in stratification of risk.  
At Risk 
Non 367                  311  136  11 
Smoker 444                                     375  189  23 
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 Non smoker 60 events (PDAC) 
 Ever smoker 99 events (PDAC) 
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4.7 Diabetes and cancer development in FPC 
 
Evidence surrounding the influence of diabetes on PDAC risk in sporadic cases remains 
conjectural, with conflict continuing as to whether the relationship is one of affect or effect. 
In the EUROPAC cohort of FPC families, only one family demonstrated an apparent 
relationship between affected family members and a diagnosis of diabetes. This evidence is 
insufficient to utilise diagnosis of diabetes as a rationale for risk stratification in the 
screening of FPC kindreds. 
4.8 Genetic modifiers 
4.8.1 ABO group and cancer risk 
 
Genome wide analysis work into potential genetic modifiers which may be key in the 
development of PDAC have highlighted a possible influential role of the ABO gene. It is 
widely established that Group A individuals have an increased lifetime risk for the 
development of gastric cancer. It is proposed that such a link may also be of significance in 
PDAC. Data collected from sporadic PDAC individuals by our group is largely drawn from the 
North West of England and North Wales. Historical data concerning distribution of ABO 
groups across the UK reveals an increased prevalence of group O within this region, with the 
suggestion that group O has a frequency of 28.5% higher in North Wales and 16.6% higher in 
North West England than group A. It should be noted that this distribution is based on data 
from 1970 [125]. Although there is likely to have been an element of population shift in this 
time, this data suggests that one would expect to see an increased prevalence of pancreatic 
cancer cases in blood group O, due to the elevated frequency compared to A.  
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Sporadic cancer and ABO group –  analysis of tissue database data 
ABO group data from a series of 232 cases of sporadic pancreatic adenocarcinoma treated 
in our centre revealed 107 (47%) individuals were of blood group A; 86 (37%) ABO group O; 
32 (14%) group B and just 7 (3%) AB. With regard to Rhesus status, only 39 of the 232 total 
patients were Rhesus negative, with 16 of the 107 group A patients included within this 
figure. In order to determine whether this risk factor is of any significance in pancreatic 
cancer development, greater numbers are required and the geographical context of the 
cohort taken into account due to the heavily population dependent nature of ABO grouping. 
 
4.9 Novel mutations 
 
4.9.1 PALB2 
 
A number of novel mutations have been proposed as candidate genes in the causation of 
FPC. PALB2 (partner and localiser of BRCA2) is a DNA repair gene localised to chromosome 
16.  Families recruited as part of my work towards this thesis were included in the analysis 
of a series of 81 European kindreds [197]. In total, 3 PALB2 mutations were identified across 
the 81 families. One specific example is the recognition of a frameshift mutation in exon 11 
of the PALB2 gene, which is demonstrated in Figure 22 below. Analysis across 81 European 
kindreds was undertaken by members of the EUROPAC team in co-operation with our 
German collaborators Slater et al [197]. My role was in the recruitment of families included 
in the analysis. 
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Figure 22: Frameshift mutation in exon 11 of PALB2. 
Demonstrating SNPs relating to PALB2 in affected individuals within one EUROPAC FPC kindred. A total of 81 European 
kindreds were included in the analysis which was undertaken by members of the EUROPAC team and our collaborators in 
Germany [197]. 
 
  
159 
 
4.10 RESULTS: Secondary screening study 
4.10.1 Total numbers currently recruited to secondary screening (UK 
figures) and total number of screening procedures 
 
Table 7 records the number of individuals participating in the EUROPAC secondary screening 
study across our UK collaborating centre at the time of writing of this thesis. 
Table 7: Screening centres and numbers recruited to the EUROPAC secondary screening study 
Screening Centre  FPC  HP  
Liverpool  47  22 
London  17 6  
Nottingham  5  0  
Leeds  3  0  
Southampton  1  2  
Glasgow  2 1  
Leicester  1  0  
Newcastle  1  1 
Edinburgh  0  3 
Other  5 3  
TOTAL  82 38  
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4.10.2 Experience with ERCP for juice collection and associated 
complications 
 
HP 
A total of 23 ERCP procedures were undertaken in HP individuals under the auspices of the 
EUROPAC secondary screening study. No occurrences of pancreatitis were reported in this 
patient cohort at the time of completion of this thesis. The definition of post ERCP 
pancreatitis in our group being: greater than three times elevation of normal serum 
amylase. It is surmised that the apparent low risk of post-ERCP pancreatitis in the EUROPAC 
HP cohort may be attributable to the abnormal anatomy, and more specifically, presence of 
pancreatic ductal dilatation seen in the HP screening sub-group, as compared to the normal 
anatomy seen in FPC. 
 
FPC 
The EUROPAC secondary screening protocol has been outlined earlier in this work. As part 
of their participation in the study, participants are offered ERCP for pancreatic juice 
collection for the analysis of molecular markers. This technique and analysis has been 
detailed in an earlier sub-chapter. Participants in the secondary screening study were 
invited to undergo ERCP following an informed consent process and explanation of risk. 
There is a procedure associated risk of pancreatitis associated with ERCP. In the earlier 
phase of screening, 7 cases of ERCP pancreatitis were recorded during 16 procedures 
between 2003 and 2007. In order to minimise this risk, the measures of temporary 
pancreatic stenting and the administration of an anti-inflammatory medication (Diclofenac) 
per rectally post-procedure were introduced during my work towards this thesis. The 
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technique of ERCP with self-expelling pancreatic stent deployment and administration of 
Diclofenac has been described in the materials and methods section. 
4.10.3 Diclofenac and pancreatic stents in the reduction of ERCP 
pancreatitis 
 
The early experience of EUROPAC in the use of ERCP for pancreatic juice collection for 
molecular analysis between 2003-2007 yielded a concerning rate of ERCP associated 
pancreatitis of 7/16 (43.8%) in the FPC cohort. In order to minimise this risk, the measures 
of temporary self-expelling stents and administration of per rectal Diclofenac were 
implemented in an amendment to the EUROPAC secondary screening protocol. These 
measures resulted in a significant reduction in the rate of ERCP pancreatitis in the EUROPAC 
FPC screening cohort. In the subsequent period following instigation of self-expelling 
pancreatic stents and Diclofenac, a total of 31 ERCP procedures were undertaken in FPC 
individuals. Of these 31 procedures, a diagnosis of acute pancreatitis, as defined by the 
biochemical parameter described above, was recorded in 3 individuals. Hence, a significant 
reduction in ERCP associated pancreatitis to 9.7% from 43.8% (p=0.020). The current overall 
rate of ERCP pancreatitis from 2003 is 10/47 procedures (21.3%). 
 
4.11 Analysis of secretin stimulated duodenal aspirate as a surrogate for 
pancreatic juice 
 
The risk of ERCP associated acute pancreatitis in the EUROPAC FPC cohort poses a significant 
threat of morbidity in this, usually otherwise well, group [271]. A fundamental requirement 
of any feasible screening test is to do no harm. In view of this, our group has undertaken 
work to evaluate the diagnostic merit of analysis of molecular markers in surrogate 
162 
 
pancreatic juice. Collection of secretin stimulated pancreatic juice within the duodenum 
may yield similar diagnostic value in the determination of FPC risk, while avoiding invasive 
cannulation of the pancreatic duct, and the associated morbidity of acute pancreatitis. 
EUROPAC has ethical approval for the collection and analysis of pancreatic juice for 
molecular markers using the methodology described earlier in this thesis. The same 
technique for analysis of duodenal juice as a surrogate marker following secretin stimulation 
has received ethical approval as described above (Figure 6). As part of the work towards this 
thesis, a prospective cohort study of molecular markers in duodenal aspirate and pancreatic 
juice from individuals with pancreatic cancer, chronic pancreatitis and benign biliary disease 
controls was designed and approved. 
  
4.12 Secretin stimulated duodenal juice sampling: provisional results 
from cohort of PDAC, CP and biliary controls 
 
Recruitment of individuals from three cohorts: pancreatic cancer, chronic pancreatitis (CP) 
and benign biliary disease was undertaken.  Secretin stimulated duodenal aspirate and 
pancreatic juice samples were collected from a total of 173 patients. The numbers recruited 
in each of the subgroups described is outlined in Table 8 below. 
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Table 8: Numbers recruited and median age 
COHORT TOTAL MEDIAN AGE (Years)/ IQR 
Cancer 38 68                               (62-75) 
 CP 23 57                               (41-67) 
Control 112 56                                (57-78) 
 
A total of 173 patients underwent sample collection and analysis. Analysis of duodenal 
aspirate and pancreatic juice for TP53 and K-RAS2 mutation and CDKN2A methylation 
yielded results as recorded in Table 9 below. 
Table 9: Results of analysis of TP53 mutation, CDKN2A methylation and K-RAS2 mutation in pancreatic cancer, chronic 
pancreatitis and benign biliary controls 
COHORT NUMBER TP53 mutation 
(%) 
CDKN2A 
methylation 
>12% (%) 
K-RAS2 mutation 
(%) 
CANCER 38 2                     
(6%) 
17                 
(50%) 
14                  
(38%) 
CP 23 0                          
(0%) 
12                 
(52%) 
10                  
(43%) 
CONTROL 112 5                     
(4%) 
48                 
(43%) 
69                   
(62%) 
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Table 10: Sensitivity and specificity of molecular markers in duodenal aspirate in cancer and benign disease 
 NUMBER TP53 mutation  
(%)                        
(n = 162) 
CDKN2A 
methylation 
>12% (%)             
(n = 164) 
K-RAS2 mutation 
(%)                        
(n = 172) 
MALIGNANT 38 2 17 14 
BENIGN 135 5 60 79 
p VALUE  N/A 0.517 0.426 0.049 
SENSITIVITY (95% CI) 
SPECIFICITY (95% CI) 
 0.06 (0.01-0.23) 
0.96 (0.91-0.99) 
0.41 (0.25-0.59) 
0.66 (0.57-0.74) 
0.40 (0.24-0.58) 
0.42 (0.34-0.51) 
 
The results, as outlined in Table 10, demonstrate that the specificity and sensitivity of the 
detection of molecular markers in duodenal aspirate do not correlate with that of 
pancreatic juice collected by cannulation of the pancreatic duct at ERCP. Only analysis of 
wild type K-RAS2 demonstrated an apparent trend in correlation nearing significance. On 
current evidence, secretin stimulated collection of duodenal aspirate is not sufficiently 
sensitive or specific to be utilised as a surrogate marker for risk stratification in high risk 
individuals. It is hypothesised that this may be due to the comparative high volume of junk 
DNA present within the duodenum, despite aspiration prior to collection. This effect may be 
exacerbated as a result of pH change within the duodenum compared to the comparatively 
alkaline pancreatic duct. Work by our group continues in the exploration of factors which 
may aid detection of early pancreatic cancer in high risk individuals. The aim of EUROPAC is 
in optimising the safety and efficacy of screening for pancreatic cancer in those at highest 
risk, whilst continuing efforts in the identification of candidate genes to definitively 
delineate FPC.  
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5. DISCUSSION  
 
The aims of this thesis were in the identification of subpopulations of high risk kindreds at 
greatest risk, to offer targeted screening for early pancreatic cancer; and to ensure the 
safety of those individuals undergoing screening. I was able to achieve this aim through 
completion of a number of objectives outlined earlier in this work. My first objective was in 
the registration of families with an apparent or recognised autosomal dominant 
predisposition for the development of PDAC and obtaining full epidemiological data. A total 
of 1000 families have been recruited to the FPC and HP registries at the time of writing. The 
numbers of individuals and kindreds recruited during the period of work towards this thesis 
are demonstrated in Table 3 and Table 5. Data obtained through individual, family history 
and collaborating clinician questionnaires at the time of registration enabled me to achieve 
my second objective in the comparison of age of onset in sporadic pancreatic cancer with 
age of onset of cancer in high risk kindreds. In my analysis of the age of onset in affected 
family members I have shown that the previously proposed phenomenon of increased 
familial risk associated with early age of onset; as reported by Brune et al [270], may be 
artefactual. In Figures 12-19 of section 4.4.2, in the analysis of EUROPAC FPC kindreds, I 
have demonstrated that the apparent phenomenon of early age of onset affecting risk can 
be explained by ascertainment bias. The recognition of this is important in ensuring that 
screening is not offered inappropriately merely on the basis of young age of onset within 
kindreds or at an unduly young age. Thus, minimising exposure to the potential risks 
associated with screening for early pancreatic cancer. There does appear to be a caveat to 
this, and that is in the recognition of those families which display the phenomenon of 
anticipation. Previous work in the analysis of EUROPAC FPC kindreds has demonstrated that 
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onset can occur at increasingly earlier age in certain families, with a clear autosomal 
dominant pattern affecting successive generations [158]. This phenomenon of anticipation, 
i.e. progressively earlier onset across multiple successive generations, and a higher total 
number of affected family members, are both associated with increased familial risk. 
Therefore, the number affected, and age of onset in successive generations should be 
elicited in the stratification of risk. However, the presence of few, or isolated, early age of 
onset affected family members, does not confer any increase in risk; according to the 
findings from my work towards this thesis. In addition to risk stratification according to age, 
my analysis of data pertaining to lifestyle characteristics and other demographics in familial 
and sporadic PDAC fulfilled my third objective as stated earlier in this work.  The influence of 
specific lifestyle factors on the development of sporadic PDAC has been extensively 
reported. My work towards risk stratification in FPC and HP kindreds included analysis of the 
influence of environmental risk factors which have been implicated in pancreatic 
carcinogenesis. There is established evidence, across many populations, to support a 
relationship between cigarette smoking and PDAC. Figures 20 and 21 of section 4.5 illustrate 
survival analysis according to smoking status in the EUROPAC FPC cohort. I determined that 
recall bias in the reporting of smoking status by sensitised, unaffected individuals creates an 
apparent trend of poorer survival within the smoking sub-group. This can be shown to be as 
a result of the over-reporting of smoking status as demonstrated in Figures 20 and 21. 
Through the collection and analysis of epidemiological data, I have been able to evaluate the 
influence of specific lifestyle factors upon cancer risk in both EUROPAC FPC and HP cohorts. 
In a cohort of EUROPAC HP patients, I analysed the effect of diabetes and smoking upon age 
of cancer development. In HP, the age of onset of diabetes has been demonstrated to 
exhibit an effect upon age of death from cancer. However, further analysis in sub-groups, 
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according to smoking status, reveal that any effect of diabetes is confounded by the 
overwhelming effect of smoking upon cancer risk in HP. These findings are highlighted in the 
survival analyses in Figures 7-10 in subchapter 4.3.3.  
Evidence from the analysis of sporadic PDAC has consistently proposed an increase in risk 
with cigarette smoking. Analysis of other lifestyle factors in the implication of pancreatic 
carcinogenesis has failed to yield such conclusive evidence. Other proposed environmental 
risk factors for pancreatic carcinogenesis include obesity. With regard to the EUROPAC FPC 
cohort, obesity was not found to confer any significant influence upon risk as discussed in 
section 4.6. It is proposed that the recording of BMI over time can exhibit significant 
variation. Therefore, an isolated BMI measurement; reported at the time of registration as 
an FPC kindred is unlikely to be useful in the stratification of risk. Similarly, when considering 
diabetes as an aid to risk stratification; analysis of the FPC cohort only demonstrates a 
consistent relationship between diabetes and PDAC in one family. This is discussed more 
fully in section 4.7. Controversy has existed regarding the role of diabetes as cause or effect 
in sporadic pancreatic carcinogenesis, and its concomitant diagnosis does not appear to be a 
reliable risk modifier in FPC.  
Through my recruitment of families to the EUROPAC registry I was able to contribute to 
fulfilling another of my thesis objectives in the investigation of genetic factors that could be 
used in stratification of risk within kindreds and in sporadic pancreatic cancer. Through 
individual and family registration, our group compiled epidemiological data to aid risk 
stratification and collected DNA and cell line samples.   In association with their registration, 
our group has obtained DNA from 111 affected and 509 unaffected individuals, and cell line 
samples from 48 and 240 affected and unaffected individuals, following recruitment to the 
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FPC registry. The collection and storage of DNA and cell lines from kindreds with an 
apparent autosomal dominant predisposition to PDAC allows for ongoing work into 
potential candidate genes. The identification of novel mutations which may be implicated in 
FPC continues to be a key focus of the work undertaken by EUROPAC. During work towards 
this thesis, our group reported an association with a novel mutation in PALB2. In a series of 
81 families, 3 PALB2 mutations were identified. This analysis is discussed in section 4.9.1 and 
Figure 22.  
In genome wide association studies, an association between PDAC and the ABO gene locus 
has been reported [129]. In data collected from 232 sporadic cases treated in our unit, 
101/232 (47%) of individuals were blood group A. However, it is difficult to draw significant 
conclusions from this due to the population and geographical dependence of ABO group 
distribution. Further work on larger Europe wide populations would be required to ascertain 
meaningful results.  Work contributing towards the recognition of PALB2 and potential role 
of ABO fulfil my thesis objective of the investigation of genetic factors in risk stratification in 
FPC kindreds. 
My final thesis objectives pertained to secondary screening for early pancreatic cancer in 
high risk groups. At the time of writing a total of 82 FPC and 38 HP individuals had been 
recruited to the respective EUROPAC screening studies for early PDAC as denoted in Table 7. 
The paramount aim of any screening strategy must first be to do no harm. Prior to my work 
in revising the EUROPAC screening protocol, a significant number of participants had 
suffered from post-ERCP pancreatitis with an associated morbidity and potential mortality. 
As part of this work, I helped to introduce a novel approach to the collection of pancreatic 
juice with the intention of reducing risks from screening. The use of Diclofenac and 
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pancreatic stenting reduced the incidence of ERCP-associated pancreatitis in our screening 
cohort (from 43.8% to 9.7% [p=0.020]). The results are discussed in section 4.10.3. The 
improvement of participant safety in our screening cohort was an important aim of this 
thesis; the significant reduction in procedure-associated morbidity demonstrates that I have 
achieved this objective. In further work towards the aim of improved participant safety, I 
also established a protocol for the collection and analysis of duodenal aspirate, as a 
proposed surrogate marker for pancreatic juice. The technique is discussed earlier in this 
thesis and results are highlighted in Tables 8-10 in section 4.12. It minimised the risk of ERCP 
related pancreatitis by negating the need for pancreatic duct cannulation. Although, results 
from the subset analysis of benign and malignant cases do not yet support a role for 
duodenal juice in the analysis of molecular markers in early pancreatic cancer; this thesis 
stands as a basis for expanding this study and as such achieves the aim of furthering patient 
safety and increasing screening yield.  
In achieving my thesis objectives, we are now better able to understand the factors which 
influence penetrance in FPC. This has implications for risk stratification in FPC and hence, in 
the targeted screening of those at highest risk. In parallel, refinement of techniques utilised 
in the EUROPAC secondary screening study for early pancreatic cancer, reduce the exposure 
of asymptomatic individuals to procedure associated morbidity. The recruitment of high risk 
kindreds undertaken as part of this thesis has facilitated the collection of DNA and cell lines 
in affected and unaffected individuals with an apparent familial predisposition to PDAC. 
Work towards the identification of potential candidate genes continues in parallel to 
screening in high risk groups. Until the advent of the discovery of a causative gene for FPC, 
work continues into the stratification of risk and optimisation of EUROPAC secondary 
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screening modalities to ensure targeted screening of those at highest risk whilst ensuring 
minimal harm. This thesis has contributed to fulfilling this aim through the demonstration of 
demographic and lifestyle factors which influence risk and appropriate advent of screening. 
The identification of potential bias in age related risk in FPC is an important concept in 
ensuring that screening and any associated risks are not undertaken in young individuals in 
the absence of a genuine predisposition. Future work continues into further stratification of 
risk with the potential for the development of a risk stratification clinical interface and in the 
exploration of duodenal aspirate as a surrogate marker for pancreatic juice to minimise 
ERCP related morbidity and improve participant safety in secondary screening for early 
PDAC. 
 
 
 
 
 
 
 
 
 
 
171 
 
 
 
Bibliography 
 
1. Ferlay, J., et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J 
Cancer, 2010. 127(12): p. 2893-917. 
2. Parkin, D.M., et al., Fifty years of cancer incidence: CI5 I-IX. Int J Cancer, 2010. 127(12): p. 
2918-27. 
3. Fitzsimmons, D., et al., Trends in stomach and pancreatic cancer incidence and mortality in 
England and Wales, 1951-2000. Br J Surg, 2007. 94(9): p. 1162-71. 
4. Altekruse SF, K.C., Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, 
Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, 
Stinchcomb DG, Edwards BK (eds). , SEER Cancer Statistics Review, 1975-2007, National 
Cancer Institute. Bethesda, MD. 2007. 
5. Neoptolemos, J.P., et al., A randomized trial of chemoradiotherapy and chemotherapy after 
resection of pancreatic cancer. N Engl J Med, 2004. 350(12): p. 1200-10. 
6. Neoptolemos, J.P., et al., Adjuvant chemoradiotherapy and chemotherapy in resectable 
pancreatic cancer: a randomised controlled trial. Lancet, 2001. 358(9293): p. 1576-85. 
7. Bassi, C., et al., Influence of surgical resection and post-operative complications on survival 
following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled 
trial. Dig Surg, 2005. 22(5): p. 353-63. 
8. Oettle, H., et al., Adjuvant chemotherapy with gemcitabine vs observation in patients 
undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. 
JAMA, 2007. 297(3): p. 267-77. 
9. Shimizu, Y., et al., Small carcinoma of the pancreas is curable: new computed tomography 
finding, pathological study and postoperative results from a single institute. J Gastroenterol 
Hepatol, 2005. 20(10): p. 1591-4. 
10. Alexakis, N., et al., Current standards of surgery for pancreatic cancer. Br J Surg, 2004. 
91(11): p. 1410-27. 
11. Shapiro, T.M., Adenocarcinoma of the pancreas: a statistical analysis of biliary bypass vs 
Whipple resection in good risk patients. Ann Surg, 1975. 182(6): p. 715-21. 
12. Gudjonsson, B., Cancer of the pancreas. 50 years of surgery. Cancer, 1987. 60(9): p. 2284-
303. 
13. Sohn, T.A., et al., Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, 
and prognostic indicators. J Gastrointest Surg, 2000. 4(6): p. 567-79. 
14. Raut, C.P., et al., Impact of resection status on pattern of failure and survival after 
pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg, 2007. 246(1): p. 52-60. 
15. van Heek, N.T., et al., Hospital volume and mortality after pancreatic resection: a systematic 
review and an evaluation of intervention in the Netherlands. Ann Surg, 2005. 242(6): p. 781-
8, discussion 788-90. 
16. Buchler, M.W., et al., Changes in morbidity after pancreatic resection: toward the end of 
completion pancreatectomy. Arch Surg, 2003. 138(12): p. 1310-4; discussion 1315. 
172 
 
17. Birkmeyer, J.D., et al., Effect of hospital volume on in-hospital mortality with 
pancreaticoduodenectomy. Surgery, 1999. 125(3): p. 250-6. 
18. Seiler, C.A., et al., Randomized clinical trial of pylorus-preserving duodenopancreatectomy 
versus classical Whipple resection-long term results. Br J Surg, 2005. 92(5): p. 547-56. 
19. Tran, K.T., et al., Pylorus preserving pancreaticoduodenectomy versus standard Whipple 
procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic 
and periampullary tumors. Ann Surg, 2004. 240(5): p. 738-45. 
20. Pedrazzoli, S., et al., Standard versus extended lymphadenectomy associated with 
pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the 
pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. 
Ann Surg, 1998. 228(4): p. 508-17. 
21. Yeo, C.J., et al., Pancreaticoduodenectomy with or without distal gastrectomy and extended 
retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized 
controlled trial evaluating survival, morbidity, and mortality. Ann Surg, 2002. 236(3): p. 355-
66; discussion 366-8. 
22. Henne-Bruns, D., et al., Surgery for ductal adenocarcinoma of the pancreatic head: staging, 
complications, and survival after regional versus extended lymphadenectomy. World J Surg, 
2000. 24(5): p. 595-601; discussion 601-2. 
23. Bold, R.J., et al., Major vascular resection as part of pancreaticoduodenectomy for cancer: 
radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg, 1999. 3(3): p. 233-43. 
24. van Geenan RC, t.K.F., de Wit LT et al. , Segmental resection and wedge excision of the portal 
or superior mesenteric vein during pancreatoduodenectomy. Surgery, 2001. 129: p. 158-163. 
25. Nakagohri, T., et al., Survival benefits of portal vein resection for pancreatic cancer. Am J 
Surg, 2003. 186(2): p. 149-53. 
26. Moertel, C.G., et al., Combined 5-fluorouracil and supervoltage radiation therapy of locally 
unresectable gastrointestinal cancer. Lancet, 1969. 2(7626): p. 865-7. 
27. Kalser, M.H. and S.S. Ellenberg, Pancreatic cancer. Adjuvant combined radiation and 
chemotherapy following curative resection. Arch Surg, 1985. 120(8): p. 899-903. 
28. Klinkenbijl, J.H., et al., Adjuvant radiotherapy and 5-fluorouracil after curative resection of 
cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal 
tract cancer cooperative group. Ann Surg, 1999. 230(6): p. 776-82; discussion 782-4. 
29. Neoptolemos, J.P., et al., Adjuvant chemotherapy with fluorouracil plus folinic acid vs 
gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA, 
2010. 304(10): p. 1073-81. 
30. Ansary-Moghaddam, A., et al., The effect of modifiable risk factors on pancreatic cancer 
mortality in populations of the Asia-Pacific region. Cancer Epidemiol Biomarkers Prev, 2006. 
15(12): p. 2435-40. 
31. Qiu, D., et al., Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. 
J Epidemiol, 2005. 15 Suppl 2: p. S157-67. 
32. Horner MJ, R.L., Krapcho M, et al (eds). , SEER Cancer Statistics Review, 1975-2006, National 
Cancer Institute. Bethesda,MD, http://seer.cancer.gov/csr/1975_2006/, based on November 
2008 SEER data submission, posted to the SEER web site, 2009. 2009. 
33. Lowenfels, A.B. and P. Maisonneuve, Epidemiology and risk factors for pancreatic cancer. 
Best Pract Res Clin Gastroenterol, 2006. 20(2): p. 197-209. 
34. Anderson, L.N., M. Cotterchio, and S. Gallinger, Lifestyle, dietary, and medical history factors 
associated with pancreatic cancer risk in Ontario, Canada. Cancer Causes Control, 2009. 
20(6): p. 825-34. 
35. Blackford, A., et al., Genetic mutations associated with cigarette smoking in pancreatic 
cancer. Cancer Res, 2009. 69(8): p. 3681-8. 
36. Stevens, R.J., et al., Factors associated with incident and fatal pancreatic cancer in a cohort 
of middle-aged women. Int J Cancer, 2009. 124(10): p. 2400-5. 
173 
 
37. Lowenfels, A.B., et al., Pancreatitis and the risk of pancreatic cancer. International 
Pancreatitis Study Group. N Engl J Med, 1993. 328(20): p. 1433-7. 
38. Yun, J.E., et al., Cigarette smoking, elevated fasting serum glucose, and risk of pancreatic 
cancer in Korean men. Int J Cancer, 2006. 119(1): p. 208-12. 
39. Partanen, T.J., et al., Pancreas cancer, tobacco smoking and consumption of alcoholic 
beverages: a case-control study. Cancer Lett, 1997. 116(1): p. 27-32. 
40. Mizuno, S., et al., A multi-institute case-control study on the risk factors of developing 
pancreatic cancer. Jpn J Clin Oncol, 1992. 22(4): p. 286-91. 
41. Luo, J., et al., Body mass index, physical activity and the risk of pancreatic cancer in relation 
to smoking status and history of diabetes: a large-scale population-based cohort study in 
Japan--the JPHC study. Cancer Causes Control, 2007. 18(6): p. 603-12. 
42. Lo, A.C., et al., Lifestyle, occupational, and reproductive factors in relation to pancreatic 
cancer risk. Pancreas, 2007. 35(2): p. 120-9. 
43. Larsson, S.C., et al., Overall obesity, abdominal adiposity, diabetes and cigarette smoking in 
relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J 
Cancer, 2005. 93(11): p. 1310-5. 
44. Hassan, M.M., et al., Passive smoking and the use of noncigarette tobacco products in 
association with risk for pancreatic cancer: a case-control study. Cancer, 2007. 109(12): p. 
2547-56. 
45. Inoue, M., et al., Epidemiology of pancreatic cancer in Japan: a nested case-control study 
from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). 
Int J Epidemiol, 2003. 32(2): p. 257-62. 
46. Ghadirian, P., A. Simard, and J. Baillargeon, Tobacco, alcohol, and coffee and cancer of the 
pancreas. A population-based, case-control study in Quebec, Canada. Cancer, 1991. 67(10): 
p. 2664-70. 
47. Fryzek, J.P., et al., A case-control study of self-reported exposures to pesticides and pancreas 
cancer in southeastern Michigan. Int J Cancer, 1997. 72(1): p. 62-7. 
48. Gallicchio, L., et al., Active cigarette smoking, household passive smoke exposure, and the 
risk of developing pancreatic cancer. Prev Med, 2006. 42(3): p. 200-5. 
49. Falk, R.T., et al., Life-style risk factors for pancreatic cancer in Louisiana: a case-control study. 
Am J Epidemiol, 1988. 128(2): p. 324-36. 
50. Bonelli, L., et al., Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a 
case-control study in northern Italy. Pancreas, 2003. 27(2): p. 143-9. 
51. Siemiatycki, J., et al., Associations between cigarette smoking and each of 21 types of cancer: 
a multi-site case-control study. Int J Epidemiol, 1995. 24(3): p. 504-14. 
52. Silverman, D.T., et al., Cigarette smoking and pancreas cancer: a case-control study based on 
direct interviews. J Natl Cancer Inst, 1994. 86(20): p. 1510-6. 
53. Anderson, K.E., et al., Dietary intake of heterocyclic amines and benzo(a)pyrene: associations 
with pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 2005. 14(9): p. 2261-5. 
54. Harnack, L.J., et al., Smoking, alcohol, coffee, and tea intake and incidence of cancer of the 
exocrine pancreas: the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev, 
1997. 6(12): p. 1081-6. 
55. Coughlin, S.S., et al., Predictors of pancreatic cancer mortality among a large cohort of 
United States adults. Cancer Causes Control, 2000. 11(10): p. 915-23. 
56. Iodice, S., et al., Tobacco and the risk of pancreatic cancer: a review and meta-analysis. 
Langenbecks Arch Surg, 2008. 393(4): p. 535-45. 
57. Liaw, K.M. and C.J. Chen, Mortality attributable to cigarette smoking in Taiwan: a 12-year 
follow-up study. Tob Control, 1998. 7(2): p. 141-8. 
58. Nishi, M., et al., Dose-response relationship between coffee and the risk of pancreas cancer. 
Jpn J Clin Oncol, 1996. 26(1): p. 42-8. 
174 
 
59. Hanley, A.J., et al., Physical activity, anthropometric factors and risk of pancreatic cancer: 
results from the Canadian enhanced cancer surveillance system. Int J Cancer, 2001. 94(1): p. 
140-7. 
60. Jemal, A., et al., Cancer statistics, 2009. CA Cancer J Clin, 2009. 59(4): p. 225-49. 
61. Muscat, J.E., et al., Smoking and pancreatic cancer in men and women. Cancer Epidemiol 
Biomarkers Prev, 1997. 6(1): p. 15-9. 
62. Nilsen, T.I. and L.J. Vatten, A prospective study of lifestyle factors and the risk of pancreatic 
cancer in Nord-Trondelag, Norway. Cancer Causes Control, 2000. 11(7): p. 645-52. 
63. Howe, G.R., et al., Cigarette smoking and cancer of the pancreas: evidence from a 
population-based case-control study in Toronto, Canada. Int J Cancer, 1991. 47(3): p. 323-8. 
64. Gapstur, S.M., et al., Abnormal glucose metabolism and pancreatic cancer mortality. JAMA, 
2000. 283(19): p. 2552-8. 
65. Ji, B.T., et al., Cigarette smoking and alcohol consumption and the risk of pancreatic cancer: a 
case-control study in Shanghai, China. Cancer Causes Control, 1995. 6(4): p. 369-76. 
66. Brand, R.E., et al., Pancreatic cancer patients who smoke and drink are diagnosed at younger 
ages. Clin Gastroenterol Hepatol, 2009. 7(9): p. 1007-12. 
67. Wynder, E.L., N.E. Hall, and M. Polansky, Epidemiology of coffee and pancreatic cancer. 
Cancer Res, 1983. 43(8): p. 3900-6. 
68. Gold, E.B., et al., Diet and other risk factors for cancer of the pancreas. Cancer, 1985. 55(2): 
p. 460-7. 
69. Durbec, J.P., et al., Diet, alcohol, tobacco and risk of cancer of the pancreas: a case-control 
study. Br J Cancer, 1983. 47(4): p. 463-70. 
70. Alguacil, J. and D.T. Silverman, Smokeless and other noncigarette tobacco use and pancreatic 
cancer: a case-control study based on direct interviews. Cancer Epidemiol Biomarkers Prev, 
2004. 13(1): p. 55-8. 
71. Hassan, M.M., et al., Risk factors for pancreatic cancer: case-control study. Am J 
Gastroenterol, 2007. 102(12): p. 2696-707. 
72. Villeneuve, P.J., et al., Environmental tobacco smoke and the risk of pancreatic cancer: 
findings from a Canadian population-based case-control study. Can J Public Health, 2004. 
95(1): p. 32-7. 
73. Bao, Y., et al., Passive smoking and pancreatic cancer in women: a prospective cohort study. 
Cancer Epidemiol Biomarkers Prev, 2009. 18(8): p. 2292-6. 
74. Crous-Bou, M., et al., Lifetime history of tobacco consumption and K-ras mutations in 
exocrine pancreatic cancer. Pancreas, 2007. 35(2): p. 135-41. 
75. Hruban, R.H., et al., K-ras oncogene activation in adenocarcinoma of the human pancreas. A 
study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction 
analysis and allele-specific oligonucleotide hybridization. Am J Pathol, 1993. 143(2): p. 545-
54. 
76. Jiao, L., et al., K-ras mutation and p16 and preproenkephalin promoter hypermethylation in 
plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas, 2007. 
34(1): p. 55-62. 
77. Malats, N., et al., Ki-ras mutations in exocrine pancreatic cancer: association with clinico-
pathological characteristics and with tobacco and alcohol consumption. PANK-ras I Project 
Investigators. Int J Cancer, 1997. 70(6): p. 661-7. 
78. Berger, D.H., et al., Mutational activation of K-ras in nonneoplastic exocrine pancreatic 
lesions in relation to cigarette smoking status. Cancer, 1999. 85(2): p. 326-32. 
79. Slebos, R.J., et al., K-ras and p53 in pancreatic cancer: association with medical history, 
histopathology, and environmental exposures in a population-based study. Cancer Epidemiol 
Biomarkers Prev, 2000. 9(11): p. 1223-32. 
175 
 
80. Duell, E.J., et al., A population-based, case-control study of polymorphisms in carcinogen-
metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst, 2002. 
94(4): p. 297-306. 
81. Suzuki, H., et al., Interaction of the cytochrome P4501A2, SULT1A1 and NAT gene 
polymorphisms with smoking and dietary mutagen intake in modification of the risk of 
pancreatic cancer. Carcinogenesis, 2008. 29(6): p. 1184-91. 
82. Bartsch, H., et al., Genetic polymorphism of CYP genes, alone or in combination, as a risk 
modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev, 2000. 9(1): p. 3-28. 
83. Li, D., et al., Polymorphisms of cytochrome P4501A2 and N-acetyltransferase genes, smoking, 
and risk of pancreatic cancer. Carcinogenesis, 2006. 27(1): p. 103-11. 
84. Jiao, L., et al., Glutathione S-transferase gene polymorphisms and risk and survival of 
pancreatic cancer. Cancer, 2007. 109(5): p. 840-8. 
85. Jiao, L., et al., Selected polymorphisms of DNA repair genes and risk of pancreatic cancer. 
Cancer Detect Prev, 2006. 30(3): p. 284-91. 
86. Jiao, L., et al., XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J 
Gastroenterol, 2008. 103(2): p. 360-7. 
87. Li, D., et al., Significant effect of homologous recombination DNA repair gene polymorphisms 
on pancreatic cancer survival. Cancer Res, 2006. 66(6): p. 3323-30. 
88. Larsson, S.C., N. Orsini, and A. Wolk, Body mass index and pancreatic cancer risk: A meta-
analysis of prospective studies. Int J Cancer, 2007. 120(9): p. 1993-8. 
89. Jee, S.H., et al., Body mass index and cancer risk in Korean men and women. Int J Cancer, 
2008. 123(8): p. 1892-6. 
90. Rapp, K., et al., Fasting blood glucose and cancer risk in a cohort of more than 140,000 adults 
in Austria. Diabetologia, 2006. 49(5): p. 945-52. 
91. Wolk, A., et al., A prospective study of obesity and cancer risk (Sweden). Cancer Causes 
Control, 2001. 12(1): p. 13-21. 
92. Michaud, D.S., et al., Physical activity, obesity, height, and the risk of pancreatic cancer. 
JAMA, 2001. 286(8): p. 921-9. 
93. Stolzenberg-Solomon, R.Z., et al., Adiposity, physical activity, and pancreatic cancer in the 
National Institutes of Health-AARP Diet and Health Cohort. Am J Epidemiol, 2008. 167(5): p. 
586-97. 
94. Samanic, C., et al., Obesity and cancer risk among white and black United States veterans. 
Cancer Causes Control, 2004. 15(1): p. 35-43. 
95. Nkondjock, A., et al., Dietary patterns and risk of pancreatic cancer. Int J Cancer, 2005. 
114(5): p. 817-23. 
96. Jiao, L., et al., Alcohol use and risk of pancreatic cancer: the NIH-AARP Diet and Health Study. 
Am J Epidemiol, 2009. 169(9): p. 1043-51. 
97. Talamini, R., et al., Tobacco smoking, alcohol consumption and pancreatic cancer risk: a case-
control study in Italy. Eur J Cancer, 2010. 46(2): p. 370-6. 
98. Suzuki, T., et al., Alcohol drinking and one-carbon metabolism-related gene polymorphisms 
on pancreatic cancer risk. Cancer Epidemiol Biomarkers Prev, 2008. 17(10): p. 2742-7. 
99. Wang, L., et al., Genetic polymorphisms in methylenetetrahydrofolate reductase and 
thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol, 2005. 3(8): p. 
743-51. 
100. Matsubayashi, H., et al., Pancreaticobiliary cancers with deficient methylenetetrahydrofolate 
reductase genotypes. Clin Gastroenterol Hepatol, 2005. 3(8): p. 752-60. 
101. Kanda, J., et al., Impact of alcohol consumption with polymorphisms in alcohol-metabolizing 
enzymes on pancreatic cancer risk in Japanese. Cancer Sci, 2009. 100(2): p. 296-302. 
102. Everhart, J. and D. Wright, Diabetes mellitus as a risk factor for pancreatic cancer. A meta-
analysis. JAMA, 1995. 273(20): p. 1605-9. 
176 
 
103. Jee, S.H., et al., Fasting serum glucose level and cancer risk in Korean men and women. 
JAMA, 2005. 293(2): p. 194-202. 
104. Chow, W.H., et al., Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort 
study in Sweden. J Natl Cancer Inst, 1995. 87(12): p. 930-1. 
105. Berrington de Gonzalez, A., et al., Pancreatic cancer and factors associated with the insulin 
resistance syndrome in the Korean cancer prevention study. Cancer Epidemiol Biomarkers 
Prev, 2008. 17(2): p. 359-64. 
106. Batty, G.D., et al., Diabetes status and post-load plasma glucose concentration in relation to 
site-specific cancer mortality: findings from the original Whitehall study. Cancer Causes 
Control, 2004. 15(9): p. 873-81. 
107. Calle, E.E., et al., Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of 
United States adults. Cancer Causes Control, 1998. 9(4): p. 403-10. 
108. Stattin, P., et al., Prospective study of hyperglycemia and cancer risk. Diabetes Care, 2007. 
30(3): p. 561-7. 
109. Stolzenberg-Solomon, R.Z., et al., Insulin, glucose, insulin resistance, and pancreatic cancer in 
male smokers. JAMA, 2005. 294(22): p. 2872-8. 
110. Levine, W., et al., Post-load plasma glucose and cancer mortality in middle-aged men and 
women. 12-year follow-up findings of the Chicago Heart Association Detection Project in 
Industry. Am J Epidemiol, 1990. 131(2): p. 254-62. 
111. Meinhold, C.L., et al., Predictors of fasting serum insulin and glucose and the risk of 
pancreatic cancer in smokers. Cancer Causes Control, 2009. 20(5): p. 681-90. 
112. Wideroff, L., et al., Cancer incidence in a population-based cohort of patients hospitalized 
with diabetes mellitus in Denmark. J Natl Cancer Inst, 1997. 89(18): p. 1360-5. 
113. Zendehdel, K., et al., Cancer incidence in patients with type 1 diabetes mellitus: a population-
based cohort study in Sweden. J Natl Cancer Inst, 2003. 95(23): p. 1797-800. 
114. Huxley, R., et al., Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J 
Cancer, 2005. 92(11): p. 2076-83. 
115. Ragozzino, M., et al., Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, 
residents with diabetes mellitus. J Chronic Dis, 1982. 35(1): p. 13-9. 
116. Cuzick, J. and A.G. Babiker, Pancreatic cancer, alcohol, diabetes mellitus and gall-bladder 
disease. Int J Cancer, 1989. 43(3): p. 415-21. 
117. Gullo, L., R. Pezzilli, and A.M. Morselli-Labate, Diabetes and the risk of pancreatic cancer. N 
Engl J Med, 1994. 331(2): p. 81-4. 
118. Wang, W., et al., Incidence of pancreatic cancer in chinese patients with chronic pancreatitis. 
Pancreatology, 2011. 11(1): p. 16-23. 
119. Dite, P., et al., Incidence of pancreatic carcinoma in patients with chronic pancreatitis. 
Hepatogastroenterology, 2010. 57(101): p. 957-60. 
120. Moskaluk, C.A., R.H. Hruban, and S.E. Kern, p16 and K-ras gene mutations in the intraductal 
precursors of human pancreatic adenocarcinoma. Cancer Res, 1997. 57(11): p. 2140-3. 
121. Yan, L., et al., Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk 
groups. Gastroenterology, 2005. 128(7): p. 2124-30. 
122. Farrow, B. and B.M. Evers, Inflammation and the development of pancreatic cancer. Surg 
Oncol, 2002. 10(4): p. 153-69. 
123. Whitcomb, D. and J. Greer, Germ-line mutations, pancreatic inflammation, and pancreatic 
cancer. Clin Gastroenterol Hepatol, 2009. 7(11 Suppl): p. S29-34. 
124. Hussain, S.P., L.J. Hofseth, and C.C. Harris, Radical causes of cancer. Nat Rev Cancer, 2003. 
3(4): p. 276-85. 
125. Aird, I., H.H. Bentall, and J.A. Roberts, A relationship between cancer of stomach and the 
ABO blood groups. Br Med J, 1953. 1(4814): p. 799-801. 
126. Itzkowitz, S.H., et al., Cancer-associated alterations of blood group antigen expression in the 
human pancreas. J Natl Cancer Inst, 1987. 79(3): p. 425-34. 
177 
 
127. Melzer, D., et al., A genome-wide association study identifies protein quantitative trait loci 
(pQTLs). PLoS Genet, 2008. 4(5): p. e1000072. 
128. Amundadottir, L., et al., Genome-wide association study identifies variants in the ABO locus 
associated with susceptibility to pancreatic cancer. Nat Genet, 2009. 41(9): p. 986-90. 
129. Wolpin, B.M., et al., ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst, 
2009. 101(6): p. 424-31. 
130. Vogelstein, B. and K.W. Kinzler, The multistep nature of cancer. Trends Genet, 1993. 9(4): p. 
138-41. 
131. Caldas, C., et al., Frequent somatic mutations and homozygous deletions of the p16 (MTS1) 
gene in pancreatic adenocarcinoma. Nat Genet, 1994. 8: p. 27-32. 
132. Schutte, M., et al., Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all 
pancreatic carcinomas. Cancer Res, 1997. 57(15): p. 3126-30. 
133. Maitra, A., et al., Multicomponent analysis of the pancreatic adenocarcinoma progression 
model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol, 2003. 
16(9): p. 902-12. 
134. Wilentz, R.E., et al., Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct 
lesions: loss of intranuclear expression. Cancer Res, 1998. 58(20): p. 4740-4. 
135. Basturk, O., I. Coban, and N.V. Adsay, Pancreatic cysts: pathologic classification, differential 
diagnosis, and clinical implications. Arch Pathol Lab Med, 2009. 133(3): p. 423-38. 
136. Bosman, F.T., World Health Organization., and International Agency for Research on Cancer., 
WHO classification of tumours of the digestive system. 4th ed. World Health Organization 
classification of tumours2010, Lyon: International Agency for Research on Cancer. 417 p. 
137. Cooper, C.L., S.A. O'Toole, and J.G. Kench, Classification, morphology and molecular 
pathology of premalignant lesions of the pancreas. Pathology, 2013. 45(3): p. 286-304. 
138. Singh, M. and A. Maitra, Precursor lesions of pancreatic cancer: molecular pathology and 
clinical implications. Pancreatology, 2007. 7(1): p. 9-19. 
139. Biankin, A.V., et al., Molecular pathogenesis of precursor lesions of pancreatic ductal 
adenocarcinoma. Pathology, 2003. 35(1): p. 14-24. 
140. Shi, C. and R.H. Hruban, Intraductal papillary mucinous neoplasm. Hum Pathol, 2012. 43(1): 
p. 1-16. 
141. Schnelldorfer, T., et al., Experience with 208 resections for intraductal papillary mucinous 
neoplasm of the pancreas. Arch Surg, 2008. 143(7): p. 639-46; discussion 646. 
142. Tanaka, M., et al., International consensus guidelines for management of intraductal 
papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. 
Pancreatology, 2006. 6(1-2): p. 17-32. 
143. Chadwick, B., et al., Histologic, immunohistochemical, and molecular classification of 52 
IPMNs of the pancreas. Appl Immunohistochem Mol Morphol, 2009. 17(1): p. 31-9. 
144. Mohri, D., et al., Different subtypes of intraductal papillary mucinous neoplasm in the 
pancreas have distinct pathways to pancreatic cancer progression. J Gastroenterol, 2012. 
47(2): p. 203-13. 
145. Yamao, K., et al., Clinicopathological features and prognosis of mucinous cystic neoplasm 
with ovarian-type stroma: a multi-institutional study of the Japan pancreas society. 
Pancreas, 2011. 40(1): p. 67-71. 
146. Thompson, L.D., et al., Mucinous cystic neoplasm (mucinous cystadenocarcinoma of low-
grade malignant potential) of the pancreas: a clinicopathologic study of 130 cases. Am J Surg 
Pathol, 1999. 23(1): p. 1-16. 
147. Zamboni, G., et al., Mucinous cystic tumors of the pancreas: clinicopathological features, 
prognosis, and relationship to other mucinous cystic tumors. Am J Surg Pathol, 1999. 23(4): 
p. 410-22. 
148. Cote, G.A., et al., Technologies for imaging the normal and diseased pancreas. 
Gastroenterology, 2013. 144(6): p. 1262-71 e1. 
178 
 
149. Maire, F., et al., Pancreatic intraepithelial neoplasia in patients with intraductal papillary 
mucinous neoplasms: the interest of endoscopic ultrasonography. Pancreas, 2013. 42(8): p. 
1262-6. 
150. Khashab, M.A., et al., Should we do EUS/FNA on patients with pancreatic cysts? The 
incremental diagnostic yield of EUS over CT/MRI for prediction of cystic neoplasms. Pancreas, 
2013. 42(4): p. 717-21. 
151. Shimizu, Y., et al., Predictors of malignancy in intraductal papillary mucinous neoplasm of the 
pancreas: analysis of 310 pancreatic resection patients at multiple high-volume centers. 
Pancreas, 2013. 42(5): p. 883-8. 
152. Khalid, A., et al., Pancreatic cyst fluid DNA analysis in evaluating pancreatic cysts: a report of 
the PANDA study. Gastrointest Endosc, 2009. 69(6): p. 1095-102. 
153. Al-Haddad, M., et al., Safety and efficacy of cytology brushings versus standard fine-needle 
aspiration in evaluating cystic pancreatic lesions: a controlled study. Endoscopy, 2010. 42(2): 
p. 127-32. 
154. Brugge, W.R., et al., Diagnosis of pancreatic cystic neoplasms: a report of the cooperative 
pancreatic cyst study. Gastroenterology, 2004. 126(5): p. 1330-6. 
155. Yachida, S., et al., Distant metastasis occurs late during the genetic evolution of pancreatic 
cancer. Nature, 2010. 467(7319): p. 1114-7. 
156. Lynch, H.T., et al., Familial pancreatic cancer: clinicopathologic study of 18 nuclear families. 
Am J Gastroenterol, 1990. 85(1): p. 54-60. 
157. Klein, A.P., et al., Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. 
Cancer Res, 2004. 64(7): p. 2634-8. 
158. McFaul, C.D., et al., Anticipation in familial pancreatic cancer. Gut, 2006. 55(2): p. 252-8. 
159. Schenk, M., et al., Familial risk of pancreatic cancer. J Natl Cancer Inst, 2001. 93(8): p. 640-4. 
160. James, T.A., et al., Risk factors associated with earlier age of onset in familial pancreatic 
carcinoma. Cancer, 2004. 101(12): p. 2722-6. 
161. Rulyak, S.J., et al., Risk factors for the development of pancreatic cancer in familial pancreatic 
cancer kindreds. Gastroenterology, 2003. 124(5): p. 1292-9. 
162. Yeo, T.P., et al., Assessment of "gene-environment" interaction in cases of familial and 
sporadic pancreatic cancer. J Gastrointest Surg, 2009. 13(8): p. 1487-94. 
163. Howes, N., et al., Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin 
Gastroenterol Hepatol, 2004. 2(3): p. 252-61. 
164. Le Bodic, L., et al., The hereditary pancreatitis gene maps to long arm of chromosome 7. Hum 
Mol Genet, 1996. 5(4): p. 549-54. 
165. Whitcomb, D.C., et al., Hereditary pancreatitis is caused by a mutation in the cationic 
trypsinogen gene. Nat Genet, 1996. 14(2): p. 141-5. 
166. Whitcomb, D.C., et al., A gene for hereditary pancreatitis maps to chromosome 7q35. 
Gastroenterology, 1996. 110(6): p. 1975-80. 
167. Grocock, C.J., et al., The variable phenotype of the p.A16V mutation of cationic trypsinogen 
(PRSS1) in pancreatitis families. Gut, 2010. 59(3): p. 357-63. 
168. Rinderknecht, H., et al., Mesotrypsin: a new inhibitor-resistant protease from a zymogen in 
human pancreatic tissue and fluid. Gastroenterology, 1984. 86(4): p. 681-92. 
169. Pfutzer, R., et al., Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause 
autosomal dominant hereditary pancreatitis. Gut, 2002. 50(2): p. 271-2. 
170. Teich, N., et al., Chronic pancreatitis associated with an activation peptide mutation that 
facilitates trypsin activation. Gastroenterology, 2000. 119(2): p. 461-5. 
171. Ferec, C., et al., Mutations in the cationic trypsinogen gene and evidence for genetic 
heterogeneity in hereditary pancreatitis. J Med Genet, 1999. 36(3): p. 228-32. 
172. Domínguez-Muñoz, J.E., Clinical pancreatology for practising gastroenterologists and 
surgeons2005, Malden, Mass.: Blackwell Pub. xix, 535 p. 
179 
 
173. Gorry, M.C., et al., Mutations in the cationic trypsinogen gene are associated with recurrent 
acute and chronic pancreatitis. Gastroenterology, 1997. 113(4): p. 1063-8. 
174. Sahin-Toth, M., Hereditary pancreatitis-associated mutation asn(21) --> ile stabilizes rat 
trypsinogen in vitro. J Biol Chem, 1999. 274(42): p. 29699-704. 
175. Sahin-Toth, M., Human cationic trypsinogen. Role of Asn-21 in zymogen activation and 
implications in hereditary pancreatitis. J Biol Chem, 2000. 275(30): p. 22750-5. 
176. Sahin-Toth, M. and M. Toth, Gain-of-function mutations associated with hereditary 
pancreatitis enhance autoactivation of human cationic trypsinogen. Biochem Biophys Res 
Commun, 2000. 278(2): p. 286-9. 
177. Simon, P., et al., Hereditary pancreatitis caused by a novel PRSS1 mutation (Arg-122 --> Cys) 
that alters autoactivation and autodegradation of cationic trypsinogen. J Biol Chem, 2002. 
277(7): p. 5404-10. 
178. Nemoda, Z. and M. Sahin-Toth, Chymotrypsin C (caldecrin) stimulates autoactivation of 
human cationic trypsinogen. J Biol Chem, 2006. 281(17): p. 11879-86. 
179. Kereszturi, E., et al., Hereditary pancreatitis caused by mutation-induced misfolding of 
human cationic trypsinogen: a novel disease mechanism. Hum Mutat, 2009. 30(4): p. 575-82. 
180. Hahn, S.A., et al., BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer 
Inst, 2003. 95(3): p. 214-21. 
181. Goggins, M., et al., Germline BRCA2 gene mutations in patients with apparently sporadic 
pancreatic carcinomas. Cancer Res, 1996. 56(23): p. 5360-4. 
182. Ferrone, C.R., et al., BRCA germline mutations in Jewish patients with pancreatic 
adenocarcinoma. J Clin Oncol, 2009. 27(3): p. 433-8. 
183. Lynch, H.T. and A.J. Krush, Heredity and malignant melanoma: implications for early cancer 
detection. Can Med Assoc J, 1968. 99(1): p. 17-21. 
184. Lynch, H.T., et al., Familial atypical multiple mole-melanoma (FAMMM) syndrome: 
segregation analysis. J Med Genet, 1983. 20(5): p. 342-4. 
185. Lynch, H.T., et al., Phenotypic variation in eight extended CDKN2A germline mutation familial 
atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical 
mole melanoma-pancreatic carcinoma syndrome. Cancer, 2002. 94(1): p. 84-96. 
186. Bartsch, D.K., et al., Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-
prone families. Clin Genet, 2010. 77(4): p. 333-41. 
187. van Lier, M.G., et al., High cancer risk in Peutz-Jeghers syndrome: a systematic review and 
surveillance recommendations. Am J Gastroenterol, 2010. 105(6): p. 1258-64; author reply 
1265. 
188. Giardiello, F.M., et al., Very high risk of cancer in familial Peutz-Jeghers syndrome. 
Gastroenterology, 2000. 119(6): p. 1447-53. 
189. Kastrinos, F., et al., Risk of pancreatic cancer in families with Lynch syndrome. JAMA, 2009. 
302(16): p. 1790-5. 
190. Lynch, H.T., et al., Tumor variation in three extended Lynch syndrome II kindreds. Am J 
Gastroenterol, 1988. 83(7): p. 741-7. 
191. Birch, J.M., et al., Relative frequency and morphology of cancers in carriers of germline TP53 
mutations. Oncogene, 2001. 20(34): p. 4621-8. 
192. Kleihues, P., et al., Tumors associated with p53 germline mutations: a synopsis of 91 families. 
Am J Pathol, 1997. 150(1): p. 1-13. 
193. Pogue-Geile, K.L., et al., Palladin mutation causes familial pancreatic cancer and suggests a 
new cancer mechanism. PLoS Med, 2006. 3(12): p. e516. 
194. Klein, A.P., et al., Absence of deleterious palladin mutations in patients with familial 
pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 2009. 18(4): p. 1328-30. 
195. Slater, E., et al., Palladin mutation causes familial pancreatic cancer: absence in European 
families. PLoS Med, 2007. 4(4): p. e164. 
180 
 
196. Jones, S., et al., Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility 
gene. Science, 2009. 324(5924): p. 217. 
197. Slater, E.P., et al., PALB2 mutations in European familial pancreatic cancer families. Clin 
Genet, 2010. 78(5): p. 490-4. 
198. Stadler, Z.K., et al., Germline PALB2 mutation analysis in breast-pancreas cancer families. J 
Med Genet, 2011. 48(8): p. 523-5. 
199. Ghiorzo, P., et al., Contribution of germline mutations in the BRCA and PALB2 genes to 
pancreatic cancer in Italy. Fam Cancer, 2012. 11(1): p. 41-7. 
200. Tersmette, A.C., et al., Increased risk of incident pancreatic cancer among first-degree 
relatives of patients with familial pancreatic cancer. Clin Cancer Res, 2001. 7: p. 738-44. 
201. Brentnall, T.A., et al., Early diagnosis and treatment of pancreatic dysplasia in patients with a 
family history of pancreatic cancer. Ann Intern Med, 1999. 131(4): p. 247-55. 
202. Canto, M.I., et al., Screening for pancreatic neoplasia in high-risk individuals: an EUS-based 
approach. Clin Gastroenterol Hepatol, 2004. 2(7): p. 606-21. 
203. Poley, J.W., et al., The yield of first-time endoscopic ultrasonography in screening individuals 
at a high risk of developing pancreatic cancer. Am J Gastroenterol, 2009. 104(9): p. 2175-81. 
204. Langer, P., et al., Five years of prospective screening of high-risk individuals from families 
with familial pancreatic cancer. Gut, 2009. 58(10): p. 1410-8. 
205. Verna, E.C., et al., Pancreatic cancer screening in a prospective cohort of high-risk patients: a 
comprehensive strategy of imaging and genetics. Clin Cancer Res, 2010. 16(20): p. 5028-37. 
206. Vasen, H.F., et al., Magnetic resonance imaging surveillance detects early-stage pancreatic 
cancer in carriers of a p16-Leiden mutation. Gastroenterology, 2011. 140(3): p. 850-6. 
207. Al-Sukhni, W., et al., Screening for pancreatic cancer in a high-risk cohort: an eight-year 
experience. J Gastrointest Surg, 2012. 16(4): p. 771-83. 
208. Canto, M.I., et al., International Cancer of the Pancreas Screening (CAPS) Consortium summit 
on the management of patients with increased risk for familial pancreatic cancer. Gut, 2013. 
62(3): p. 339-47. 
209. Kimmey, M.B., et al., Screening and surveillance for hereditary pancreatic cancer. 
Gastrointest Endosc, 2002. 56(4 Suppl): p. S82-6. 
210. Schneider, N.I., et al., Pancreatic adenocarcinoma with multiple eosinophilic extracellular 
deposits consistent with noncalcified psammoma bodies. Virchows Arch, 2011. 459(6): p. 
623-5. 
211. Halloran, C.M., et al., Carbohydrate antigen 19.9 accurately selects patients for laparoscopic 
assessment to determine resectability of pancreatic malignancy. Br J Surg, 2008. 95(4): p. 
453-9. 
212. Gattani, A.M., J. Mandeli, and H.W. Bruckner, Tumor markers in patients with pancreatic 
carcinoma. Cancer, 1996. 78(1): p. 57-62. 
213. Niederau, C. and J.H. Grendell, Diagnosis of pancreatic carcinoma. Imaging techniques and 
tumor markers. Pancreas, 1992. 7(1): p. 66-86. 
214. Itzkowitz, S.H. and Y.S. Kim, New carbohydrate tumor markers. Gastroenterology, 1986. 
90(2): p. 491-4. 
215. Tempero, M.A., et al., Relationship of carbohydrate antigen 19-9 and Lewis antigens in 
pancreatic cancer. Cancer Res, 1987. 47(20): p. 5501-3. 
216. Pannala, R., et al., Prevalence and clinical profile of pancreatic cancer-associated diabetes 
mellitus. Gastroenterology, 2008. 134(4): p. 981-7. 
217. Canto, M.I., et al., Frequent detection of pancreatic lesions in asymptomatic high-risk 
individuals. Gastroenterology, 2012. 142(4): p. 796-804; quiz e14-5. 
218. Ludwig, E., et al., Feasibility and yield of screening in relatives from familial pancreatic cancer 
families. Am J Gastroenterol, 2011. 106(5): p. 946-54. 
181 
 
219. Roche, C.J., et al., CT and pathologic assessment of prospective nodal staging in patients with 
ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol, 2003. 180(2): p. 
475-80. 
220. Martin, S.P. and C.D. Ulrich, 2nd, Pancreatic cancer surveillance in a high-risk cohort. Is it 
worth the cost? Med Clin North Am, 2000. 84(3): p. 739-47, xii-xiii. 
221. Megibow, A.J., et al., Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of 
resectability--report of the Radiology Diagnostic Oncology Group. Radiology, 1995. 195(2): p. 
327-32. 
222. Vellet, A.D., et al., Adenocarcinoma of the pancreatic ducts: comparative evaluation with CT 
and MR imaging at 1.5 T. Radiology, 1992. 183(1): p. 87-95. 
223. Kalra, M.K., et al., State-of-the-art imaging of pancreatic neoplasms. Br J Radiol, 2003. 
76(912): p. 857-65. 
224. Harewood, G.C., et al., Influence of EUS training and pathology interpretation on accuracy of 
EUS-guided fine needle aspiration of pancreatic masses. Gastrointest Endosc, 2002. 55(6): p. 
669-73. 
225. Varadarajulu, S., A. Tamhane, and M.A. Eloubeidi, Yield of EUS-guided FNA of pancreatic 
masses in the presence or the absence of chronic pancreatitis. Gastrointest Endosc, 2005. 
62(5): p. 728-36; quiz 751, 753. 
226. Lemoine, N.R., et al., Ki-ras oncogene activation in preinvasive pancreatic cancer. 
Gastroenterology, 1992. 102(1): p. 230-6. 
227. Sugio, K., et al., K-ras mutations and allelic loss at 5q and 18q in the development of human 
pancreatic cancers. Int J Pancreatol, 1997. 21(3): p. 205-17. 
228. Luttges, J., et al., The K-ras mutation pattern in pancreatic ductal adenocarcinoma usually is 
identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium. 
Cancer, 1999. 85(8): p. 1703-10. 
229. Kondoh, S., et al., Detection of Ki-ras and p53 gene mutations in tissue and pancreatic juice 
from pancreatic adenocarcinomas. J Gastroenterol, 1998. 33(3): p. 390-6. 
230. Yamashita, K., et al., K-ras point mutations in the supernatants of pancreatic juice and bile 
are reliable for diagnosis of pancreas and biliary tract carcinomas complementary to 
cytologic examination. Jpn J Cancer Res, 1999. 90(2): p. 240-8. 
231. Furuya, N., et al., Long-term follow-up of patients with chronic pancreatitis and K-ras gene 
mutation detected in pancreatic juice. Gastroenterology, 1997. 113(2): p. 593-8. 
232. Van Laethem, J.L., et al., Relative contribution of Ki-ras gene analysis and brush cytology 
during ERCP for the diagnosis of biliary and pancreatic diseases. Gastrointest Endosc, 1998. 
47(6): p. 479-85. 
233. Tada, M., et al., Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas 
without pancreatic disease. Gastroenterology, 1996. 110(1): p. 227-31. 
234. Yanagisawa, A., et al., Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of 
pancreas suffering from chronic inflammation. Cancer Res, 1993. 53(5): p. 953-6. 
235. Rozenblum, E., et al., Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res, 
1997. 57(9): p. 1731-4. 
236. Whelan, A.J., D. Bartsch, and P.J. Goodfellow, Brief report: a familial syndrome of pancreatic 
cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med, 
1995. 333(15): p. 975-7. 
237. Fukushima, N., et al., Aberrant methylation of preproenkephalin and p16 genes in pancreatic 
intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol, 2002. 160(5): 
p. 1573-81. 
238. Ueki, T., et al., Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer 
Res, 2000. 60(7): p. 1835-9. 
239. Fukushima, N., et al., Diagnosing pancreatic cancer using methylation specific PCR analysis of 
pancreatic juice. Cancer Biol Ther, 2003. 2(1): p. 78-83. 
182 
 
240. Matsubayashi, H., et al., Methylation of cyclin D2 is observed frequently in pancreatic cancer 
but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res, 2003. 
9(4): p. 1446-52. 
241. Klump, B., et al., Methylation status of p14ARF and p16INK4a as detected in pancreatic 
secretions. Br J Cancer, 2003. 88(2): p. 217-22. 
242. Barton, C.M., et al., Abnormalities of the p53 tumour suppressor gene in human pancreatic 
cancer. Br J Cancer, 1991. 64: p. 1076-82. 
243. Yamaguchi, Y., et al., Detection of mutations of p53 tumor suppressor gene in pancreatic 
juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-
ras mutation. Clin Cancer Res, 1999. 5: p. 1147-53. 
244. Casey, G., et al., p53 mutations are common in pancreatic cancer and are absent in chronic 
pancreatitis. Cancer Lett, 1993. 69(3): p. 151-60. 
245. Wang, Y., et al., Detection of p53 gene mutations in the supernatant of pancreatic juice and 
plasma from patients with pancreatic carcinomas. Pancreas, 2004. 28(1): p. 13-9. 
246. Flaman, J.M., et al., A simple p53 functional assay for screening cell lines, blood, and tumors. 
Proc Natl Acad Sci U S A, 1995. 92(9): p. 3963-7. 
247. Waridel, F., et al., Field cancerisation and polyclonal p53 mutation in the upper aero-
digestive tract. Oncogene, 1997. 14(2): p. 163-9. 
248. Herman, J.G., et al., Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with 
aberrant DNA methylation in all common human cancers. Cancer Res, 1995. 55(20): p. 4525-
30. 
249. Lo, Y.M., et al., Quantitative analysis of aberrant p16 methylation using real-time 
quantitative methylation-specific polymerase chain reaction. Cancer Res, 1999. 59(16): p. 
3899-903. 
250. Cotton, P.B., et al., Risk factors for complications after ERCP: a multivariate analysis of 
11,497 procedures over 12 years. Gastrointest Endosc, 2009. 70(1): p. 80-8. 
251. Cheng, C.L., et al., Risk factors for post-ERCP pancreatitis: a prospective multicenter study. 
Am J Gastroenterol, 2006. 101(1): p. 139-47. 
252. Wang, P., et al., Risk factors for ERCP-related complications: a prospective multicenter study. 
Am J Gastroenterol, 2009. 104(1): p. 31-40. 
253. Christensen, M., et al., Complications of ERCP: a prospective study. Gastrointest Endosc, 
2004. 60(5): p. 721-31. 
254. Pungpapong, S., et al., Endoscopic ultrasound and IL-8 in pancreatic juice to diagnose chronic 
pancreatitis. Pancreatology, 2007. 7(5-6): p. 491-6. 
255. Iguchi, H., et al., Analysis of Ki-ras codon 12 mutations in the duodenal juice of patients with 
pancreatic cancer. Gastroenterology, 1996. 110(1): p. 221-6. 
256. Wilentz, R.E., et al., K-ras mutations in the duodenal fluid of patients with pancreatic 
carcinoma. Cancer, 1998. 82(1): p. 96-103. 
257. Vandervoort, J., et al., Risk factors for complications after performance of ERCP. Gastrointest 
Endosc, 2002. 56(5): p. 652-6. 
258. Masci, E., et al., Complications of diagnostic and therapeutic ERCP: a prospective multicenter 
study. Am J Gastroenterol, 2001. 96(2): p. 417-23. 
259. Zuber-Jerger, I., et al., A new grading system to evaluate the risk of endoscopic retrograde 
cholangiopancreatography. J Gastroenterol, 2009. 44(2): p. 160-5. 
260. Devereaux, B.M., et al., Facilitation of pancreatic duct cannulation using a new synthetic 
porcine secretin. Am J Gastroenterol, 2002. 97(9): p. 2279-81. 
261. Pereira, S.P., et al., Prospective comparison of secretin-stimulated magnetic resonance 
cholangiopancreatography with manometry in the diagnosis of sphincter of Oddi dysfunction 
types II and III. Gut, 2007. 56(6): p. 809-13. 
262. Jorpes, J.E. and V. Mutt, The gastrointestinal hormones, secretin and cholecystokinin-
pancreozymin. Ann Intern Med, 1961. 55: p. 395-405. 
183 
 
263. Jowell, P.S., et al., A double-blind, randomized, dose response study testing the 
pharmacological efficacy of synthetic porcine secretin. Aliment Pharmacol Ther, 2000. 
14(12): p. 1679-84. 
264. Christ, A., et al., Human secretin. Biologic effects and plasma kinetics in humans. 
Gastroenterology, 1988. 94(2): p. 311-6. 
265. Mariani, A., et al., Diagnostic yield of ERCP and secretin-enhanced MRCP and EUS in patients 
with acute recurrent pancreatitis of unknown aetiology. Dig Liver Dis, 2009. 41(10): p. 753-8. 
266. Czako, L., Diagnosis of early-stage chronic pancreatitis by secretin-enhanced magnetic 
resonance cholangiopancreatography. J Gastroenterol, 2007. 42 Suppl 17: p. 113-7. 
267. Raimondo, M., M. Imoto, and E.P. DiMagno, Rapid endoscopic secretin stimulation test and 
discrimination of chronic pancreatitis and pancreatic cancer from disease controls. Clin 
Gastroenterol Hepatol, 2003. 1(5): p. 397-403. 
268. Moolsintong, P. and F.R. Burton, Pancreatic function testing is best determined by the 
extended endoscopic collection technique. Pancreas, 2008. 37(4): p. 418-21. 
269. Conwell, D.L., et al., An endoscopic pancreatic function test with cholecystokinin-octapeptide 
for the diagnosis of chronic pancreatitis. Clin Gastroenterol Hepatol, 2003. 1(3): p. 189-94. 
270. Brune, K.A., et al., Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer 
Inst, 2010. 102(2): p. 119-26. 
271. Williams, E.J., et al., Risk factors for complication following ERCP; results of a large-scale, 
prospective multicenter study. Endoscopy, 2007. 39(9): p. 793-801. 
 
 
